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Abstract
Alzheimer’s disease is a neurodegenerative disorder and the most common
causeofdementia. No treatment tohalt or slow theprogressive cognitivedecline
observed in Alzheimer’s disease patients is available. A better understanding
of the disease mechanism is urgently needed to further improve diagnosis and
develop novel treatment strategies. The amyloid precursor protein (APP) and
its processing are central to the pathology of Alzheimer’s disease. APP is a
transmembraneprotein that is cleaved into variouspeptide fragments, including
Aβ and the APP intracellular domain (AICD). Increased Aβ secretion and
aggregation is thought to trigger a cascade of toxic events that eventually results
in the development of Alzheimer’s disease. AICD, in turn, is transcriptionally
active and is involved in neurogenesis as well as apoptosis, however, its
regulation and functional role remain poorly understood.
The aim of this thesis is to gain molecular and mechanistic insights into the
regulation and function of AICD and shed light on a potential contribution of
AICD to the pathology of Alzheimer’s disease.
In the first results part of this thesis, chapter 3, I analyze nuclear localization
of the intracellular domains of APP and its homologues, APP-like protein 1
and 2 (APLP1 and APLP2). As APP, APLP1 and APLP2 undergo proteolytic
processing and release intracellular domains. I demonstrate that, similar to
AICD, the intracellular domain of APLP2 forms, together with the adaptor
protein Fe65 and the histone acetyltransferase Tip60, spherical nuclear com-
plexes (AFT-complexes), which are thought to be transcriptionally active. In
contrast, the intracellular domain of APLP1, despite binding to Fe65, does not
translocate to the nucleus. I further show that the intracellular domains of APP
and APLP1 are degraded by the proteasome and that the N-terminal amino
acids of the intracellular domains determine its degradation rates. Together,
these results suggest that different nuclear signaling capabilities of APP and
its homologues are due to different rates of full-length protein processing
and proteasomal degradation of intracellular domains. These results provide
evidence in support of a common nuclear signaling function for APP and
APLP2 that is absent in APLP1.
The results presented in chapter 3 uncover a novel aspect of AICD regulation,
the degradation by the ubiquitin-proteasome system. Therefore, I analyze in
chapter 4 the proteasomal degradation of different AICD species. AICD species
of different lengths are generated by processing of APP. Interestingly, various
mutations that result in the development of Alzheimer’s disease are known to
cause a shift from shorter AICD50 to longer AICD51. Here, I show that AICD
species undergo different proteasomal degradations. Extensive biochemical
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analyses reveal that the proteasomal degradation of AICD is independent
of ubiquitination. These results show that the identity of the N-terminal of
AICD is crucial for proteasomal degradation and argue for an N-end rule-like
degradation of AICD. Further, I provide evidence for a different proteasomal
degradation of AICD species by Alzheimer’s disease-causing mutations, which
may result in altered transcriptional regulation and may contribute to the
disease progression.
In chapter 5, I present a novel transgenic mouse line for studying regulation
and function of AICD in vivo. This mouse line expresses an APP transgene
fused to the Gal4 DNA binding domain (APPGal4 line). After crossing the
APPGal4 line to a UAS-reporter mouse line, the spatiotemporal pattern of
transcriptional activity of AICD in the mouse brain can be analyzed. Using
immunocytochemical analysis of primary neurons, I validate the functionality
of the APPGal4 mice. In this course, I also underline nuclear signaling and the
transcriptional activity of AICD experimentally.
v
Zusammenfassung
Die Alzheimer-Krankheit ist eine degenerative Erkrankung des Gehirns und
die häufigste Ursache für die Entwicklung von Demenz. Gegenwärtig gibt es
keine Behandlungsmöglichkeiten welche die kognitive Verschlechterung der
Betroffenen eindämmen oder gar aufhalten. Um eine bessere Diagnose und
neue Behandlungswege zu entwickeln, ist es unerlässlich, ein besseres Ver-
ständnis des pathologischen Mechanismus der Krankheit zu bekommen. Eine
zentrale Rolle in der Pathologie der Alzheimer-Krankheit spielt das amyloid
precursor protein (APP). APP ist ein Intermembranprotein, das in mehrere
Peptidfragmente zerteilt wird. Diese beinhalten unter anderem Aβ und die
Intrazellulardomäne AICD (APP intracellular domain). Es wird angenom-
men, dass erhöhte Sekretion und Aggregation von Aβ eine Reihe toxischer
Effekte bedingt, die letztendlich zu der Entwicklung der Alzheimer-Krankheit
führen. AICD hingegen ist ein Regulator von Genexpression, und es wurde
aufgezeigt, dass AICD eine Rolle in der Neurogenese und Apoptose spielt.
Dennoch ist unser Wissen über die Regulierung und Funktion von AICD nur
bruchstückhaft.
Das Ziel dieser Doktorarbeit ist es, ein besseres Verständnis für die Regu-
lierung und Funktion von AICD zu gewinnen. Des Weiteren soll untersucht
werden ob AICD möglicherweise zur Pathologie der Alzheimer-Krankheit
beitragen könnte.
Im ersten Ergebnisteil dieser Doktorarbeit, dies ist Kapitel 3, untersuche
ich die Zellkernlokalisierung der Intrazellulardomänen von APP und der
APP homologen Proteine APLP1 (APP-like protein 1) und APLP2 (APP-like
protein 2). APLP1 und APLP2 werden ähnlich wie APP geschnitten und setzen
ebenfalls Intrazellulardomänen frei. Ich zeige, dass die Intrazellulardomäne
von APLP2 ebenso wie jene von APP, gemeinsammit demAdaptarprotein Fe65
und der Histonacetyltransferase Tip60, kugelförmige nukleare Komplexe bildet
(AFT-Komplexe), von welchen angenommen wird, dass sie transkriptionelle
Funktionen erfüllen. Im Gegensatz zu APP und APLP2 wird die Intrazellular-
domäne von APLP1 nicht in den Kern transportiert, obwohl auch APLP1 an
Fe65 bindet. Des Weiteren zeige ich, dass die Intrazellulardomänen von APP
und APLP1 von dem Proteasom abgebaut werden, und dass die N-terminalen
Aminosäuren der Intrazellulardomänen die Degradationsrate des jeweiligen
Peptids bestimmen. Zusammengenommen deuten diese Resultate darauf hin,
dass das unterschiedlichen Vermögen von APP und seinen homologen Protei-
nen, Kernsignale zu entsenden, durch unterschiedlicheRaten der Prozessierung
und der Degradation bedingt wird. Diese Resultate unterstützen die Idee einer
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gemeinsamen Kernsignalfunktion von APP und APLP2, die nicht in APLP1
vorhanden ist.
Die im Kapitel 3 zum ersten Mal beschriebene Regulierung von AICD durch
das Ubiquitin-Proteasom-System veranlassen mich dazu, diese Regulierung
weitergehend zu analysieren. Daher untersuche ich in Kapitel 4 die proteaso-
male Degradation unterschiedlicher AICD Spezies, die von APP abgespalten
werden und sich in ihrer Länge unterscheiden. Es ist wichtig anzumerken, dass
viele Mutationen die zur Entwicklung der Alzheimer-Krankheit führen auch
zu einer veränderten Produktion von AICD Spezies führen. Dies bedeutet, dass
vermehrt längeres AICD51 produziert wird, wohingegen die Produktion von
kürzerem AICD50 zurückgeht. Ich zeige hier, dass AICD Spezies unterschied-
lich von dem Proteasom degradiert werden. Weitergehende biochemischen
Analysen machen deutlich, dass die Degradation von AICD nicht abhängig
von dessen Ubiquitinierung ist. Diese Resultate zeigen, dass die N-terminalen
Aminosäuren entscheidend für die Degradation sind und deuten darauf hin,
dass ein N-end-rule-ähnlicher Mechanismus für die Degradation von AICD
verantwortlich ist. Des Weiteren präsentiere ich Anhaltspunkte für eine unter-
schiedliche Degradation von AICD durch Alzheimer-Krankheit auslösende
Mutationen. Diese Veränderungen können zu einer veränderten Genregulie-
rung führen und auf diese Weise möglicherweise zum Voranschreiten der
Alzheimer-Krankheit beitragen.
In Kapitel 5 präsentiere ich eine neue transgene Mauslinie, die es erlau-
ben soll, die Funktionen von AICD in vivo zu untersuchen. Die APPGal4
Mauslinie exprimiert APP, das an die DNA-Bindedomäne Gal4 gekoppelt ist.
Nach Verpaarung der APPGal4 Mauslinie mit einer UAS-Reporter Mauslinie
soll das raumzeitliche Muster der transkriptionellen Aktivität von AICD im
Mausgehirn untersucht werden können. Ich zeige hier die Funktionalität der
APPGal4 Mauslinie mit Hilfe von immunozytochemischen Analysen primärer
Neuronen auf. In diesem Zusammenhang bekräftige ich auch experimentell
die Zellkernlokalisierung und transkriptionelle Funktion von AICD.
vii
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1 Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a chronic and progressive degenerative disorder
of the brain. Symptoms of AD are typically impairments of cognitive functions
includingmemory and language deficits in the early stages of the disease. In the
course of the disease further symptoms are observed, such as executive dysfunc-
tion, behavioral disturbances, and psychiatric symptoms, including depression,
together strongly impeding activities of daily living of patients (Alzheimer’s
Association, 2015). As the disease progresses—diagnostic criteria differentiate
three consecutive stages: mild, moderate, and severe disease—activities of
daily living of AD patients become increasingly impaired, thus requiring also a
increasing amount of assistance. At severe stages, full dependence on assistance
is required.
1.1.1 Diagnosis and prevalence of Alzheimer’s disease
To identify the development of AD as early as possible, the International Work
Group (IWG), a working group of twenty-four clinician-researcher led by Bruno
Dubois, has suggested a set of criteria for the diagnosis of AD (Cummings
et al., 2013). In addition to the necessary core diagnostic criterion, which is an
early and significant episodic memory impairment, one or more supportive
features must be met to diagnose probable AD. These supportive features are:
(i) presence of medial temporal lobe atrophy, (ii) abnormal cerebrospinal fluid
biomarkers including but not restricted to Aβ and tau, (iii) a specific pattern in
functional neuroimaging with PET such as glucose metabolism and amyloid
imaging, and (iv) proven AD autosomal-dominant mutations. However, a
definitive diagnosis of the disease can still only be made post-mortem.
Besides the emotional burden for patients and relatives, AD equally is a
financial burden to caregivers and the healthcare system. As of 2012, worldwide
prevalence is estimated to be as high as twenty-four million people (Mayeux
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and Stern, 2012).1 More than 5% of people aged sixty-five years or older are
suffering from AD, and the prevalence rises with age, thus affecting nearly one
forth of the people aged ninety years or older (Bachman et al., 1992). The latest
World Alzheimer report on the global economic impact of AD estimated global
cost of AD and other dementias to be approximately US$ 600 billion annually
(Wimo and Prince, 2010). The increase in world population accompanied
by global population aging is expected to lead to a dramatic increase in AD
incidences and related costs in the future. Therefore, it is alarming that currently
no treatment for AD is available. Available medications are only symptomatic
but do not halt or at least slow disease progression (Broadstock et al., 2014).
Over the last decade, multiple compounds have failed in clinical studies because
of unacceptable safety profile or lack of beneficial effects (Karran et al., 2011;
Doody et al., 2013). A current clinical study of a new compound has shown to
be beneficial and thus raised hopes for a treatment within reach.2 Nevertheless,
it is clear that for both, better diagnosis and treatment, a clear understanding
of the disease mechanism is required.
1.1.2 Neuropathology of Alzheimer’s disease
Cerebral atrophy accompanied by dilation of the lateral ventricles is the charac-
teristic macroscopic abnormality observed in the brains of AD patients (Mott
and Hulette, 2005). Loss of brain volume due to neuronal loss predominantly
takes place in brain regions responsible for memory functions and thus re-
flects the clinical symptoms observed. Earliest degeneration is observed in
the entorhinal cortex, a region critical for the formation of new memories
(Tapiola et al., 2008). As the disease progresses, atrophy in other brain regions,
such as hippocampus and cortex, is observed (Perl, 2010). The two cardinal
histopathological feature of AD visible in microscopic inspection are extracellu-
lar neuritic plaques and neurofibrillary tangles (NFTs). Neuritic plaques—also
called senile or amyloid plaques—are protein deposits predominantly com-
posed of aggregated form of amyloid-β (Aβ). Aβ develops a β-pleated sheet
conformation in plaques, which is then typically extending to reach a size of
10–160µm. Amyloid plaques are found in most of the neocortex but, inter-
estingly, entorhinal cortex and hippocampus are relatively spared (Braak and
1 A report of the Alzheimer’s Association estimated that currently (i.e. 2015) approximately
5.3 million people live with AD in the USA (Alzheimer’s Association, 2015). More recent
estimates of global prevalence are not available.
2 Results of the clinical phase 1b study of BIIB37 were presented by Jeffrey Sevigny at the 12th
International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological
Disorders (AD/PD) held in Nice, France (March 18–22, 2015).
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Braak, 1997). NFTs are predominantly composed of paired helical filaments of
hyperphosphorylated forms of the microtubule-associated protein tau. NFTs
are mainly observed in the entorhinal cortex, hippocampus, amygdala, and
neocortex (Perl, 2010).
1.1.3 Genetic disposition and risk factors for Alzheimer’s disease
Thegreatest risk factor for developingAD is aging. However, ourunderstanding
what aging (and healthy aging) means in a complex biological system and how
this influences the development of AD remains fragmentary—and moreover
no cure for aging was found (Fontana et al., 2014). Nevertheless, aging alone is
not sufficient to cause AD and different factors predispose for the development
of AD.
Approximately 300 autosomal-dominant mutations are known that cause
AD, which is thus also referred to as autosomal-dominant Alzheimer’s disease
(ADAD; Bateman et al., 2011). All described mutations are restricted to the
coding regions of three genes, which encode the amyloid precursor protein
(APP), presenilin 1 (PSEN1), and presenilin 2 (PSEN2), commonly referred to as
familialAlzheimer’s disease (FAD)mutations.3 APP, as indicatedby thename, is
the precursor protein of Aβ, whereas later is derived from former by proteolytic
processing. PSEN1 and PSEN2 are aspartic proteases and are the catalytic core
of proteolytic-active γ-secretase complexes—shortly referred to as γ-secretase.
γ-secretase is a major secretase for regulated intramembrane proteolysis (RIP)
and, importantly, responsible for the final cleavage of APP, resulting in the
release of Aβ. FADmutations are characterized by a predominantly early onset
of AD symptoms, generally between the age of thirty and fifty years.4 However,
it should be noted that autosomal-dominant mutations are described that have
a mean late onset, and the mean age-of-onset of a mutation even within a
given family can vary considerably (Ryman et al., 2014). Autosomal-dominant
mutations causing AD are rare, and it is estimated that ADAD accounts for
less than 1% of all AD cases (Bateman et al., 2011).
The vast majority of AD (i.e., > 99%) is not caused by autosomal-dominant
mutations. Both genetic and environmental risk-factors have been identified
3 The term FAD mutations will be used for autosomal-dominant mutations in APP and the
presenilins. However, it should be noted, as pointed out by Bateman et al. (2011), that FAD
may also be caused by other means than autosomal-dominant mutations as for example the
4 allele of ApoE.
4 Early onset of AD is generally defined as appearance of symptoms before the age of sixty-five.
Correspondingly, appearance of disease symptoms in people of age sixty-five and older is
described as late onset. Accordingly, the terms early-onset AD (EOAD) and late-onset AD
(LOAD) are used.
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that are causative for these cases of AD. The 4 allele of the apolipoprotein
E (ApoE) gene is the strongest identified genetic risk factor and also the most
repeatedly confirmed one. Heterozygous and homozygous carriers of the 4
allele have a three- and twelve-fold, respectively, increased risk to develop
AD compared to 3 allele carriers. However, mechanistically, the role of the
ApoE protein remains enigmatic. Besides the 4 allele of ApoE, large cohort
genome-wide association studies (GWAS) have identified over three dozen
potential susceptibility loci for AD (Bertram, 2011). However, the risk conferred
by these susceptibility loci is small, and consistent replication of these results
is missing (Bertram and Tanzi, 2009).5 In contrast to mutations in APP and the
presenilins, genetic risk factors, including the ApoE 4 variant, only increase
the risk to develop the disease but are not sufficient to cause it. Other causes
that have been reported to increase the risk for AD include environmental
factors (e.g., exposure to toxins such as DDT), vascular risk factors, diabetes,
and cholesterol levels (Alzheimer’s Association, 2014). Similar to the identified
genetic risk factors, the list of environmental risk factors is long (and growing)
but the conferred susceptibility not high.
Together, our current knowledge suggests that non-ADAD is caused by a
combination of multiple genetical and environmental factors that individually
have only a small risk but mutually act towards AD. Thus, it is evident that
general pathological mechanisms must be identified to allow the development
of efficient treatments. Although genetically and etiologically AD appears to
be a dichotomous disease—autosomal-dominant mutations on one hand; a
multitude of risk factors with low susceptibility on the other—phenotypically
and clinically the disease is highly similar, and mostly, except for the age-of-
onset, indistinguishable (Selkoe, 2001). Therefore, ADAD is, despite its low
incidence, a critically important area of study.
1.1.4 The amyloid cascade hypothesis
The observations that Aβ is the main component of amyloid plaques found
in the brains of people suffering from AD, and that mutations in APP and its
processing enzymes result in autosomal-dominant form of AD have led to
the formulation of the amyloid cascade hypothesis (Hardy and Higgins, 1992;
Selkoe, 2001; Hardy and Selkoe, 2002). The amyloid cascade hypothesis states
that a series of events, starting with Aβ, eventually results in the neuronal
degeneration and cognitive decline observed in patients suffering from AD.
Increased levels or altered composition of Aβ oligomers act as trigger for
5 For a regularly updated collection of identified risk factors for AD visit the AlzRisk AD
Epidemiology Database under http://www.alzrisk.org.
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the cascade by exerting its toxicity on synapses. The raised and sustained
inflammatory response, by means of activation of microglia and astrocytes,
leads to a further progressive synaptic and neuritic injury. In the following,
altered neuronal ionic homeostasis sets ground for oxidative injury, which in
turn leads to altered kinase activation. Extensive phosphorylation by kinases
permits unusual fibrilization of tau and formation of NFTs. These events finally
cause a widespread neuritic dysfunction and neuronal cell death, which is
clinically reflected by the cognitive impairments observed in AD.
APP processing and thus formation of Aβ takes place also under normal
conditions (i.e., in healthy people) without observations of cognitive impair-
ments. Therefore, the amyloid cascade hypothesis further states that a relative
increase of longer Aβ42 (i.e., Aβ42-to-Aβ40 ratio), which is more toxic and
prone to aggregation than Aβ40, is believed to trigger the cascade. This is
also in line with the observation that FAD mutations result in an increased
Aβ42-to-Aβ40 ratio. Similarly, AD that is not caused by autosomal-dominant
mutations is believed to be also triggered by a relative increase in Aβ42. In
this respect, it became evident that also other mechanisms than disturbance of
APP processing can results in increased Aβ42-to-Aβ40 ratio, as for example
alteration in Aβmetabolism (e.g., decreased degradation of Aβ42). A plethora
of studies has supported individual parts of the hypothesis, yet it remains still
debated. In particular the role of one of the two cardinal histopathological
features of AD and initial premises of the hypothesis, the Aβ plaques, remains
elusive.
1.2 The amyloid precursor protein APP
1.2.1 Structure and general features of APP
The amyloid precursor protein (APP), as already lined out, is a central protein in
AD, which is also carrying out diverse physiological functions. APP is a type I
transmembrane glycoprotein, with a long ectodomain and a short cytoplasmatic
domain. The complete structure of APP has yet to be identified, but various
distinct folded subdomains in the ectodomain were identified (Müller and
Wild, 2013). The N-terminal E1 domain contains a growth-factor-like domain
(GFLD), copper-binding domain (CuBD), and Kunitz type protease inhibitor
domain (KPI). The more C-terminal, but still extracellular, E2 domain consists
of a coiled-coil dimerization motif. Both E1 and E2 domains were shown to
play a role in dimerization of APP and might thus influence its processing
(Müller and Wild, 2013). APP spans the membrane with a single α-helical
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transmembrane domain (TMD), and unlike the ectodomain, the cytoplasmic
C-terminus does not fold in a particular structure. In humans APP is encoded
by a single gene on chromosome 21q21 (Kang et al., 1987). The eighteen exons
of APP are alternatively spliced into three major isoforms—APP695, APP751,
and APP770.6 APP is ubiquitously expressed with high expression levels in
the brain (Slunt et al., 1994). APP695, which is lacking the KPI domain, is the
predominant isoform expressed in neurons. Upon expression APP matures
through the constitutive secretory pathway to reach the cell surface (Haass
et al., 2012). From the cell surface, APP can be internalized by endocytosis and
transported via the endosomal system back to the cell surface or the trans-Golgi
network. Degradation of APP can take place via the lysosomal pathway. This
complex and manifold trafficking of APP is also closely interconnected with
the processing of APP.
1.2.2 Processing of APP
APP is processed by a series of proteolytic cleavage reactions (see figure 1.1
for a schematic presentation of APP processing; Selkoe, 2001). In the non-
amyloidogenic pathway, APP is cleaved by α-secretase at the cell surface in the
luminal juxtamembrane region, releasing its N-terminal fragment sAPPα into
the extracellular space. The remaining membrane-bound C-terminal fragment
(CTF) C83, subsequently undergoes RIP by the γ-secretase (Lichtenthaler
et al., 2011). This cleavage releases the APP intracellular domain (AICD)
into the cytosol and the p3 peptide. Initial cleavage in the amyloidogenic
pathway is conducted by the β-secretase BACE1. However, unlike α-secretase
cleavage, APP cleavage by BACE1 does not take place at the cell surface, but
requires endocytosis of APP. Furthermore, cleavage by BACE1 takes place more
distant to the membrane than α-secretase cleavage, thus releasing the slightly
shorter sAPPβ. The correspondingly longer CTF C99 then also undergoes
RIP by γ-secretase, releasing AICD into the cytosol and the Aβ peptide. It is
important to note that, because of different localization of non-amyloidogenic
and amyloidogenic processing, cleavage products of the two pathways also
differ in their subcellular localization. This applies in particular to AICD, which
is identical in the two pathways in terms of its primary sequence, but was
shown to exert different functions, likely because of its different localization.
Aβ in turn is released into the lumen of endosomes and can subsequently get
secreted from the cell. Furthermore, Aβ can form multiple aggregated forms,
ranging from dimers to large fibrils, which are part of the amyloid plaques.
6 The sequence of APP695 isoformwill be used as reference for amino acid position throughout
this thesis.
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Interestingly, γ-secretase cleavage of CTFs displays a certain impreciseness,
resulting in the release of Aβ and AICD species of different lengths. For the
different Aβ species it was shown that they posses different toxic potential (e.g.,
Aβ42 is more toxic than Aβ40). In contrast the role of different AICD species
remain enigmatic. It also should be noted that even the general processing
of APP is not completely understood. In this respect, cleavage by a hitherto
unknown enzyme, the η-secretase, was reported recently, which appears to
be involved in a novel, different route of APP processing.7 As yet, it is not
clear how η-secretase processing of APP could influence levels of other APP
fragments or contribute to ADpathology. However, discovery of the η-secretase
clearly emphasizes the complexity of the regulation of APP processing and the
need for further research.
1.2.3 Functions of APP and its cleavage products
In addition to the toxic function of Aβ, multiple and diverse physiological
functions have been discovered for other APP cleavage products and APP itself
(for a comprehensive review of identified APP functions see Zheng and Koo,
2011). In analogy to other type 1 transmembrane proteins such as Notch-1,
APP has been proposed to act as a cell surface receptor. Multiple candidate
ligands for APP have been identified (e.g., Aβ and F-spondin), and downstream
signaling effects of these binding events have been observed, including altered
APP processing and binding of downstream molecules to its cytoplasmatic
domain. APP can form homo- and hetero-dimers in cis as well as in trans.
Particularly, the observed trans-cellular interactions have suggested that APP
can act as an adhesionmolecule and recent work has shown that this interaction
induces presynaptic specialization (Stahl et al., 2014). Multiple studies have
shown a role of sAPPα in synaptotrophic and neuroprotective activities (e.g.,
Mattson et al., 1993). sAPPβ in contrast does not display these functions and
could even act toxic (Nikolaev et al., 2009). Analysis of APP knockout mice also
underlined the diverse functions of APP and its cleavage products. Loss of APP
resulted in various phenotypes in the central and peripheral nervous system.
Most notably, APP knockout mice show behavioral deficits and defects in
long-term potentiation (LTP; Zheng et al., 1995; Seabrook et al., 1999). Altered
spine density was observed in independent studies, although with different
outcomes possibly due to different brain regions that were looked at (Bittner
7 η-secretase processing of APP was presented by Michael Willem at the 12th International
Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
(AD/PD) held in Nice, France (March 18–22, 2015), and is as yet (date of submission of this
thesis) not published.
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et al., 2009; Tyan et al., 2012). Further, APP knockout mice show reduced grip
strength, which is likely due to an altered neuromuscular junction that was
repeatedly reported. For a comprehensive review of APP knockout mice and
their phenotypes see Müller and Zheng (2012).
1.3 The APP intracellular domain AICD
1.3.1 Structure and molecular architecture of AICD
Cleavage of APP by γ-secretase releases its C-terminal domain, also referred
to as APP intracellular domain or AICD.8 AICD is, neither before nor after
release by γ-secretase, adopting a stable configuration or structure. However,
the forty-eight to fifty amino acid long peptide possesses three well-preserved
motifs, which reflect its diverse functions (Müller and Wild, 2013). The most
N-terminal motif is the YxxΦ9 basolateral sorting motif (653YTSI sequence),
which was shown to regulate APP trafficking (Kozik et al., 2010). The second
motif is the PTE motif within the 667VTPEER sequence. Threonine 668
has been established as the major phosphorylation site of APP and affects
processing of APP. Mechanistically, it has been suggested that the prolyl
isomerase Pin1 is catalyzing the cis-trans isomerization of the threonine-proline
peptide bond. Additionally, binding of 14-3-3γ seems to stabilize binding of
other proteins to AICD. The 682YENPTY sequence with a NPxY motif, which
is a described internalization signal for membrane proteins is the best studied
motif of AICD. The YENPTY domain of AICD is a central protein binding site,
which allows binding of adaptor proteins via their phosphotyrosine-binding
(PTB) domain. Multiple interactions with PTB-containing proteins have been
described, including the Fe65, Mint, Dab, and Jip protein families (Muller
et al., 2008). The interaction with the adaptor protein Fe65 has attained special
attention because it might execute multiple functions. Fe65 is a multi-domain
adaptor protein that is predominantly expressed in the brain, and Fe65 and
its family members are essential for brain development (Guenette et al., 2006).
Binding of Fe65 to AICD is thought to results in structural changes in both Fe65
and APP, and might thus result in the observed alterations in APP localization
and processing and exert transcriptional function. Among the binding partners
8 Although C-terminal domain and AICD denote the same part of APP, commonly the term
C-terminal domain is exclusively used for the sequence as long as it is part of APP or CTFs
(i.e., before γ-secretase cleavage) while AICD commonly denotes the cytoplasmatic protein
released after γ-secretase cleavage or the sequence itself.
9 x denotes any residue and Φ denotes large hydrophobic residue according to Aasland et al.
(2002).
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Figure 1.1 Schematic presentation of APP processing, AFT-complex formation, and tran-
scriptional function of AICD. The type 1 transmembrane protein APP is either cleaved by
α-secretase and γ-secretase (non-amyloidogenic pathway) or BACE1 and γ-secretase (amy-
loidogenic pathway). In the non-amyloidogenic pathway that takes place at the membrane,
sAPPα is released and the membrane bound C83 is further cleaved to release p3 and AICD. In
the amyloidogenic pathway that takes place in endosomes, sAPPβ is released and the mem-
brane bound C99 is further cleaved to release Aβ and AICD. AICD can undergo degradation by
the insulin-degrading enzyme (IDE) or form trimeric nuclear complexes with a adaptor protein
(e.g., Fe65, X11α or Jib1) and the histone-acetyltransferase Tip60. These AFT-complexes are
thought to be transcriptionally active and regulate gene expression.
of AICD, binding to Fe65 is also special because the binding surface stretches
along more than the half of the AICD sequence (Radzimanowski et al., 2008).
1.3.2 Functions of AICD
AICD, before and after release by γ-secretase, has been implicated in multiple
functions. Binding of Pat1a to AICD for example regulates localization of APP,
which in turn was suggested to lead to increased amyloidogenic processing
of APP (Kuan et al., 2006). Cao and Sudhof (2001) were the first to show that
AICD forms a multimeric complex with Fe65 and the Tat-interacting protein 60
kDa (Tip60) and, importantly, that these complexes are transcriptionally active
in luciferase-based UAS/Gal4 assays. Tip60 is a histone-acetyltransferase,
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which has been shown to be involved in a variety of signaling pathways
including transcriptional regulation, DNA damage repair, and chromatin
remodeling (Sapountzi et al., 2006; Sun et al., 2010). Tip60 is predominantly
localized in the nucleus, and interaction with AICD-bound Fe65 is believed
to take place via the second PTB domain of Fe65. Multiple studies have
confirmed the formation of multimeric protein complexes containing AICD,
Fe65, and Tip60 (AFT-complexes; von Rotz et al., 2004) and have shown that
AFT-complexes co-localizewithmarkers of active transcription (Konietzko et al.,
2010). See also figure 1.1 for a schematic presentation ofAFT-complex formation
and transcriptional function of AICD. The initial observation that AICD is
transcriptionally active has triggered the identification of AICD-regulated
target genes. To-date approximately thirty genes regulated by AICD have been
identified (for a comprehensive list of AICD-regulated genes see Grimm et al.,
2013). Some of the identified genes are involved in metabolism of APP and
its proteolytic products, such as the β-secretase BACE1, the metalloprotease
neprilysin (MME), which is degrading Aβ, or APP itself (Pardossi-Piquard
et al., 2005; von Rotz et al., 2004). Regulation of these genes is suggesting that
the transcriptional function of AICD is controlling the function of APP and its
proteolytic products by various feedback and feedforward mechanisms that
could also contribute to the progression of AD. Identification of other genes
regulated by AICD, such as the tumor suppressor p53 (TP53), the glycogen
synthase kinase-3β (GSK3β; GSK3B), and the epidermal growth factor receptor
receptor (EGFR) suggest that AICD has also a function in other signaling
pathways as for example apoptosis and cell cycle regulation (Kim et al., 2003;
Alves da Costa et al., 2006; Zhang et al., 2007). Nakayama et al. (2008) for
example corroborated a role of AICD in apoptosis by showing that AICD
expression resulted in increased DNA fragmentation and neuron-specific cell
death. Ma et al. (2008) describe also a role of AICD in neurogenesis, but it
remains unknown whether this is mediated by the transcriptional function
of AICD or by a different mechanism (e.g., inducing structural changes in
Fe65). It should be noted that problems have been reported to confirm the
regulation of individual genes by AICD, which could partially be explained
by usage of different biological systems but might also suggest that AICD
transcriptional activity is itself subject to, yet unknown, regulatory mechanism
(Hebert et al., 2006; Chen and Selkoe, 2007). Although, it is clear that not
all phenotypes reported for APP knockout mice (described above) can be
attributed to AICD (because APP knockout mice lack also all other APP-
derived proteolytic fragments), an important function of AICD in multiple
signaling mechanisms is evident.
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1.3.3 Regulation of AICD levels and functions
AICD levels are, as expected for a transcriptional regulator, very low. Half-
life was suggested to range from less than 5min (Cupers et al., 2001) to
35min (Ring et al., 2007). The fast turnover and its relatively small size
have led to technical difficulties in detecting AICD, resulting in mostly usage
of AICD overexpression or analysis by usage of in vitro assays. Formally,
AICD is generated by proteolytic processing by the non-amyloidogenic and
amyloidogenic pathway. Since APP processing takes mainly place via the non-
amyloidogenic pathway, it is expected that also most AICD is generated from
this pathway. However, ample evidence suggests that only AICD generated in
the amyloidogenic pathway (β-γ-cleavage) is transcriptional active. Goodger
et al. (2009) show that inhibition of β-secretase, but not inhibition of α-secretase,
in HEK cells strongly decreases number of AFT-complex-positive cells. Further,
they show that BACE KO mouse embryonic fibroblasts (MEFs), in contrast to
WT MEFs, fail to produce AFT-complexes. Hoey et al. (2009) similarly show,
using a UAS/Gal4-based luciferase assay, that only inhibition of β-secretase
activity significantly reduced AICD transcriptional activity. Belyaev et al. (2010)
add further functional evidence by showing that regulation of the AICD target-
gene NEP is dependent on β-secretase activity and independent of α-secretase
activity. Deletion of BACE1 in APP-overexpressing mice resulted in decreased
synaptic plasticity as well as performance in learning and memory tasks and
AICD was the only APP-derived fragment that correlated with the changes
(Ma et al., 2007). So far no study has identified differences in AICD generated
from the amyloidogenic and non-amyloidogenic pathways, and we have to
assume that the primary AICD sequence generated from the two pathways
is the same. Therefore, it is assumed that the functional differences of AICD
generated from the two pathways are a result of different sites of generation. In
this respect experimental evidence has suggested that retrograde transported
of APP in signaling endosomes in the amyloidogenic pathways results in
generation of AICD in closer vicinity to the nucleus (Goodger et al., 2009). A
second, though not necessarily independent, possibility is that AICD generated
from the amyloidogenic pathway is stabilized differently. Indeed, data was
presented that AICD is stabilized by Fe65 and that Fe65 shifts APP processing
towards the amyloidogenic pathway, but equally, several reports claiming the
opposite have been published (Kimberly et al., 2001; Kinoshita et al., 2002;
Wiley et al., 2005; Huysseune et al., 2007). Finally, several other PTB-containing
proteins could selectively modulate AICD-mediated gene transactivation in
the APP processing pathways.
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In contrast to productionofAICD, only fewstudies have looked at degradation
of AICD. AICD generated in vitro is degraded, as Aβ, by the insulin degrading
enzyme (IDE), but it remains to be determined whether this degradation takes
also place under physiological conditions (Edbauer et al., 2002; Farris et al.,
2003; Buoso et al., 2012). Conflicting reports have also been published whether
the ubiquitin-proteasome system (UPS) plays a role in AICD degradation
(Cupers et al., 2001; Nunan et al., 2003). However, since both reports have used
AICD peptides of atypical length, our understanding of the role of the UPS
in AICD degradation remains vague. Vingtdeux et al. (2007) also show that
AICD is degraded via the endosomal-lysosomal pathway. Clear evidence exists
for cleavage of AICD by caspases yielding a fragment called C31 (Lu et al.,
2000). However, whether caspase cleavage of AICD takes place before or after
γ-secretase cleavage and, thus, whether it directly contributes to degradation
of transcriptionally active AICD remains to be determined.
1.4 Scope of this thesis
Processing of APP is a central event in the pathology of AD. Understanding
the function of APP and its cleavage products promises to be instrumental
to decipher AD pathology and is essential for efficient and save therapeutics.
In particular, regulation, physiological function, and a possible pathological
contribution of the C-terminal fragment of APP, AICD, remains unclear. There-
fore, the general aim of this thesis is to improve our understanding of AICD
regulation and function.
In the first results part of this thesis, I present differences in the nuclear
signaling capability of the intracellular domains (ICDs) from different APP
family members. Based on these observations, I hypothesize that differences
in the nuclear signaling capability are due to sequence determinants in the
respective ICDs. The specific aim of the experiments presented in the first
results part is, therefore, to unveil possible sequence determinants of nuclear
signaling of AICD. Knowledge of these sequence determinants will allow to
investigate separately APP- and AICD-mediated functions.
The results presented in the first results part of this thesis uncover the
regulation of AICD by the ubiquitin-proteasome system and point towards
an important role of the N-terminus of AICD is this process. Therefore,
I hypothesize that proteasomal degradation of different AICD species is
dependent on the identity of their N-terminal residue. The specific aims of the
experiments in the second results part are (i) to uncover different proteasomal
degradation of AICD species, (ii) to understand the mechanism of proteasomal
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degradation of AICD, and (iii) to evaluate a possible contribution of AICD
species to AD pathology.
The transcriptional function of AICD and its regulation was predominantly
shown in vitro. I hypothesize that AICD also posses transcriptional function in
vivo. The experiments in the third results part aim to explore the regulation
and function of AICD in vivo. To this end, a novel transgenic mouse line is
generated and analyzed.
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2 Material and Methods
In this chapter we give detailed descriptions of the materials and experimental
procedures used in this thesis. Standard buffers and reagents are listed in
table 2.1.
2.1 Molecular methods and reagents
General. Restriction enzymes, antarctic phosphatase, T4 DNA ligase, and
Quick Ligation kit were purchased from NEB and used according to the
manufacturer’s protocol. Oligonucleotides were ordered from Microsynth.
DNA was separated in 1% agarose gels (diluted in TAE and supplemented
with 0.1% ethidium bromide) at 100V. One Shot Top10 competent bacteria
Table 2.1 Buffer and reagent composition.
Name Composition
LB media 10 g/l tryptone, 5 g/l yeast extract, 10 g/l NaCl, pH 7.0
LB agar LB media, 15 g/l agar
Lysis buffers
RIPA 50mM Tris-HCl pH 7.6, 150mM NaCl, 1% NP40, 0.1% SDS,
0.5% sodium deoxycholate, 2mM EDTA, protease inhibitors (Roche)
Modiﬁed RIPA 10mM Tris Hl pH 7.6, 50mM NaCl, 0.25% NP40, 1% Triton X-100,
2mM EDTA, protease inhibitors
Pull-down 150mM KCl, 20mM HEPES pH 7.2, 10mM NaCl, 5% glycerol,
1% Triton X-100, 2mM DTT, 5mM phenanthroline, protease inhibitor
Tail 50mM Tris-HCl pH 8.0, 20mM NaCl, 1% SDS, 1mM EDTA,
20mg/ml proteinkinase K (Sigma-Aldrich)
PBS 140mM NaCl, 2.7mM KCl, 10mM Na2HPO4, 1.8mM KH2PO4, pH 7.4Running buffer 1M Tris-HCl, 1M tricine, 1% SDS
TAE 40mM Tris-acetate, 1mM EDTA, pH 8.0
TBS 50mM Tris-HCl, 150mM NaCl, pH 7.6
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Table 2.2 Standard PCR cycler program.
Temperature Duration Cycles
95 ◦C 2min 1
95 ◦C 30 s  3057 ◦C 30 s72 ◦C 1min/1.000bp72 ◦C 10min 1
(Invitrogen) were used for plasmid transformation by 30 s heat shock at 42 ◦C.
Bacteria were plated on LB agar plates with 100µg/ml ampicillin or 50µg/ml
kanamycin antibiotics depending on the plasmid backbone. Individual colonies
were picked and grown overnight in LB medium with the respective antibiotic.
Mini- and maxi-preparation kits as well as DNA purification and DNA agarose
extraction kits were purchased from Sigma-Aldrich and used according to
the manufacturer’s protocol. For DNA sequencing services from GATC or
Microsynth were used.
PCR-based cloning methods. For PCR-based cloning primer with desired
restriction sites were designed to have a melting temperature of approxi-
mately 59 ◦C of the binding part.1 PCR reaction mixtures were set up in
thin-walled PCR-tubes as following: 10 ng plasmid, 1µl of 10mM dNTP mix,
1µl 10 nmol/ml forward primer, 1µl 10 nmol/ml reverse primer, 5µl of 10X
Pfu polymerase buffer, 1µl of 2.5U PfuTurbo polymerase (Stratagene), filled
with H20 to reach a total volume of 50µl. Thermocycling of PCR reactions
was done according to table 2.2. PCR-driven overlap extension was used to
construct scarless protein-fusion constructs and the instructions in Heckman
and Pease (2007) were followed.
Site-directed mutagenesis. To mutate base-pairs in plasmids site-directed
mutagenesis (SDM) was used. SDM primer containing the desired mutations
were designed that both flanking regions of the mutations have a melting
temperature of approximately 59 ◦C. Reaction mixture as for regular PCR was
set up and applied to thermocycling according to table 2.3. After thermocycling
1µl Dpn1 restriction enzymewas added, mixed gently, and incubated in a 37 ◦C
1 For calculation of oligonucleotide annealing temperatures the Oligo Calc online tool of
the Northwestern University was used, which can be found under http://www.basic.
northwestern.edu/biotools/oligocalc.html.
16
Molecular methods and reagents 2.1
Table 2.3 Site-directed mutagenesis cycler program.
Temperature Duration Cycles
95 ◦C 30 s 1
95 ◦C 30 s  2255 ◦C 1min68 ◦C 1min/1.000bp68 ◦C 7min 1
water bath for one hour. 5µl of reaction mix were used for transformation of
bacteria.
General remarks about used expression constructs. The pUKBK plasmid line,
based on an in-house constructed plasmid backbone previously described
in Kohli et al. (2012), was used for protein expression, unless plasmids from
external sources were obtained—for a graphical representation of the pUKBK
plasmid line see figure A.1 in the appendix. The coding sequence of pUKBK
plasmids is flanked by SfiI and PmeI cleavage sites. A AscI cleavage site is
present in the forty-eight base pair (bp) linker, which allows the C-terminal
attachment of different tags or fluorescence proteins. The promoter region
is preceded by a SspI cleavage site. The modular character of the pUKBK
plasmid line allows simple exchange of regulatory elements and genes by
restriction-based and PCR-based cloning. The following abbreviations are
used for the individual elements in the plasmid nomenclature. Promoters:
C (CMV promoter), G (GAPDH promoter), P (human PGK promoter). Tags:
HA (triple HA-tag), myc (triple myc-tag), SBP (streptavidin-binding protein).
Fluorescence proteins: Cer (cerulean), Cit (citrine).
Plasmids expressing APP, APLPs, and derivatives thereof. Plasmids expressing
C-terminally citrine- and HA-tagged APP (pUKBK-C-APP-Cit, pUKBK-C-APP-
HA) have been described previously (von Rotz et al., 2004). pUKBK-G-myc-
APP-HA was constructed by inserting a myc-tag coding oligonucleotide after
the APP signal peptide (SP) by restriction based cloning. Cerulean- and
SBP-tagged plasmids (APP-Cer, APP-SBP) were obtained by restriction-based
exchange of citrine. To find sequence determinants of nuclear signaling of
APP, APP residues were exchanged to corresponding APLP1 residues (APP-
to-APLP1 mutations) by SDM or PCR-driven overlap extension. Citrine- and
HA-tagged chimeric APP/APLP1 constructs, APP-AL1ICD and APLP1-AICD
were derived fromAPP andAPLP1 constructs by PCR-driven overlap extension.
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Lysine-to-arginine exchange and introduction of FAD mutations in APP was
achieved by SDM. Plasmids containing APLP1 (purchased from RZPD) and
APLP2 (obtained from Stefan Kins, TU Kaiserslautern) were used to amplify
open reading frames and ICDs and cloned into the pUKBK expression vector
system (pUKBK-C-APLP1-Cit, pUKBK-C-APLP2). N-terminally myc-tagged
APLP1 and APLP2 constructs were obtained by replacing APP in pUKBK-G-
myc-APP-HA with APLP1 and APLP2 by restriction-based cloning. Cerulean-
and HA-tagged plasmids (APLP1-Cer, APLP2-Cer, APLP1-HA, APLP2-HA)
were obtained by restriction-based exchange of citrine. For the constructs
Cit-AICD, Cit-AL1ICD, Cit-AL2ICD, and Cer-AL2ICD fluorescence proteins
were fused to the N-terminus of the respective ICD sequence by PCR-based
cloning. AICD-Cit was cloned by PCR-driven overlap extension.
Fe65 and Tip60 plasmids. HA-Fe65 and CFP-Tip60 expressing constructs have
been described previously (von Rotz et al., 2004). To generate myc-Tip60, CFP
was exchanged with a myc-tag by restriction-based cloning.
Ubiquitin-expressing and ubiquitin-fusion plasmids. The ubiquitin-fusion (Ub-
fusion) construct Ub-R-GFP was purchased from Addgene (ID11939; Dantuma
et al., 2000). Ha-taggedUb-fusion constructs ofAICD50 andAICD51 (pUKBK-C-
Ub-AICD50-HA, pUKBK-C-Ub-AICD51-HA) were constructed by PCR-driven
overlap extension. These constructs were used to create EGFP-Ub-fusion
constructs (pUKBK-C-EGFP-Ub-AICD50-HA, pUKBK-C-EGFP-Ub-AICD51-
HA), in turn used for construction of lentivirus plasmids. A plasmid encoding
N-terminally HA-tagged ubiquitin (p-HA-Ub) was obtained from Michael
Potente (Goethe University; Guarani et al., 2011).
β-galactosidase assay related constructs. A plasmid expressing APP contain-
ing the Gal4-DBD (DNA binding domain) within its C-terminal domain
(p-APPGal4) was obtained from Thomas Südhof (Stanford University) and was
described in Cao and Sudhof (2001). A plasmid containing four upstream acti-
vating sequence (UAS) elements upstream of lacZwas used for β-galactosidase
assays. A plasmids containing lacZ under the control of the CMV-promoter
(p-C-lacZ) was obtained from Deniz Gökbuget and Uli Suter (ETH Zurich).
By fusing UAS repeats to the N-terminus of a citrine-containing plasmid, the
p-UAS-Cit was obtained. Plasmids expressing only Gal4-DBD, Gal4-DBD fused
to Gal4-AcD (activation domain), and Gal4-DBD fused to VP16 were obtained
fromWalter Schaffner (University Zurich).
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Lentivirus plasmids. pSicoR-C-MCS, described in Huber et al. (2013), and
pCCL-P-EGFP, described in Cusimano et al. (2012), lentivirus plasmids were
obtained from Uli Suter (ETH Zurich). EGFP-Ub-fusion constructs of AICD
species (pSicoR-C-EGFP-Ub-AICD50-HA and pSicoR-C-EGFP-Ub-AICD51-
HA) were obtained by PCR-based cloning into the MCS of pSicoR-C-MCS. By
replacing EGFP in pCCL-P-EGFP with a Ub-fusion construct of AICD51 using
PCR-based cloning, pCCL-P-Ub-AICD51-HA was obtained.
2.2 Cell culture methods and reagents
Cells. Human embryonic kidney (HEK-293, HEK), HEK293-T, and mouse neu-
roblastoma N2a (N2a) cells were purchased from DSMZ (Deutsche Sammlung
von Mikroorganismen und Zellkulturen). UBR1−/− UBR2−/− (abbreviated to
UBR1/2 dKO) mouse embryonic fibroblasts (MEFs) were received from Yong
Tae Kwon (University of Pittsburgh) and have been described in Tasaki et al.
(2005). Wildtype MEFs were received from Bart De Strooper (University of
Leuven). Cells were cultured at 37 ◦C and 5% CO2 in DMEM (Dulbecco’s mod-
ified eagle medium; Invitrogen) supplemented with 10% FCS (Gibco) and 1%
penicillin/streptomycin (Invitrogen). For maintenance of cells, confluent cells
were washed with PBS (Gibco) detached and dissociated with trypsin/EDTA
(Gibco) and plated at a dilution of 1:10. For experiments antibiotic-free media
were used. Plastic dishes were coated with poly-D-lysine (Sigma-Aldrich)
for experiments with HEK cells. Glass specimen slides were coated with
poly-ornithine and fibronectin (both Sigma-Aldrich).
Generation of stable cell lines. The HEK(UAS-Cit) stable cell line was created
by antibiotic resistance–mediated selection. The UAS-Cit plasmid, carrying a
hygromcin-resistance gene, was transfected into HEK cells (see below for trans-
fection method used). One day after transfection, hygromycin B (300µg/ml;
Sigma-Aldrich) was supplemented to media and media changed every second
day. After approximately twenty days, selection pressure was removed and the
mixed culture tested for harboring the construct by immunhistochemistry (see
results). HEK cells stably expressing HA-tagged EGFP-Ub-fusion constructs
of AICD50 and AICD51 (HEK(Ub-AICD50-HA) and HEK(Ub-AICD51-HA))
were generated by lentivirus-mediated genome-integration (see below for
virus production). HEK cells were infected by adding virus-containing media
(low-titer virus). Efficiency of integration was similar in both cell lines as
evaluated by EGFP fluorescence intensity. Cell media was replaced six hours
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after infection and cells passaged at least four times before considered to have
stably integrated the virus.
Preparation of primary neurons. Primary neuronal cultures were prepared
from one-day-old mice as described in Goodger et al. (2009). Briefly, newborn
mice were sacrificed and brains removed. Cortices and hippocampi were
dissected and cells dissolved mechanically and by enzymatic digestion with
papain (Worthington). Cells were counted and plated at a concentration of
54 × 103 cells/cm2 in laminin- (Invitrogen) andpoly-D-lysine-coated cell culture
dishes with DMEM supplemented with 10% horse serum (Invitrogen). Three
hours after plating, media were changed to Neurobasal-A (Gibco) medium
supplemented with Glutamax (Gibco), sodium pyruvate (sodium pyruvate),
and B27 (Invitrogen). Media were changed every three to four days and cells
analyzed after ten to fourteen days in vitro (DIV).
Delivery of plasmids and virus infection. For transfection Lipofectamine 2000
(Invitrogen) was used according to the manufacturer’s protocol. Medium
was replaced three hours after transfection and cells fixed or homogenized
twenty to twenty-four hours after transfection if not indicated differently. For
virus infection with low-titer virus 50% of cell media was replaced by virus-
containing media pre-warmed to 37 ◦C. High-titer viruses were first mixed
with pre-warmed media and then added to cells.
siRNA-mediated knockdown. siRNAs were delivered using Lipofectamine
RNAiMAX transfection reagent (Invitrogen) according to the manufacturer’s
protocol. Three siRNAs recognizing different regions of the same mRNA target
were used with final concentration of 10 nM. As control, two negative control
siRNAs were used to match the concentration of target siRNAs. The following
siRNAs were used (all purchased from Life Technologies): UBA1 (catalogue
numbers: 4427038-s599, 4427038-s600, 4427038-s601), UBA6 (catalogue num-
bers: 4427037-s30515, 4427037-s30516, 4427037-s30517), and negative control
(catalogue numbers: 4390843, 4390846).
Pharmacological reagents. See table 2.4 for a list of pharmacological com-
pounds used for cell culture experiments in this study. All compounds were
diluted in DMSO (Sigma-Aldrich) to stock concentration and DMSO was used
as control treatment.
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Table 2.4 Pharmacological compounds used for cell culture experiments.
Reagent Name Supplier (Cat. No.) Concentration Duration
Cycloheximide (CHX) Sigma-Aldrich (66-81-9) 100µg/ml 0.5–4h
DAPT Sigma-Aldrich (D5942) 1µM 24h1
Epoxomicin (EPX) Calbiochem (324801) 1µM1 4h1
MG132 Enzo Life Sciences (BML-PI102R) 1µM1 4h1
PYR41 Sigma-Aldrich (N2915) 27µM 6h
1 If not indicated otherwise.
Live antibody incubation. For analysis of APP/APLP endocytosis live an-
tibody incubation was carried out in HEK cells. Twenty-four hours after
transfection, cells were incubated with myc-tag antibody (1:100, Roche) at 4 ◦C
for 10min or 30min. After washing with ice-cold PBS, cells were fixed and
stained for HA- and myc-tags as described below.
Virus production. Lentiviruses were prepared by transfecting HEK293-T pla-
ted in 15-cm dishes with 33µg transfer vector and helper plasmids (7.7µg
pVSVg. 22µg pDMLG, and 5.5µg pREV) using 25 kDa polyethylenimine
(PEI; Polysciences). Forty-eight hours after transfection supernatants were
transferred to Falcon tubes and centrifuged 15min at 500 rcf and 4 ◦C to remove
cellular debris. Virus containing media was either aliquoted and stored at
−80 ◦C for direct usage (low-titer virus) or applied to virus concentration. For
virus concentration, virus-containing media was centrifuged at 25.000 rpm for
2.5 h at 4 ◦C using a Beckman ultracentrifuge with 70Ti rotor. Supernatant
was discarded and the pellet resuspended in 200µl PBS. High-titer containing
solution was aliquoted, frozen using liquid nitrogen, and stored at −80 ◦C until
usage.
2.3 Animals and related methods
All animal experiments were performed according to the Swiss animal pro-
tection law (TschG) and approved by the local animal committee (Kantonales
Veterinäramt Zürich). Genotyping of mice was done by PCR on DNA extracted
from mouse tail tissue with the primers listed in table 2.6. 20µl tail lysis buffer
(table 2.1) were added to tails and incubated 30min in a 55 ◦C heat block at
maximal agitation. After addition of 200µl H2O the suspension was incubated
12min in a 95 ◦C heat block at maximal agitation. Suspension was stored at
−20 ◦C and centrifuged 5min at 14.000 rcf before usage for genotype PCR. PCR
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Table 2.5 PCR cycler program for genotyping.
Temperature Duration Cycles
95 ◦C 2min 1
94 ◦C 30 sec  3055 ◦C for APPGal4 & ArcAβ; 64 ◦C for UAS-lacZ 30 sec72 ◦C 50 sec72 ◦C 7min 1
reaction mixtures were set up in thin-walled PCR-tubes as following: 1µl
genomic DNA from lysed tails, 0.4µl of 10mM dNTP mix, 0.4µl 10 nmol/ml
forward primer, 0.4µl 10 nmol/ml reverse primer, 2µl of 10X RedTaq poly-
merase buffer, 1µl of 1U RedTaq polymerase (Sigma-Aldrich), filled with H20
to reach a total volume of 20µl. Thermocycling of PCR reactions was done
according to table 2.5.
Generation of APPGal4 transgenic mice. For generation of the APPGal4 trans-
genic mouse line a APP-Gal4 fusion protein was used, which was originally
generated by Cao and Sudhof (2001) and characterized in in vitro experiments.
The APP-Gal4 fusion protein is composed of the extracellular and transmem-
brane region of APP (APP residues 1–651), followed by a six amino acid long
linker, the 147 amino acid long Gal4-DBD (Gal4 residues 1–147), a nine amino
acid long linker, and the remainder of the cytoplasmatic region of APP (APP
residues 652–695). The coding sequence of the APP-Gal4 fusion protein was
cloned into the pMoPrp plasmid, which is carrying a prion protein promoter
(PrP) for protein expression, and which was previously used for the generation
the ArcAβ transgenic mouse line (Knobloch et al., 2007). This construct was
used by the Institut für Labortierkunde (University Zurich) for generation of
APPGal4 transgenic mice by embryo transfer. Three different founder lines
were provided and probed for transgene expression by western blotting with
an antibody recognizing exclusively human APP (6E10). The founder line with
highest transgene expression was chosen for subsequent experiments. Mice
were backcrossed to C57BL/6J background.
Other mouse strains used. UAS-lacZmice, originally generated by Govindara-
jan et al. (2005), were obtained from Freddy Radtke (EPFL; Smith et al., 2012).
The construct used for generation of these mice contains six tandem copies of
the UAS element linked to a minimal thymidine kinase promoter and followed
by the lacZ gene encoding β-galactosidase (see table 2.6 for genotyping primer.
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Table 2.6 Genotyping primer.
Genotype Primer
APPGal4/ArcAβ 5’-CAGAACTGAACCATTTCAACCGAGC-3’
5’-TCAGTGGGTACCTCCAGCGCCCGAG-3’
UAS-lacZ 5’-ATCCTCTGCATGGTCAGGTC-3’
5’-CGTGGCCTGATTCATTCC-3’
C57Bl/6J mice, used for preparation of primary neurons, were purchased
from The Jackson Laboratory. The ArcAβ mouse line was generated in our
laboratory, and mice were genotyped with the same primer and thermocycling
program as APPGal4 mice (Knobloch et al., 2007).
2.4 Biochemical methods and reagents
Generation of protein lysates. For generation of protein samples, cells were
washedwith ice-cold PBS and scraped in RIPAormodifiedRIPA lysis buffer (see
table 2.1 for lysis buffer composition). For detection of ubiquitinated proteins
RIPA was supplemented with MG132 (5µM) and NEM (N-ethylmaleimide;
20mM; Sigma-Aldrich)—in the following denoted RIPA-Ub—to prevent protea-
somal degradation and deubiquitination, respectively. Samples were incubated
15min on a rotating wheel at 4 ◦C followed by 5min centrifugation at 22.000 rcf
and 4 ◦C to remove cellular debris. Supernatants were transferred to fresh
Eppendorf tubes and stored at −80 ◦C until usage.
Western blotting. For western blotting the Novex NuPAGE SDS-PAGE gel
system (Invitrogen) was used. Protein samples were mixed with loading buffer
(NuPAGE LDS sample buffer (Invitogen) and 5% β-mercaptoethanol) and
placed in a 99 ◦C heating block for 5min. Equal amounts of supernatants
were separated on 10–20% Tricine gels (Invitrogen), if not stated otherwise
(see table 2.1 for running buffer composition). Protein separation was done at
100V for approximately 90min. SeeBlue Plus2 Pre-Stained protein standard
(Invitrogen) was used as a molecular weight marker. Proteins were transferred
to nitrocellulose transfer membranes (pore size 0.1µm; Protran) by semi-dry
blotting with 2X Tris-Glycine Transfer Buffer (Invitrogen) supplemented with
10% methanol. Membranes were blocked for one hour at RT with 5% skim
milk diluted in PBS and then washed with PBS. Membranes were incubated
overnight at 4 ◦Cwith primary antibodies dissolved in PBS—for a list of primary
and secondary antibodies used for western blotting see table 2.7. The next
23
2 Material and Methods
day, membranes were washed, incubated with secondary antibody diluted in
blocking buffer.
To increase detection of HA-tagged AICD (derived from full-length APP
and Ub-fusion constructs) in western blots with HA-tag antibody a protocol
described in Pimplikar and Suryanarayana (2011) was followed. After transfer
membranes were dried for approximately half an hour and then incubated
with boiling PBS for 5min. Washing of membranes was done with TBS
supplemented with 0.1% Tween 20 (TBST) and blocking with 10% FCS in
TBST. HA-tag antibody was used at a concentration of 1:250 and secondary
antibody was diluted in FCS-based blocking buffer. To increase detection of
Aβ in western blots a protocol described in Shankar et al. (2011) was followed.
After transfer membranes were boiled in PBS in a microwave at 800W for 5min
and let then stand for additional 5min in the hot PBS. Membranes were washed
in TBS. Synthetic Aβ42 was purchased from American Peptide.
Protein bands were visualized by ECL (Thermo Scientific) using a LAS 3000
(Fuji) or LAS 4000 (GE Healthcare) imager, both equipped with Fuji CCD
cameras. Quantification of protein bands was done by densitometric analysis
using Multi Gauge (Fuji) or ImageQuant (GE Healthcare) software. Proteins
levels were normalized to α-tubulin levels and expressed in arbitrary unit (AU),
unless otherwise stated. Biological replicates loaded to separate western blots
were normalized by the sum of the replicates as outlined by Degasperi et al.
(2014). Statistical analysis was done with Prism 6 (GraphPad) and the used
statistical tests are indicated in the respective experiments.
Dynabeads-streptavidin pull-down. Pull-down of proteins fused to strepta-
vidin-binding protein (SBP) was done as described previously (Kohli et al.,
2012). Cells, transfected with APP-SBP and HA-Fe65, were lysed in pull-down
lysis buffer and centrifuged for 10min at 800 rcf (see table 2.1 for lysis buffer
composition). Supernatant was incubated with dynabeads-streptavidin M280
(Invitrogen) for four hours at 4 ◦C. Beads were separated with a magnet and
washed four times with homogenization buffer. For protein elution, beads were
incubated with a buffer containing 700 nmol biotin for 30min at 4 ◦C. Equal
amounts of protein elution were loaded on 10–20% Tricine gels and processed
as described above.
Immunoprecipitation. For immunoprecipitation of AICD and detection of its
ubiquitination the Dynabeads Protein A Immunoprecipitation kit (Invitrogen)
was used according to the manufacturer’s protocol. For antibody-to-dynabeads
binding, 50µl dynabeads were transferred to a fresh tube and supernatant
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Table 2.7 Antibodies used in this study for western blotting.
Protein/Epitope Supplier (Cat. No.) Host Dilution
Primary antibodies
AICDneo (AICD50 neo-epitope) non-commercial1 rabbit 1:1000
AICD non-commercial2 guinea pig 1:1000
APP, C-terminal Epitomics (1565-1) rabbit 1:1000
human APP, Aβ-region (6E10) Covance (39320) mouse 1:500
c-jun Santa Cruz Biotechnology (1694) rabbit 1:1000
c-myc (myc-tag) Roche (11667149001) mouse 1:1000
GAPDH Meridian Life Science (H86504M) mouse 1:2000
GFP and derivatives (e.g., citrine) Roche (11814460001) mouse 1:1000
HA-tag Roche (11867432001) rat 1:1000
α-tubulin Sigma-Aldrich (T-9026) mouse 1:1000
Ubiquitin DAKO (Z0458) rat 1:1000
UBA1 Bethyl (A301-126A) rabbit 1:1000
UBA6 non-commercial3 rabbit 1:1000
Secondary antibodies 4
mouse IgG GE Healthcare (NA931V) sheep 1:2000
guinea pic IgG Jackson (106-035-003) goat 1:2000
rabbit IgG GE Healthcare (NA934V) donkey 1:2000
rat IgG GE Healthcare (NA935V) goat 1:2000
1 AICDneo antibody was obtained from Patrick May (Eli Lilly) and has been described in Chávez-
Gutiérrez et al. (2012).
2 AICD antibody was raised against a peptide corresponding to the fourteen N-terminal amino
acids of AICD by the Institut für Labortierkunde (University Zurich).
3 UBA6 antibody was obtained from Wade Harper (Harvard University) and has been described
in Jin et al. (2007).
4 All secondary antibodies used in western blot are coupled to horseradish peroxidase (HRP).
removed by retaining beads with a magnet. Antibodies, diluted 1:50 in 200µl
AB Binding &Washing Buffer (PBS with 0.01% Tween 20), were added to beads
and incubated for 10min at RT. Unbound antibody was discarded by removal
of the supernatant and beads washed with AB Binding & Washing Buffer. Cell
lysates harvested in RIPA-Ub buffer were added to the antibody-bead-complex,
and incubated for one and a half hours at RT. Unbound protein in supernatant
was then removed and beads washed three times with washing buffer provided
by the kit. Beads were transferred to fresh tubes and eluted with elution buffer
(provided by the kit and supplemented with NuPAGE LDS sample buffer
and 5% β-mercaptoethanol) for 10min in a 99 ◦C heat block under maximal
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Table 2.8 Primary antibodies used for immunocyto- and immunohistochemistry.
Protein/Epitope Supplier (Cat. No.) Host Dilution
β-galactosidase Abcam (ab9361) ckicken 1:100
c-myc (myc-tag) Roche (11667149001) mouse 1:100
GFP and derivatives (e.g., citrine) Invitrogen (A11122) rabbit 1:100
HA-tag Roche (11867432001) rat 1:100
agitation. Eluates were loaded directly on SDS-PAGE or stored at −80 ◦C until
further usage.
Immunocytochemistry. Cells were fixed for 20min with 4% paraformalde-
hyde (PFA), washed with TBS containing 0.05% Triton X-100 and blocked for
one hour with TBS containing 0.2% Triton X-100, 5% horse serum, and 5% goat
serum. Fixed cells were incubated overnight with primary antibodies (table 2.8)
diluted in blocking solution at 4 ◦C. Cells were washed and incubated one to
two hours with secondary antibodies (table 2.9) diluted in blocking solution
at room temperature (RT). After subsequent washing, cells were embedded
in Mowiol (Sigma-Aldrich) supplemented with Dabco (Sigma-Aldrich) to de-
crease bleaching. To stain DNA DAPI was added to washing solution in some
experiments as indicated. Stained cells were analyzed by confocal microscopy.
β-galactosidase assay. The lacZ gene, encoding the enzymeβ-galactosidase, is
a reporter gene used to visualize and quantify transcriptional activity. Presence
of β-galactosidase is visualized by cleavage of the synthetic substrate X-Gal,
which is yielding a blue and insoluble product (5,5’-dibromo-4,4’-dichloro-
indigo). Staining of cultured cells for β-galactosidase was done with the
β-Gal Staining kit (Invitrogen) according to the manufacturer’s protocol. Cells
grown on coverslips were washed with PBS and fixed with fixative solution
for 10min at RT. After washing staining solution (containing 2mg/ml X-Gal
substrate ) was added to cover the cell and incubated one to two hours at 37 ◦C.
Cells were then washed and embedded in Mowiol. Quantification of HEK
cells and primary neurons stained for β-galactosidase was done manually.
Semiquantitative categories were chosen to classify reporter activity. These
categories were: no ( 0) , low (< 10), medium (≥ 10 and < 100), and high (≥
100 β-galactosidase-positive cells per coverslip). β-galactosidase-positive cells
were counted by two researchers independently and blinded.
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Table 2.9 Secondary antibodies used for immunocyto- and immunohistochemistry.
Epitope Fluorophore Supplier (Cat. No.) Host Dilution
chicken IgG Cy3 Jackson (703-165-155) donkey 1:250
mouse IgG Cy3 Jackson (715-165-151) donkey 1:250
mouse IgG Cy5 Jackson (715-175-150) donkey 1:250
rat IgG Cy2 Jackson (712-225-153) donkey 1:250
rat IgG Cy3 Jackson (711-165-153) donkey 1:250
rat IgG Cy5 Jackson (712-175-153) donkey 1:250
rabbit IgG Alexa 488 Life Technologies (A11008) goat 1:250
Cytotoxicity assay. For analysis of cytotoxicity of proteasomal inhibitor, release
of lactate dehydrogenase (LDH) was measured with the Cytotoxicity Detection
kit (Roche) according the manufacturer’s protocol. Cells were washed with
PBS twice prior to addition of proteasomal inhibitor–containing media. Care
was taken that equal amount of media was added to the cells. At the end of
treatment, cell media was transferred to Eppendorf tubes and centrifuged 4min
at 400 rcf and 4 ◦C to remove cellular debris. LDH standards were prepared
in fresh media. 75µl media sample and standard were pipetted to individual
wells of a 96-well plate and 75µl LDH Mastermix added and gently mixed.
After approximately one hour incubation in the dark at RT, absorbance was
measured with a Tecan workstation at 490 nm. Media from Triton X-100 lysed
cells was used as 100% cytotoxicity. Media from DMSO control-treated cells
was set as zero toxicity.
Immunohistochemistry. Immunohistochemical preparation and analysis was
done as described previously (Ferretti et al., 2012). Adult APPGal4/UAS-lacZ
and APPGal4 mice were deeply anesthetized with ketamine/xylazine and
perfused transcardiallywith PBS for approximately 2min. Brainswere removed
and fixed in 4% PFA for twenty-four hours at 4 ◦C, followed by incubation
in 30% sucrose for approximately twenty-four hours at 4 ◦C. Fixed brains
were cut coronally into 40µm thick sections with a freezing sledge microtome
(Microm HM 450, Thermo Scientific) at working temperature of approximately
−20 ◦C. Free-floating sections were washed and permeabilized using PBS-T
(PBS supplemented with 0.2% Triton X-100) and blocked for one hour at RT
with blocking buffer (5% goat serum, 5% donkey serum, 0.2% Triton X-100
in PBS). Sections were incubated overnight at 4 ◦C with anti-β-galactosidase
antibody (Abcam) diluted 1:500 in blocking buffer. The next day, sections were
washed and incubated for two hours in secondary antibody (Cy3-coupled anti-
chicken-IgG; Jackson) diluted 1:200 in blocking buffer at RT. Prior to mounting
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with Hydromount (National Diagnostics), sections were washed and nuclei
stained with DAPI. Analysis was done using a Leica DM 4000 B fluorescence
microscope.
2.5 Microscopy and image analysis
Fluorescence microscopy. Fluorescence, brightfield, and differential interfer-
ence contrast (DIC) images were acquired on inverted DM IRE 2, DM 4000 B,
SP2, and SP8 microscopes (all Leica). For confocal images of AFT-complexes,
SP2 or SP8 confocal microscope with a 63X water or glycerol immersion objec-
tives were used. The 458-nm and 514-nm lines of the argon laser were used to
excite CFP and citrine, respectively. For detection of CFP PMT (photomultiplier
tube) windowwas set to 465–485 nm, for citrine to 525–545 nm. For excitation of
Cy3 the 543-nm laser was used and detected in PMTwindow set to 553–600 nm.
DAPI was excited at 405 nm and detected at a PMT window set to 410–430 nm.
Approximately ten images were acquired in z-axis and subjected to maximum
projection.
FRET measurements. FRET (Förster resonance energy transfer) was used to
analyze APP/APLP co-localization and dimerization. For FRETmeasurements,
cerulean was excited with the 458-nm laser and citrine emission was read at
525–555 nm. Expression of fluorophores individually was used to determine
cerulean bleach-through and citrine cross-excitation signals. Based on rawFRET
values calculation of NFRET was done as described in von Rotz et al. (2004).
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3 Regulation of Nuclear Signaling Capability
of the Amyloid Precursor Protein Family
Members
In this chapter, we investigate nuclear signaling capability of the ICDs from
different APP family members. The majority of the results in this chapter have
been published in Gersbacher et al. (2013).
3.1 Introduction
APP is a member of a highly conserved family of glycoproteins, which includes
APP-like protein 1 (APLP1) and APP-like protein 2 (APLP2) in vertebrates,
APPL in Drosophila, and APL-1 in C. elegans. APP and APLP2 are ubiquitously
expressed, with high expression in the brain (Tanzi et al., 1988; Slunt et al., 1994),
while APLP1 expression is neuron specific (Lorent et al., 1995). Interestingly,
amyloid precursor-like proteins, i.e., APLP1 and APLP2 (APLPs), lack the
Aβ-domain, which is a feature unique to APP (Bayer et al., 1999; Thinakaran
and Koo, 2008). In humans, APLP2 is located on chromosome 11q23–q25
and exists in two alternatively spliced forms, one of which, similarly to APP,
contains a KPI domain (Wasco et al., 1993; Van Nostrand et al., 1994; Bayer et al.,
1999). Human APLP1 is located on chromosome 19q13.1 and, as yet, no spliced
transcripts have been identified (Wasco et al., 1992; Lenkkeri et al., 1998). All
APP family members have been shown to bind zinc and heparin (Bush et al.,
1994) and are thought to play an important role in cell adhesion in homo- and
heterotypic manner (Coulson et al., 2000; Soba et al., 2005).1 Furthermore, all
APP family members interact with PAT1a (protein interacting with APP tail
1a) via their basolateral sorting signal, and this interaction is promoting their
intracellular transport and processing (Kuan et al., 2006).
1 The term APP family members is used in this thesis to denote exclusively the mammalian
members of the APP superfamily which are APP, APLP1, and APLP2.
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Despite the structural homology and conserved domain structure of APP fam-
ily members, it has been shown that their subcellular localization differs strik-
ingly. A recent study byKaden et al. (2009) showed that APP andAPLP2mainly
localize within intracellular compartments, such as ER (endoplasmic reticulum)
and endosomes, while onlyminor levelswere detected at the plasmamembrane.
In contrast, APLP1 was found to mainly localize to the plasma membrane,
corresponding to an increased tendency to form in trans interactions at cell-cell
contacts, highlighting an important role for APLP1 in cell adhesion (Kaden
et al., 2009). Further studies investigating the binding of the APP family to
adaptor proteins have also identified differences between family members. For
example, the binding of JIP1 (JNK interacting protein) to APP has been shown
to result in transcriptional activation, whereas expression of JIP1 with APLP1
or APLP2 showed little or no transcriptional activity (Scheinfeld et al., 2003).
Studies using knockout mice have revealed important insights into the
relationship between different APP family members. Single knockout of APP,
APLP1, or APLP2 cause less pronounced phenotypes, probably due to a
redundancy of certain functions within the APP gene family (Zheng et al.,
1995; von Koch et al., 1997; Heber et al., 2000). However, it is also clear that the
different APP family members exhibit different functions. Mice with disrupted
APP and APLP1 are viable and fertile, while those that are double knockout for
APP and APLP2 or double knockout for APLP1 and APLP2 die shortly after
birth. These findings point to an important developmental role for APLP2,
which is essential when either APP or APLP1 are absent. APP/APLP2 double
knockout mice exhibit a poorly formed neuromuscular junction and reduced
numbers of presynaptic vesicles (Wang et al., 2005), which is in line with
findings from Drosophilawith mutant APPL (Merdes et al., 2004), implicating a
role for the APP family in the regulation of synaptogenesis. Triple knockout
mice, lacking all three APP family members, were found to die soon after birth
and display cortical dysplasia, which resembles human type II lissencephaly,
and is characterized by fragmented basal lamina and over-migration of neurons
(Herms et al., 2004). This phenotype is very similar to the phenotype reported
of Fe65 family knockout mice, highlighting the importance of the AICD-Fe65
interaction in the function of the APP family members (Guenette et al., 2006).
Both APLP1 and APLP2, like APP, are cleaved by α-, β-, and γ-secretase, and
intracellular domains (ICDs) are released after γ-secretase cleavage at the -site
(Walsh et al., 2003; Eggert et al., 2004; Pastorino et al., 2004; Yanagida et al.,
2009). Furthermore, BACE1 cleavage of APLP1 has recently been shown to
result in the release of an Aβ-like peptide, which does not aggregate and could
be used as surrogate marker for increased γ-secretase cleavage by cerebrospinal
fluid analysis (Yanagida et al., 2009). All three APP family members have been
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shown to be cleaved by caspases at their conserved VEVD motif within the
C-terminus, but the role of this cleavage is still debated (Galvan et al., 2002;
Harris et al., 2010).
Proteolytic processing of APP, APLP1, and APLP2 by γ-secretase at the -site
generates ICDs, which are binding to the adaptor protein Fe65 and, when
co-expressed with Fe65, can transactivate Gal4-Tip60 constructs (Scheinfeld
et al., 2002; Li and Sudhof, 2004). Transgenic mice expressing AICD and
Fe65 were reported to show pathological features of AD (Ghosal et al., 2009).
We have previously shown that AICD is transported to the nucleus by Fe65
where, together, they bind Tip60 and form spherical nuclear complexes (AFT-
complexes), which localize in transcription factories (von Rotz et al., 2004;
Konietzko et al., 2010). Here, we investigate the nuclear localization of APLP1
and APLP2 ICDs upon Fe65 and Tip60 co-expression. Furthermore, we analyze
the differences in subcellular localization and turnover of the full-length
proteins as well as their ICDs. We identify dramatic differences in subcellular
localization and signaling capability of APLP1 compared to APP and APLP2.
Our results provide evidence for a nuclear signaling function of ICDs derived
from APP and APLP2 and support a distinct functional role for APLP1.
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3.2 Results
3.2.1 Nuclear AFT-complex formation of APP family members’
ICDs
The members of the APP family—APP, APLP1, and APLP2—show a high
degree of sequence homology. In particular, the intracellular domain of APP
family members is highly conserved and contains common motifs such as a
caspase cleavage site and NPxY motif for binding of adaptor proteins. We have
previously shown that AICD bound to Fe65 translocates to the nucleus and
forms, together with Tip60, spherical nuclear AFT-complexes (Konietzko et al.,
2010). Therefore, we were interested whether APLP1 and APLP2 intracellular
domains (subsequently referred to as AL1ICD and AL2ICD) form nuclear
AFT-complexes similar to AICD.
Co-expression of Fe65, Tip60, and APP in HEK cells resulted in the retention
of Fe65-AICD complexes in the nucleus and the formation of AFT-complexes
as reported previously (von Rotz et al., 2004; Goodger et al., 2009; figure 3.1A,
top row). For detection of AFT-complexes, Tip60 and APP were fused to
citrine and CFP fluorescence proteins, while Fe65 was detected by antibody
staining. As already shown in an earlier publication, antibody access to AFT-
complexes is restricted due to their density (Goodger et al., 2009). Therefore,
the localization of Fe65 to AFT-complexes is sometimes not as clear as observed
for the fluorescently-tagged proteins. Similar to AICD, AL2ICD also formed
spherical AFT-complexes with Fe65 and Tip60 in the nucleus (figure 3.1A,
bottom row). Surprisingly, AL1ICD did not localize to the nucleus and Fe65
was retained in extranuclear compartments, co-localizing with full-length
APLP1 (figure 3.1A, middle row). Cytosolic retention of Fe65 prevented the
redistribution of Tip60 to nuclear spots, resulting in an accumulation of Tip60
in nuclear speckles.
To exclude the possibility that the observed different nuclear signaling
capabilities of APP family members were due to properties of the chosen
cell line, experiments were repeated in N2a mouse neuroblastoma cells. Co-
expression of Fe65, Tip60, and APP led to the formation of spherical nuclear
AFT-complexes (figure 3.1B, top row). Similar to our observations in HEK cells,
AL2ICD formed AFT-complexes (figure 3.1B, bottom row), while AL1ICD was
not detected in nuclear structures and, due to the sequestration of Fe65 by
full-length APLP1, Tip60 was localized to nuclear speckles (figure 3.1B, middle
row).
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Figure 3.1 ICDs derived from APP and APLP2, but not APLP1, form nuclear AFT-
complexes. A: Confocal ﬂuorescence images of HEK cells transfected with HA-Fe65, CFP-Tip60,
and APP-Cit (top row), APLP1-Cit (middle row), or APLP2-Cit (bottom row). B: Confocal ﬂuores-
cence images of N2a cells transfected with HA-Fe65, CFP-Tip60, and APP-Cit (top row), APLP1-Cit
(middle row), or APLP2-Cit (bottom row). Note the formation of spherical AFT-complexes in the
nucleus of cells transfected with APP or APLP2 in both cell lines. In contrast expression of APLP1
resulted in accumulation of APLP1 and Fe65 in extranuclear compartments and at the plasma
membrane, whereas Tip60 localized to nuclear speckles. Scale bars represent 13µm.
3.2.2 Protein turnover of APP family members
To further study the subcellular localization of the APP family members we
expressed APP/APLP with N-terminal myc-tags, preceded by the APP signal
peptide to ensure membrane insertion, and C-terminal HA-tags. A GAPDH
promoter was chosen for expression because the GAPDH gene is constitutively
expressed at high levels in almost all tissues and expression of transgenes via
this mammalian promoter yields good expression, which is weaker than with
viral promoters. Expression of APP family members in HEK cells showed
a clear intracellular localization to vesicular structures for APP and APLP2,
whereas APLP1 was mostly localized to the cell membrane (figure 3.2A). The
different subcellular localization of APP and APLP1 was also observed with
co-expression of citrine-tagged APP and cerulean-tagged APLP1 proteins
(figure 3.3A). Furthermore, a clear FRET signal was observed between APP
and APLP2 but not between APP and APLP1 in HEK cells, primary astrocytes,
and primary neurons (figure 3.3B–D). Thus, in addition to the co-localization
of APP and APLP2, these two family members can form heterodimers.
The N-terminal myc-tagged constructs allowed cell-surface labeling of
APP/APLPs on living cells (figure 3.2B). Antibody incubations were per-
formed at 4 ◦C to inhibit endocytosis that is dependent on the GTPase function.
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Figure 3.2 APP and APLP2 differ in their subcellular localization from APLP1. A: DIC
and confocal ﬂuorescence images of HEK cells expressing APP (top row), APLP1 (middle row), or
APLP2 (bottom row) and stained with myc- and HA-tag antibodies. APP and APLP2 showed a
clear intracellular localization to vesicular structures, whereas APLP1 mostly localized to the
cell membrane. B: Confocal ﬂuorescence images of HEK cells expressing APP (top row), APLP1
(middle row) or APLP2 (bottom row) after live antibody incubation. Incubation of cells with
myc-tag antibody at 4 ◦C for 10min resulted in surface labeling, especially of APLP1. After
30min of myc-tag antibody incubation, cell surface signals of APP and APLP2 reached a similar
strength as APLP1. Cells were counter-stained with HA-tag antibody after ﬁxation. Scale bars
represent 13µm.
In contrast, exocytosis, which is promoted by zippering of SNARE proteins
mediating vesicle fusion, is still able to occur in the absence of enzymatic
activity. After 10min of myc-tag antibody incubation we detected surface
labeling for all three APP family members. The strongest staining was observed
for APLP1. However, after 30min incubation, APP and APLP2 surface staining
reached similar levels as APLP1. This points towards a higher turnover of APP
and APLP2 compared to APLP1 at the plasma membrane.
To measure the half-lives of the APP family members we inhibited protein
synthesis for different durations. HEK cells were transfected with C-terminally
HA-tagged APP/APLP constructs, all driven by a GAPDH promoter to ensure
comparable expression levels. Twenty-four hours after transfection, protein
synthesis was inhibited with cycloheximide. Cells were harvested after the
indicated time of cycloheximide incubation and levels of full-length protein
determined by western blot (figure 3.4A). APP/APLP full-length levels were
normalized to the highly stable α-tubulin. APP and APLP2 displayed short
half-lives of 43min and 53min, respectively, while half-life of APLP1 was
higher than five hours (308min; figure 3.4B). The much higher stability of
APLP1 is also evident in the left column of figure 3.4A: despite the expression
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Figure 3.3 APP family members show different subcellular localization and het-
erodimerization. A: Confocal ﬂuorescence images of HEK cells transfected with APLP1-Cer
and APP-Cit. Top row shows maximum projection and middle row single sections at different
z-positions. Note the intracellular localization of APP and the prominent localization of APLP1
at the plasma membrane. In contrast, the co-expression of APP and APLP2 shows a clear
overlap and localization to the same intracellular compartments (bottom row). B: Confocal
ﬂuorescence images and FRET analysis of HEK cells expressing APLP1-Cer and APP-Cit (top row),
APLP2-Cer and APP-Cit (bottom row). C: Confocal ﬂuorescence and FRET analysis of primary
astrocytes expressing APP family members. APP-Cit was co-expressed with APP-Cer (top row),
APLP1-Cer (second row), APLP2-Cer (bottom row). D: Confocal ﬂuorescence images and FRET
analysis of primary neurons expressing APP-Cer and APP-Cit (top row) and APLP1-Cer and APP-
Cit (bottom row). In different cell types (B–D) co-expression of APP-Cit and APP-Cer revealed a
strong FRET signal due to the presence of APP homodimers. Similarly, co-expression of APP-Cit
and APLP2-Cer generated a FRET signal. In contrast, expression of APLP1-Cer and APP-Cit
resulted in minimal FRET signal, indicating the near absence of APP/APLP1 heterodimerization.
Scale bars represent 13µm.
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Figure 3.4 APP and APLP2 have a higher protein turnover than APLP1. A:Western blot
analysis of HEK cells transfected with C-terminally HA-tagged APP/APLPs after indicated times
of inhibition of protein synthesis with cycloheximide (CHX). Western blots were probed with
HA-tag antibody and full-length APP/APLP displayed. Note the strong accumulation of APLP1 as
compared to APP and APLP2. B: Quantiﬁcation of APP/APLP full-length levels from A. Mean ±
SEM of n = 3 are shown for each time point. Data was ﬁtted to exponential functions by the
least square approach. R2(APP) = 0.99; R2(APLP1) = 0.82; R2(APLP2) = 0.98.
of all three family members under the same promoter, the levels of APLP1
were much higher, again highlighting its slower turnover.
3.2.3 Nuclear signaling capabilities of APP family members’ ICDs
To investigate whether differences in nuclear localization capability of AICD
and AL1ICD are mediated by properties of their extracellular or intracellular
domains, we constructed chimeric APP/APLP1 expression plasmids. ICDs of
APP and APLP1 were joined at the -site of APLP1 and APP, resulting in the
chimeric constructs APLP1-AICD and APP-AL1ICD, respectively (figure 3.5A).
Chimeric constructs were co-transfected with Fe65 and Tip60 in HEK cells and
AFT-complex formation was observed by confocal microscopy. APP-AL1ICD
did not form AFT-complexes, despite preserved binding of Fe65 (figure 3.5B
top row). In contrast, nuclear AFT-complex formation was observed in cells
transfected with APLP1-AICD. These results suggest that the formation of
AFT-complexes is determined by the properties of the intracellular domain.
Interestingly, the size of AFT-complexes formed from APLP1-AICD appeared
to be decreased when compared to AFT-complexes formed from wildtype APP
(figure 3.5B top row).
Because the chimeric proteins carry a chimeric -site it is possible that
absent nuclear signaling of ICDs is due to impaired γ-secretase cleavage. To
investigate this possibility, HEK cells were transfected with APP, APLP1 or
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Figure 3.5 Nuclear signaling capability of APP family members is mediated by the
intracellular domain. A: Schematic presentation of wildtype and chimeric APP/APLP1
constructs. B: Confocal ﬂuorescence images of HEK cells co-transfected with HA-Fe65,
CFP-Tip60 and the chimeric constructs APP-AL1ICD-Cit (top row) or APLP1-AICD-Cit (bottom
row). Note that AFT-complexes formed in cells expressing APLP1-AICD but not APP-AL1ICD.
Scale bar represents 13µm. C:Western blot analysis of HEK cells transfected with HA-tagged
wildtype or chimeric APP/APLP1 constructs and treated with the γ-secretase inhibitor DAPT or
DMSO-control (−) for twenty-four hours. Western blots were probed with HA-tag antibody and
accumulation of CTFs was observed with all constructs. D:Western blot analysis of HEK cells
transfected with HA-tagged APP/APLP after indicated times of inhibition of protein synthesis
with cycloheximide (CHX).
the chimeric APP/APLP1 proteins and treated with the γ-secretase inhibitor
DAPT (figure 3.5C). DAPT treatment resulted in an accumulation of C-terminal
fragments (CTFs) when compared to non-treated cells, demonstrating that
γ-secretase cleavage of chimeric proteins is preserved. In line with the previous
experiments using cycloheximide, increased full-length levels and decreased
CTF levels of APLP1 indicate the slower turnover of APLP1 compared to APP.
Furthermore, these results suggest that the extracellular and/or transmembrane
regions mediate the differences in protein turnover. To better understand the
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Figure 3.6 APP family members show high sequence homology. Schematic presentation
of APP family ICD sequences and APP-to-APLP1 mutations. c.s.: cleavage site; b.s.: binding site.
turnover of APP family members, wildtype and chimeric APP-transfected
HEK cells were treated with cycloheximide to monitor the turnover of full-
length proteins. As described earlier, APP turnover is much faster than APLP1
turnover (figure 3.5D). Turnover of chimeric proteins was in between those
of wildtype proteins but resembled more closely the protein carrying the
respective extracellular domain. Together, these results suggest that both
extracellular and intracellular regions determine the turnover of APP family
members. Moreover, it is likely that the decreased AFT-complex formation
for APLP1-AICD as compared to APP is due to the decreased turnover of
APLP1-AICD, which would also lead to decreased AICD levels.
Our results show that nuclear signaling by the APP family members is
determined by properties of the highly conserved ICDs (figure 3.6). We
reasoned that the differences in AFT-complex formation capability between
APP/APLP2andAPLP1must derive fromsingle amino acid ormotif differences
between the proteins. We identified seventeen conserved residues in AICD and
AL2ICD that are not conserved in AL1ICD and could thus be responsible for
the observed differences in nuclear signaling (figure 3.6). To test this hypothesis,
we exchanged individual or multiple residues of APP by the corresponding
residues of APLP1 and investigated AFT-complex formation. APP mutated
in the NPxY motif was used as a negative control for AFT-complex formation.
NPTY-to-NATA substitution within APP abolished Fe65 binding as previously
reported (Cao and Sudhof, 2001) and prevented the nuclear translocation of
AICD (figure 3.7, row 2).2 We subsequently mutated amino acids sequentially,
either alone or in combination. (See figures A.2 to A.4 in the appendix for a
diagram depicting all APP-to-APLP1 mutations and corresponding confocal
fluorescence images.) Changing all seven non-conserved residues in the C-
2 The APP double substitution PTY685ATA is commonly referred to as NPTY-to-NATA or
NPTY–NATA and this nomenclature is also used in this thesis (Cao and Sudhof, 2001).
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Figure 3.7 N-terminal residues of APP family ICDs are crucial for nuclear signaling ca-
pability. Confocal ﬂuorescence images of HEK cells transfected with HA-Fe65, CFP-Tip60 and
co-transfected with APP-Cit, APP(NPTY–NATA)-Cit, or indicated citrine-tagged APP-to-APLP1
mutation constructs. See ﬁgure 3.6 for abbreviation of APP-to-APLP1 mutation constructs. Scale
bar represents 13µm.
terminal region of AICD that is reported to bind to Fe65 (Radzimanowski et al.,
2008) did not disrupt nuclear signaling (figure 3.7, row 3; APP(7xmut)). In
contrast, when we inserted the first twelve amino acids of AL1ICD into the APP
sequence (APP(AL1ICD-AICD38)), nuclear signaling was completely abolished
(figure 3.7, row 4). Further mutagenesis were done to identify the minimal set
of amino acids that prevent nuclear localization of AICD (figures A.2 to A.4 in
the appendix). By this means we discovered that exchange of the N-terminal
residues VML to the corresponding APLP1 residues LLR (APP(VML646LLR))
is sufficient to ablate AFT-complex formation (figure 3.7, row 5).
Co-immunoprecipitation of SBP-tagged APP and APP(VML646LLR) showed
that Fe65 binding is not impaired by exchange of N-terminal ICD residues
(figure 3.8B). DAPT treatment of cells transfected with APP(VML646LLR)
resulted in an accumulation of CTFs. This suggests that absence of nuclear
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AFT-complex formation for APP(VML646LLR) is likely not due to disturbed
γ-secretase cleavage (figure 3.8A). Interestingly, in DMSO control treated cells,
ICDs derived from APP were detected but not from APP(VML646LLR) or
APLP1. To unequivocally exclude that the replacement of N-terminal amino
acids of AICD has an effect on APP processing, APP and APP(VML646LLR)
were cloned to a expression vector with N-terminal myc-tag and C-terminal
HA-tag. Cell lysate and culture medium was subjected to western blot and
full-length APP, and its cleavage products (i.e., CTFs, AICD, sAPPs, and Aβ)
analyzed by densitometry (figure 3.8C–E). The VML646LLR mutation does not
change levels of full-length APP and products of the ectodomain shedding,
i.e., CTF and sAPP. The products of γ-secretase cleavage, Aβ and AICD are
expected to be released in a equimolar ratio. However, the VML646LLR
mutation resulted in a significant reduction of AICD levels, but not Aβ levels.
These results clearly show that the VML646LLR mutation does not impair the
processing of APP and thus suggest that decreased AICD levels are due to
faster degradation.
3.2.4 Degradation of APP family members’ ICDs
Nunan et al. (2003) have shown that a peptide corresponding to last the twenty
amino acids of AICD accumulates after inhibition of the proteasome, pointing
to a role of the proteasome in AICD degradation. However, experimental
evidence for proteasomal degradation of the complete AICD peptide and AICD
derived from APP by γ-secretase cleavage is lacking. Little is also known
about the mechanism responsible for degradation of AL1ICD and AL2ICD. We
hypothesized that APP family ICDs have a different protein turnover, resulting
in different capabilities to form nuclear AFT-complexes. To explore a possible
role of the proteasome in the degradation of AICD, we treated HEK cells
transfected with APP-Cit with two previously described proteasome inhibitors,
epoxomicin and MG132. Treatment with both inhibitors strongly increased
AICD levels, thus confirming the hypothesized degradation of AICD by the
proteasome. In addition to AICD, an increase of CTF levels was observed by
MG132 treatment, suggesting that MG132 inhibits the proteasome as well as
γ-secretase when used in higher concentrations, as reported previously (Pinnix
et al., 2001; figure 3.9A). To avoid interference with processing of APP, epox-
omicin was used for proteasomal inhibition in the following experiments. HEK
cells were transfected with APP-Cit, APP(VML646LLR)-Cit, or APLP1-Cit and
treated with epoxomicin for six hours. In control treated cells, ICDs generated
from APP(VML646LLR) were hardly visible, while clear levels were observed
for ICDs derived from wildtype APP (figure 3.9B). Treatment with epoxomicin
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Figure 3.8 Mutation of N-terminal residues of AICD results in reduced levels of AICD
but does not impair APP processing. A:Western blot analysis of HEK cells transfected with
APP-Cit, APLP1-Cit, or APP(VML646LLR)-Cit constructs with 24-hour DAPT or DMSO-control (−)
treatment. AICD-Cit transfected cell lysate was loaded to identify ICD bands and the membrane
was probed with GFP antibody. B:Western blot analysis of co-immunoprecipitation of SBP-
tagged APP or APP(VML646LLR) together with HA-tagged Fe65. Binding of Fe65 is not impaired
by the VML646LLR mutation. C:Western blot analysis of HEK cell lysate transfected with N-
terminal myc-tagged and C-terminal HA-tagged APP or APP(VML646LLR) constructs. VML646LLR
is abbreviated to VML/LLR. DAPT-treated wildtype APP sample was loaded to identify AICD
and CTF bands. D:Western blot analysis of the corresponding cell media from C. sAPPs were
detected with myc-tag antibody (top panel). 6E10 antibody was used to detect Aβ and 10ng
synthetic Aβ42 were loaded to identify monomeric Aβ (bottom panel). Dashed line indicates
removal of western blot lanes; depicted lanes derive from same western blot but different
exposure times. E: Quantiﬁcation of protein levels from C and D. Mean ± SEM of n = 3 are
shown (∗p < 0.05, t-test).
41
3 Regulation of Nuclear Signaling Capability of the Amyloid Precursor Protein Family
Members
− EPX − EPX EPX−
A
APP APLP1
APP
(VML646LLR)
G
A
P
D
H
G
FP
full-lengths
ICDs
B C
APP APP 
(VML646LLR)
APLP1
0
1
2
3
IC
D
 le
ve
ls
 [A
U
]
*
*
*
EPX
10 10 1 0.10.11
MG132
c [μM]:
full-length
− DAPT
AICDAPP
CTFs
AICD
G
A
P
D
H
G
FP
DMSO
EPX
Figure 3.9 APP family ICDs are degraded by the proteasome and N-terminal ICD
residues are crucial for their steady-state levels. A: Western blot analysis of HEK cells
transfected with APP-Cit followed by six hours treatment with indicated concentration of
MG132, epoxomicin (EPX), or DMSO-control (−). APP-Cit transfected HEK cells treated with
DMSO or DAPT and AICD-Cit transfected cells were loaded to identify CTFs and AICD bands.
Membranes were probed with GFP antibody. Note that MG132 inhibits the proteasome and
at higher concentrations also γ-secretase, whereas epoxomicin is a speciﬁc proteasome
inhibitor. B: Western blot analysis of HEK cells transfected with APP-Cit, APLP1-Cit or
APP(VML646LLR)-Cit constructs followed by six hours of proteasome inhibition with 0.1µM
epoxomicin or DMSO-control (−) treatment. The membrane was probed with GFP antibody
and GAPDH was used as a loading control. In the absence of proteasome inhibition ICDs
derived from APP are clearly visible, but not ICD derived from APP(VML646LLR) and APLP1.
C: Quantiﬁcation of ICD levels from B. GAPDH protein levels were used to normalize ICD protein
levels. Mean ± SEM of n = 3 are shown (∗p < 0.05, t-test).
significantly increased the ICDs from APP-Cit, APP(VML646LLR)-Cit, and
APLP1-Cit to detectable levels (figure 3.9B). To exclude that the observed re-
duction of ICD derived from APP(VML646)LLR under steady-state conditions
is due to the relatively large citrine-tag, we repeated the experiment with
HA-tagged constructs. Steady-state levels of ICD from APP(VML646LLR)
were clearly reduced (figure 3.10A) and inhibition of the proteasome increased
ICD levels derived from both, APP and APP(VML646LLR). To exclude a cell-
line specific effect, experiments were repeated in N2a mouse neuroblastoma
cells. As in HEK cells, a clear reduction of steady-state levels of ICD from
APP(VML646LLR) was observed (figure 3.10B–C). Additionally, inhibition of
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Figure 3.10 Levels of AICD depend on its N-terminal residues. A:Western blot analysis
of HEK cells transfected with HA-tagged APP or APP(VML646LLR) and treated with 0.1µM
epoxomicin (EPX) or DMSO-control (−) for six hours. B: Western blot analysis of N2a cells
transfected with HA-tagged APP or APP(VML646LLR) and treated with 1µM epoxomicin or
DMSO-control (−) for six hours. C: Quantiﬁcation of AICD levels from B. Mean ± SEM of n =
4 are shown (∗p < 0.05, t-test). DAPT treated samples were loaded to clearly identify CTF and
AICD bands. c-jun was detected as positive control for inhibition of the proteasome. Dashed
line indicates removal of western blot lanes; depicted lanes derive from same western and
same exposure times are displayed.
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the proteasome completely restored ICD levels, even above wildtype levels (fig-
ure 3.10B–C). In addition to the housekeeping proteins GAPDH and α-tubulin,
c-junwas detected asmarker for inhibition of the proteasome as used previously
(Taylor et al., 2007). It has to be kept in mind that analysis of samples after
inhibition of the proteasome allows only indirect conclusions about the rate
of proteasomal degradation. Indeed, not proteasomal degradation but protein
synthesis is assessed. Incomplete inhibition of the proteasome or too short treat-
ment periods (i.e., before a new steady-state is established) can obstrude result
interpretation. Together, our results from HEK and N2a cells using different
APP and APP(VML646LLR) constructs clearly show reduced steady-state levels
of ICDs derived from APP(VML646LLR). Further, these results suggest that the
half-life differs between APP family ICDs due to different proteasomal degra-
dation efficacy that is dependent on the N-terminus generated after γ-secretase
cleavage. However, we can not exclude that other mechanism (e.g., lysosomal
degradation) have a different effect on AICD with different N-termini.
Next, we asked whether the localization of APP family ICDs that do not
form AFT-complexes is changed after inhibition of the proteasome. Both
APP(VML646LLR)-Cit and APP-AL1ICD-Cit, co-expressed with Fe65 and
Tip60, formed AFT-complexes when treated with epoxomicin (figure 3.11).
These results show that both AICD and AL1ICD can be transferred to the
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Figure 3.11 Nuclear localization of APP family ICDs is regulated by proteasomal degra-
dation. Confocal ﬂuorescence images of HEK cells transfected with HA-Fe65, CFP-Tip60 and
co-transfected with APP(VML646LLR)-Cit (upper rows) or chimeric APP-AL1ICD-Cit (bottom rows)
mutation constructs with six hours epoxomicin (EPX; 0.1µM) or DMSO-control treatment. Note
that AFT-complexes are formed after epoxomicin treatment. Scale bar represents 13µm.
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Figure 3.12 AL1ICD and AL2ICD form AFT-complexes. DIC and confocal ﬂuorescence
images of HEK cells transfected with HA-Fe65, CFP-Tip60 and Cit-AL1ICD (top row) or Cit-AL2ICD
(bottom row). Note the nuclear localization of Al1ICD to nuclear complexes. Scale bars
represent 13µm.
nucleus and form AFT-complexes but under normal conditions AL1ICD is
degraded very quickly by the proteasome due to the identity of its N-terminal
residue. In line with this, we observe that AL1ICD with an N-terminal citrine-
tag—which might prolong its half-life—localizes to AFT-complexes when
co-expressed with Fe65 and Tip60 (figure 3.12A).
3.2.5 Regulation of AICD nuclear signaling by APLP1
We have shown that APLP1 does not signal to the nucleus but it nevertheless
binds to Fe65. Therefore, investigated the influence of APLP1 expression on the
nuclear signaling of AICD.We used a myc-tagged Tip60 to be able to co-express
cerulean and citrine-tagged APLP1 and APP. AICD derived from APP again
translocated to nuclear AFT-complexes in cells co-expressing Tip60 and Fe65
(figure 3.13). APLP1 bound to Fe65 with higher affinity than Tip60, as seen
by the relocalization of Fe65 away from Tip60 in the nucleus. Consequently,
co-expression of APLP1 together with APP, Fe65, and Tip60 prevented the
formation of nuclear AFT-complexes that are clearly seen in cells not expressing
APLP1 (figure 3.13; note that this experiment was performed by Zoë Goodger
and previously published in Goodger, 2009 and Gersbacher et al., 2013). These
results suggest that, although APLP1 does not directly signal to the nucleus, it
influences AICD nuclear signaling via the sequestration of Fe65.
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Figure 3.13 APLP1 expression prevents localization of AICD to AFT-complexes. Confocal
ﬂuorescence images of HEK cells transfected with HA-Fe65, myc-Tip60 and co-transfected with
APP-Cit (top row) APLP1-Cer (middle row) or both (bottom row). Note that AFT-complex forma-
tion (arrowhead) was ablated in cells expressing APP as well as APLP1 (arrows). Scale bars repre-
sent 13µm. This image is a courtesy from Zoë Goodger (Goodger, 2009; Gersbacher et al., 2013).
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3.3 Discussion
Although the APP family members share a high sequence homology and
undergo similar processing, different properties and functions of the three
proteins have been described (Kaden et al., 2009). Here, we provide further
experimental evidence for a distinct function of APLP1 among APP family
members, by reporting a unique nuclear signaling capability for the ICDs of
APP and APLP2, but not APLP1. Further, we identify sequence determinants
of AICD that are necessary for the formation of AFT-complexes.
We show that the ICDs released from APP and APLP2 localize together
with Fe65 and Tip60 to spherical nuclear AFT-complexes. In contrast, the ICD
released from APLP1 does not localize to the nucleus, although it is able to
bind Fe65. We demonstrate that nuclear localization of AL1ICD is prevented at
two steps of APLP1 processing. Firstly, slower turnover of full-length APLP1
compared toAPP results in lower levels of CTFs, which are the direct precursors
of ICDs. Secondly, sequence analyses of AICD and AL1ICD point towards
a increased proteasomal degradation of AL1ICD. Both steps ultimately and
independently result in lower levels of AL1ICD. Our results also indicate that,
although APLP1 does not signal directly to the nucleus, it has a regulatory
function in AICD nuclear localization.
The expression of full-length APP or APLP2, together with Fe65 and Tip60,
results in the translocation of their ICDs to nuclear AFT-complexes, which is
dependent on cleavage by γ-secretase (von Rotz et al., 2004). In contrast, the
ICD derived from APLP1 does not translocate to the nucleus. APLP1 binds
and sequesters Fe65 outside of the nucleus, while Tip60 remains localized in
nuclear speckles. These speckles represent a different nuclear compartment
to that occupied by nuclear AFT-complexes, which themselves are thought to
correspond to sites of transcription (Konietzko et al., 2010). Of note, AICD and
AL2ICD occupy the same nuclear sites as the transcriptional activator NICD
and interactions of AICD and NICD nuclear signaling have been described
(data not shown; Kim et al., 2011 ). This could indicate that similar genes are
regulated by the ICDs of APP and APLP2. In fact, the analysis of candidate
genes regulated by AICD has shown that neprilysin expression and activity
is reduced in fibroblasts derived from APP or APLP2 knockout mice and is
dramatically diminished in cells from double knockout mice (Pardossi-Piquard
et al., 2005). Likewise, for genes suppressed by AICD, as reported for LRP1, the
expression levels were even stronger in APP/APLP2-deficient cells compared
to single APP knockout cells (Liu et al., 2007). Taking this combined evidence
into account, these results point towards an exclusive function of APP and
APLP2 in transcriptional regulation.
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Using cell surface labeling of living cells and determination of protein half-
life time after cycloheximide-induced inhibition of translation, we show that
full-length APP and APLP2 have a clearly faster turnover than APLP1. The
stability of APLP1 is evident in different experimental settings and in stark
contrast to the rapid turnover of APP andAPLP2, whose rapid turnover kinetics
have also been reported in vivo (Lyckman et al., 1998). Investigation of the
nuclear signaling capabilities of chimeric APP/APLP1 proteins suggested that
nuclear signaling capability is an intrinsic property of the ICD sequence that is
present in APP but not in APLP1. We aligned the ICD sequences and identified
seventeen amino acids that are conserved between APP and APLP2 but differ
in APLP1. To identify sequence determinants for nuclear signaling capability
we individually or in combination exchanged all amino acids of AICD with
the corresponding APLP1 residues. Out of all single amino acid and motif
changes, only the exchange of the N-terminal amino acids VML to LLR ablated
nuclear signaling of AICD. APP(VML646LLR) binding to Fe65 and processing
by secretases were not disturbed, but the resulting ICD levels were significantly
lower than for the APP-derived ICDs, suggesting different degradation rates.
It has been reported that AICD is degraded by insulin-degrading enzyme
(IDE), the lysosomal pathway, and the proteasome, whereas degradation of
ALICDs have hardly been investigated (Buoso et al., 2010; Vingtdeux et al.,
2007). Here, we show that the ICDs of both APP and APLP1 are degraded by
the proteasome. Inhibition of proteasomal degradation by epoxomicin and
the concomitant increase in ICD levels resulted in the translocation of ICDs
derived from APP(VML646LLR) and the chimeric construct APP-ALICD to the
nucleus. Under normal conditions, the ICDs of these proteins are degraded
and do not reach the nucleus. However, ICDs released from APLP1, even with
epoxomicin treatment, did not translocate to the nucleus. This is likely because
of the slower turnover of APLP1, it accumulates to higher levels that bind and
sequester Fe65, making Fe65 thus unavailable for the transport of AL1ICD
to the nucleus. Together these results suggest that: (a) nuclear localization
is an intrinsic property of all APP family ICDs, (b) a certain threshold level
for ICDs has to be reached for nuclear translocation to occur, and (c) slow
turnover of full-length APLP1 sequesters Fe65, rendering it unavailable for
nuclear translocation of ICDs.
ICDs from APP, APP(VML646LLR), and APLP1 are degraded by the pro-
teasome, and steady-state ICD levels from APP(VML646LLR) and APLP1
are strongly reduced. These results suggest that the proteasomal degrada-
tion rate of ICDs is dependent on their N-terminal residues. Interestingly,
work by Alexander Varshavsky and colleagues has revealed a proteasomal
pathway—the N-end rule pathway of proteasomal degradation—in which the
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degradation of a protein is related to the identity of the protein’s N-terminal
residues (Varshavsky and Byrd, 1996). According to the N-end rule, leucine,
the N-terminal residue of APLP1, is a destabilizing residue, whereas valine
and methionine, the N-terminal residues of APP, are stabilizing. Since both,
APP and APLP1 are degraded by the proteasome and carry multiple lysine
residues that could potentially be ubiquitinated, it is possible that APP family
ICDs, as suggested previously (De Strooper and Annaert, 2010), are substrates
of the N-end rule pathway.
Walsh et al. (2003) reported higher stability for AL1ICD than AICD and
AL2ICD when ICDs were expressed as soluble forms. Similarly, we observe
nuclear signaling for ICDs of all three APP family members when ICDs are
expressed as soluble proteins. The apparent differences in localization for
AL1ICD derived from full-length APLP1 and soluble expressed AL1ICD are
not surprising since much higher levels of ICDs are obtained from soluble
expressed AL1ICD. Furthermore, we have shown that AL1ICD generated by
γ-secretase cleavage carries N-terminal residues that influence its degradation
rate. However, the expression of soluble ICDs necessitates the addition of a
methionine at the N-termini—for the start codon—that is likely to neutralize
the different degradation times of AICD and AL1ICD reported here.
Our results help to explain the profound effects seen in knockout mouse lines
of the APP protein family members. Animals deficient for APP and APLP2
die shortly after birth (von Koch et al., 1997; Heber et al., 2000). Knock-in
mice have been generated to identify the domain of APP responsible for these
effects. Mutation of the tyrosine residue preceding the NPxY motif (Tyr-682)
abolished Fe65 binding, and thus nuclear signaling by AICD (Barbagallo et al.,
2010). APP Y682G knock-in mice crossed to an APLP2 knockout strain were
found to be postnatally lethal with neuromuscular synaptic defects, resembling
APP/APLP2 double knockouts (Barbagallo et al., 2011). This points towards a
requirement for AICD/AL2ICD-mediated nuclear signaling in development,
a function that cannot be performed by APLP1. This is further supported by
the observation that knock-in of the sAPPα or sAPPβ ectodomains alone is not
sufficient to rescue the synaptic deficits of APP/APLP2 knockout mice (Li et al.,
2010; Weyer et al., 2011). Although the phenotypes in these mouse lines could
also originate from other aspects of APP biology—the Y682G knock-in has a
dramatically increased production of sAPPα and the sAPP knock-ins also lack
the Aβ sequence in addition to AICD—the current data combined with our
experimental evidence strongly supports a role of nuclear signaling by AICD
and AL2ICD in synapse formation that cannot be performed by AL1ICD.
We propose that AL1ICD does not have a direct physiological role in tran-
scriptional regulation, but through sequestration of Fe65 by APLP1 this family
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member might act as a repressor of AICD-mediated nuclear signaling. We
conclude that nuclear signaling is a prime function of the APP andAPLP2 ICDs.
Our results also caution the use of drugs inhibiting APP processing as treat-
ment for AD because of possible interference with APP/APLP transcriptional
function.
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In this chapter, we examine proteasomal degradation of different AICD species
and evaluate a possible contribution of AICD species to AD pathology.
4.1 Introduction
APP is a central protein in the pathology of AD. Consecutive cleavage of APP
by β- and γ-secretase releases Aβ and AICD, which are both short, biologically
active peptides. Aβ is the main component of extracellular plaques in the
brains of AD patients and is thought to trigger a toxic cascade eventually
resulting in the development of AD (Hardy and Selkoe, 2002). For AICD in turn
multiple functions have been identified, most prominently its transcriptional
activity (Cao and Sudhof, 2001). γ-secretase cleavage of APP emerged to be
very complex and different Aβ and AICD species with potentially different
functions are produced.
Work pioneered by Yasuo Ihara and colleagues has revealed that γ-secretase
is cleaving APP at multiple positions in a regulated sequence, commonly
known as sequential γ-secretase cleavage (Qi-Takahara et al., 2005; see figure 4.1
for a schematic diagram of γ-secretase cleavage). The first cleavage takes place
at the -site in the juxtamembrane region of APP, resulting in the release of
AICD into the cytosol. In the following, γ-secretase moves along the protein
stub towards its N-terminus and cleaves after every 3rd to 4th amino acid. Final
cleavage takes place at theγ-site, releasingAβ from themembrane. Importantly,
cleavage at the individual sites displays some variety (figure 4.1). As a result
AICD and Aβ species of varying lengths are produced. The predominant
AICD species found is AICD50 that is produced by γ-secretase cleavage at
the 49-site.1 Additionally, longer AICD51 is produced by cleavage at the
1 For nomenclature of AICD species, wewill use the termsAICD50 andAICD51which denotes
their length in amino acids according to the nomenclature of Aβ-species. Other commonly
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Figure 4.1 Sequential γ-secretase cleavage of APP along different product lines pro-
duces AICD and Aβ species of different length. APP peptide sequence surrounding the
γ-secretase cleavage sites is depicted. γ-secretase cleavage follows predominantly the Aβ40
product line (green). In this case, initial cleavage at the 49-site releasing AICD50 is followed bycleavages at the ζ46-, γ43-, and γ40-sites, eventually releasing Aβ40. To a lesser extent—albeitan increase is observed by the majority of FAD mutations—γ-secretase cleavage follows the
Aβ42 product line (red). Here, initial cleavage at the 48-sites releasing AICD51 is followed bycleavages at the ζ45- and γ42-site, eventually releasing Aβ42. APP amino acids are labeledaccording to their position in the APP695 isoform. Cleavage sites of γ-secretase follow the
commonly used nomenclature according to their position in C99.
48-site. Multiple shorter AICD species (AICD49, AICD48, and AICD47) were
described however their levels were extremely low and subsequent studies
have failed to detect them (Gu et al., 2001; Dimitrov et al., 2013). For Aβ, the
predominant species detected is Aβ40, produced by γ-secretase cleavage at
the γ40-site. Longer Aβ42, which is assumed to be the principal toxic agent in
AD, is produced by cleavage at the γ43-site. Additionally, longer Aβ43, which
serves as a precursor of Aβ40, as well as shorter Aβ38, Aβ37, and Aβ34 are
often detected. Accumulating evidence suggests that the position of the initial
γ-secretase cleavage at the -site determines the positions of the subsequent
sequential cleavages. Accordingly, two major product lines, commonly known
as Aβ40 and Aβ42 product lines, have been identified (Chávez-Gutiérrez et al.,
2012). Cleavage along product lines implies that production of AICD and Aβ
species are inherently linked, i.e., AICD50 is accompanied by products of the
Aβ40 product line, which is foremost Aβ40 but also Aβ43 and Aβ37. AICD51
in turn is accompanied by Aβ42 and its cleavage products Aβ38 and Aβ34. See
figure 4.1 for a schematic illustration of sequential γ-secretase cleavage along
product lines.
Mutations in the genes encodingAPP and theγ-secretase subunits PSEN1 and
PSEN2 are known to cause AD. Unsurprisingly, no unifying diseasemechanism
found terms are AICD50-99 and AICD49 for AICD50, and AICD49-99 and AICD48 for
AICD51 according to their position in C99 and their cleavage site, respectively.
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for the approximately 300 described AD-causing mutations has been found.
Multiple studies have shown that partial loss-of-function ofγ-secretase cleavage
at the -site is observed in majority of FAD mutations, albeit not all of them. In
addition, detailed analyses of γ-secretase processing at the -site have revealed
that FAD mutations can result in a shift of γ-secretase processing towards the
Aβ42 product line (Sato et al., 2003; Chávez-Gutiérrez et al., 2012; Dimitrov
et al., 2013). It is well established that AD-causing mutations result in an
increase in the Aβ42-to-Aβ40 ratio. Because Aβ42 displays higher aggregation
potential and toxicity than Aβ40, increase in the Aβ42-to-Aβ40 ratio is thought
to drive disease progression. Interestingly, the described alterations of FAD
mutations can also affect AICD. While partial loss-of-function changes AICD
quantity (i.e., decreased total AICD levels), shift in product line alters the AICD
quality (i.e., increased AICD51). In contrast to Aβ species, metabolism and
function of different AICD species have so far been hardly addressed.
Few studies have investigated the mechanisms that result in degradation of
AICD. Edbauer et al. (2002) have identified the insulin degrading enzyme (IDE)
as aAICDdegrading enzyme, whichwas confirmed by later studies (Farris et al.,
2003; Buoso et al., 2012). Degradation by the lysosomewas shown by Vingtdeux
et al. (2007). Cupers et al. (2001) have shown that synthetic peptides of longer
AICD forms (AICD57, AICD59) do not undergo proteasomal degradation.
However, the relevance of these findings is not clear because AICD species
of these lengths were never detected and are probably not generated by γ-
secretase cleavage or any other processing. In contrast, Nunan et al. (2003) show
degradation of a peptide corresponding to the last twenty amino acids of APP in
in vitro proteasome assays. In chapter 3, we show that also AICD derived from
APP by physiological γ-secretase cleavage undergoes proteasomal degradation.
Our experiments that compare proteasomal degradation of ICDs of APP family
proteins, suggest that the N-terminal amino acids are determining proteasomal
degradation. Importantly, we further show that regulation of AICD levels by
proteasomal degradation is linked to its presumed transcriptional function
in AFT-complexes. However, to the best of our knowledge, no study has
investigated degradation of specific AICD species separately.
The ubiquitin-proteasome system (UPS) is the major mechanism for selective
protein degradation and thus essential for cellular functioning (Ciechanover,
1994). Theproteasome is a large,multi-subunit protein complex that is primarily
responsible for protein degradation (Ciechanover, 2013). In eukaryotes the
proteasome is composed of the 20S core particle and the 19S regulatory
particle. The 19S regulatory particle recognizes substrate proteins, unfolds
them, and inserts them into the 20S core particle. The 20S core particle is
a barrel-like structure with multiple proteolytic sites in its central chamber
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that conducts the actual protein degradation. The most prominent substrate
recognition signal for the proteasome is polyubiquitination. The seventy-
six amino acid peptide ubiquitin is attached to substrate proteins by the
interplay of E1 Ub-activating, E2 Ub-conjugating, and E3 Ub-ligase enzymes
(Ub abbreviates ubiquitin). Ubiquitin bound to a substrate can itself be
ubiquitinated, resulting eventually in the formation of a polyubiquitin chain.
Different ubiquitination pathways exist, which are divided according to their
mode of substrate recognition (Ravid and Hochstrasser, 2008). In regular
ubiquitination, E3 Ub-ligase enzymes recognize substrate proteins via specific
structures or specific post-translational modification (PTM) patterns (e.g.,
phosphorylation). The N-end rule pathway in contrast is a specific proteasomal
degradation pathway in which the identity of the N-terminal residue of a
protein determines the protein’s stability (Bachmair et al., 1986). In the N-end
rule pathway the substrate’s N-terminus is directly recognized by specific E3
Ub-ligase enzymes, the N-recognins, which ubiquitinate substrate proteins and
by this means mark them for degradation. Four functional N-recognins (UBR1,
UBR2, UBR4, and UBR5) have been identified in the mammalian genome.
N-recognins recognize and bind only specific N-terminal amino acids and,
accordingly, the twenty naturally-occurring amino acids have stabilizing or
destabilizing function if at the N-terminal position of a protein—see table 4.1
for a list of all amino acids and their function in the N-end rule pathway. Recent
studies have indicated that destabilizing residues can be further subdivided in
type 1 and type 2 destabilizing residues due to their recognition by structurally
different but functionally similar domains of N-recognins. The UBR box, which
is present in all four functional N-recognins, binds type 1 residues which are
basic amino acids (Sriram et al., 2011). Type 2 residues in contrast are bulky
and hydrophobic amino acids and are recognized by the N-domain, which was
only found in UBR1 and UBR2. However, experimental evidence has suggested
that also UBR4 is important for degradation of proteins with N-terminal type
2 residues, thus cautioning a general residue-to-domain allocation (Tasaki
et al., 2005; Sriram et al., 2011). The N-end rule pathway is of particular
importance for proteolysis-generated peptides since they can carry other N-
terminal residues than the start codon–derived methionine (Varshavsky, 2011).
Multiple functions of the N-end rule pathway have been described, including
regulation of cardiac signaling and neurogenesis (for review see Tasaki and
Kwon, 2007). A recent study has highlighted the role of N-end rule degradation
of proteolytic fragments in various neurodegenerative diseases (Brower et al.,
2013) and the essential function of the N-end rule pathway is also underlined
by the embryonic lethality of mice deficient for the N-recognins UBR1 and
UBR2 (An et al., 2006).
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Table 4.1 Classiﬁcation of amino acids according to their function in N-end rule protea-
somal degradation. In N-end rule proteasomal degradation the N-terminal amino acid of a
protein can have either stabilizing of destabilizing function. Destabilizing residues can be further
subdivided into type 1 (basic) and type 2 (bulky, hydrophobic) residues that are recognized by
different domain of N-recognins, the UBR-box and N-domain, respectively.
Function Amino acid
Stabilizing Alanine, methionine, proline, serine, threonine, valine
Type 1 destabilizing Arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine,
glycine, histidine, lysine
Type 2 destabilizing Isoleucine, leucine, phenylalanine, tryptophan, tyrosine
We have shown in chapter 3 that AICD is degraded by the proteasome and,
importantly, that the N-terminus of AICD is crucial for its stability (Gersbacher
et al., 2013). Interestingly, the two AICD species generated by γ-secretase
processing of APP, AICD50 and AICD51, carry N-terminal residues that fall
in different categories of the N-end rule. Valine, the N-terminal residue of
AICD50, is a stabilizing residue. Leucine, the N-terminal residue of AICD51, in
contrast, is a destabilizing residue and could thus mediate faster proteasomal
degradation. However, experimental evidence for a role of the N-end rule
pathway in degradation of AICD species is lacking. The aim of this study
is, therefore, to investigate whether AICD species are differently regulated
by the N-end rule pathway and whether such a regulation could influence
transcriptional activity of AICD. We further aimed to explore whether shifting
the product line preference of γ-secretase—as it is the case by AD-causing
mutations—could result in decreased total AICD levels due to the increased
production of a potentially unstable AICD species and influence transcriptional
function of AICD.
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4.2 Results
4.2.1 Construction and validation of ubiquitin-fusion plasmids
Proteins that undergo degradation by the N-end rule pathway are normally
derived from pro-N-end rule substrates by proteolytic cleavage. This cleavage
exposes the N-terminus of N-end rule substrates, which are then targeted
by N-end rule pathway-specific E3 Ub-ligase enzymes, the N-recognins. For
studying N-end rule substrates, it is desirable to examine their catabolism
and function independently of preceding proteolytic cleavages. However,
protein expression from regular plasmids results in proteins with N-terminal
methionine due to the necessity of a start codon for initiation of ribosomal
translation. Methionine is a stabilizing residue in terms of the N-end rule, and
its N-terminal addition would mask the normal processing of an N-end rule
substrate. A way to circumvent the addition of N-terminal methionine is thus
needed for expression of N-end rule substrates.
The ubiquitin-fusion (Ub-fusion) technique allows the expression of proteins
without N-terminal start codon–derived methionine (Bachmair et al., 1986;
Lévy et al., 1996). The technique is based on the way ubiquitin is encoded
and processed in most higher eukaryotes (figure 4.2A; Kimura and Tanaka,
2010). Multiple ubiquitin-encoding sequences follow each other in a head-
to-tail configuration without interruption, resulting thus in the expression of
a linear polyubiquitin chain. However, immediately after translation of the
polyubiquitin chain—also referred to as co-translationally—deubiquitinating
enzymes (DUBs) recognize and cleave precisely at the border of two ubiquitin
moieties, thus releasing separate ubiquitin moieties. Bachmair et al. (1986)
show that a protein of interest (POI) fused in frame to the C-terminus of
ubiquitin is rapidly separated from ubiquitin. Due to the precise cleavage at
the C-terminus of a ubiquitin moiety the technique allows the expression of
POIs with desired N-termini.
Ub-fusion constructs of AICD50 and AICD51 were prepared with C-terminal
citrine or HA-tag. Ub-AICD50-Cit and Ub-AICD50-Cit constructs were ex-
pressed in HEK cells to test expression of Ub-fusion proteins and cleavage by
DUBs. Ubiquitin is successfully removed from Ub-AICD-Cit as indicated by
a major GFP-positive band at same height as regular-expressed AICD50-Cit
(figure 4.2B compare lane two and four). AICD50-Cit from both, regular and
Ub-fusion construct, were detected at approximately 7 kDa above GFP, the
expected difference by the AICD-linker fusion (figure 4.2B compare lane two
and four to lane three). Aweak GFP-positive bandwas observed approximately
9 kDa above AICD-Cit (figure 4.2B lane four), indicating that only a minor
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Figure 4.2 Ub-fusion technique allows expression of proteins with desired N-termini.
A: Schematic illustration of the Ub-fusion techniques. Ubiquitin is encoded in the mammalian
genome as tetramer (UBB). Upon expression, DUBs co-translationally and precisely separate
ubiquitin moieties. Fusion of a POI (e.g., GFP) to the N-terminus of a ubiquitin moiety results
in exposure of a desired N-terminal residue of the POI (here X) after removal of ubiquitin.
B:Western blot analysis of HEK cells non-transfected (n.t.; lane 1), or transfected with citrine-
tagged AICD50 with normal N-terminal methionine (AICD50-Cit; lane 2), Ub-fusion construct–
derived GFP (Ub-GFP; lane 3), or AICD50-Cit fused at its N-terminus to ubiquitin (Ub-AICD50-
Cit; lane 4). For both AICD-expressing constructs major GFP-positive bands were detect on
same height, indicating that ubiquitin is successfully removed co-translationally. Dashed line
indicates removal of western blot lanes; depicted lanes derive from same western blot and
same exposure times are displayed. C: Western blot analysis of HEK cells non-transfected
(n.t.; lane 1), or transfected with C-terminally HA-tagged Ub-fusion constructs of AICD50 (Ub-
AICD50; lane 2) or AICD51 (Ub-AICD51; lane 2). A clear band in the sample expressing Ub-fusion
construct of AICD50with a AICD50neo antibody conﬁrms precise removal of the ubiquitinmoiety
(upper panel). An antibody recognizing all AICD species (middle panel) and α-tubulin (bottom
panel) conﬁrm similar expression of AICD species and similar protein loading, respectively.
Western blot was processed to enhance detection of AICD as described in Material and Methods
(Pimplikar and Suryanarayana, 2011).
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fraction of Ub-AICD-Cit remained uncleaved. Usage of Ub-fusion constructs
did not lead to a overt increase in total protein ubiquitination (figure 4.2A
bottom panel). These results confirm that AICD expression from Ub-fusion
constructs and processing by DUBs is working.
To test whether cleavage ob Ub-fusion constructs by DUBs is precise—and
is thus suitable for the expression of specific AICD species—an antibody
recognizing exclusively AICD50 (AICD50neo) was used. Previous studies
have shown that the AICD50neo antibody does not detect other AICD species,
full-length APP, or other APP fragments (Chávez-Gutiérrez et al., 2012). HA-
tagged Ub-fusion constructs of AICD50 and AICD51 (Ub-AICD50-HA and
Ub-AICD51-HA) were expressed in HEK cells. Western blots were prepared
and probed with AICD50neo antibody. A strong band was detected in samples
expressing AICD50 at approximately 11 kDa, the expected height of HA-tagged
AICD50. No signal was observed in AICD51-expressing samples. An antibody
recognizing the C-terminus of AICD was used to show a similar expression
of AICD50 and AICD51 (figure 4.2C middle panel). Together, these results
show that the Ub-fusion technique allows efficient and reliable expression of
specific AICD species. This technique thus allows us to investigate degradation
and function of different AICD species separately from APP processing by
γ-secretase. Importantly, the AICD Ub-fusion constructs allow us to investigate
naturally-occurring AICD species, without a artificial start codon–derived
methionine used in previous studies.
4.2.2 Proteasomal degradation of AICD species
We aimed to determine whether AICD species undergo different proteasomal
degradation. Ub-fusion constructs of AICD50 and AICD51 were expressed
in HEK cells and treated with proteasomal inhibitor (figure 4.3A and B). We
observed that AICD51 showed significantly lower levels under DMSO control
conditions than AICD50. Both AICD species increased after inhibition of the
proteasomewith epoxomicin. In contrast to the control conditions, no difference
in AICD50 and AICD51 levels was observed after treatment with 1µM epox-
omicin. This means that the apparent differences of AICD50 and AICD51 were
repealed by inhibiting the proteasome. In turn we can conclude that AICD51
undergoes faster proteasomal degradation than AICD50. Treatment with a
lower concentration of epoxomicin (0.1µM) resulted in lower levels of AICD50
than treatment with 1µM, demonstrating that 0.1µM epoxomicin resulted in
an incomplete inhibition of the proteasome. Interestingly, incomplete inhibition
with 0.1µM epoxomicin was not sufficient to restore levels of AICD51 levels to
those of AICD50, thus providing further support for a increased proteasomal
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Figure 4.3 AICD51 displays faster proteasomal degradation than AICD50. A: Western
blot analysis of HEK cells transfected with HA-tagged Ub-fusion constructs expressing AICD50
or AICD51 and treated with the indicated concentration of epoxomicin (EPX) or DMSO-control
(−) for four hours. B: Quantiﬁcation of protein levels from A. Mean ± SEM of n ≥ 3 are shown
(∗p < 0.05, t-test). C: Analysis of LDH release from HEK cells treated with different epoxomicin
concentrations. LDH release from DMSO-treated cells was set as zero cytotoxicity. D:Western
blot analysis of HEK cells stably expressing HA-tagged Ub-fusion constructs of AICD50 and
AICD51 and treated with MG132 or DMSO-control (−) for four hours.
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turnover of AICD51 than AICD50. Incomplete inhibition of the proteasome
with 0.1µM epoxomicin is also evident by levels of the control protein c-jun,
which also increase further by the application of 1µM epoxomicin. Conversely
higher rate of proteasomal degradation of AICD51, was thus also resulting
under conditions of residual proteasome activity in lower levels of AICD51
than AICD50.
Cytotoxicity of the used concentration of epoxomicin was analyzed to exclude
that AICD levels are influenced by cell-death-related mechanisms. Release of
the cytosolic lactate dehydrogenase (LDH) fromdamaged cellswasmeasured as
amarker for cytotoxicity and cytolysis. Epoxomicin did not display significantly
altered LDH release in the tested range of 3.3 nM to 10µM (figure 4.3C).
Next, we generated HEK cells stably expressing Ub-fusion constructs of
AICD50 and AICD51 by lentivirus-mediated genomic integration. Similar to
transiently transfected cells, AICD51 levels were clearly lower than AICD50
levels in DMSO-control conditions (figure 4.3D). Treatment with the protea-
somal inhibitor MG132 increased levels of both AICD species, albeit AICD51
levels were not restored entirely. It should be kept in mind that the generally
lower AICD species levels are indicative for a slower expression rate of AICD
species in stable cells than in transient transfection. Thus, it is possible that the
duration of MG132 treatment was not sufficient to restore new AICD species
steady-state levels.
Im summary we show that AICD species are degraded by the proteasome.
We also show repeatedly reduced AICD51 levels under control conditions,
which disappeared after complete blockage of the proteasome. Together our
results strongly suggest that AICD51 undergoes faster proteasomal turnover
than AICD50 and support our hypothesis that AICD species are degraded by
the N-end rule proteasomal degradation.
4.2.3 Mechanism of AICD proteasomal degradation
The role of AICD’s lysine residues
To better understand the mechanism of proteasomal degradation of AICD,
we aimed to identify potential sites of ubiquitination that are important for
proteasomal degradation. Ubiquitination is the most prevalent signal for
proteasomal degradation, and lysine residues are the most prevalent sites
for ubiquitination (Kravtsova-Ivantsiv and Ciechanover, 2012). The amine
group of lysine residues is used in this process by E3 Ub-ligase enzymes to
form an isopeptide bond with the carboxyl group of the C-terminal glycine
(G76) of ubiquitin (Pickart, 2001). AICD harbors in total five lysine residues
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(figure 4.4A). Three lysine residues are clustering in the N-terminal region of
AICD (K649–651), of which K650 is conserved in all three APP family members.
Interestingly, this lysine-rich stretch is directly following the N-terminal VML
sequence that we have previously shown to be important for AICD levels and
AFT-complex formation (see chapter 3). The two other lysine residues (K676
and K688) are surrounding the NPxY motif, which is important for binding of
adaptor protein such as Fe65. Previous studies have shown ubiquitination of
APP at K649–K651 (Morel et al., 2013), K651 (Watanabe et al., 2012), and K688
(El Ayadi et al., 2012). However, no study has related ubiquitination of AICD
residues to its proteasomal degradation.
To prevent potential ubiquitination of AICD, lysine residues were substituted
by arginine residues that have otherwise similar physiochemical properties
(i.e., size, pK, positive charge). We reasoned that APP with lysine-to-arginine
substitutions of ubiquitination sites that are indispensable for proteasomal
degradation of AICD would result (i) in higher steady-state levels of AICD and
(ii) do not show increase in AICD levels upon inhibition of the proteasome.
Because of its partial conservation and prior evidence for ubiquitination by
Watanabe et al. (2012) and Morel et al. (2013), we started lysine-to-arginine
replacements with the N-terminal lysine residues. C-terminal citrine-tagged
APP(KKK649-651RRR) was cloned by SDM and expressed in HEK cells. AICD
derived from APP(KKK649-651RRR) showed decreased steady-state levels
compared to wildtype APP-derived AICD (figure 4.4B). Furthermore, the
substitution of N-terminal lysine residues did not ablate AICD accumulation
upon inhibition of the proteasome. Thus, despite its prominent position in
proximity to the N-terminus, KKK649-651 appears not to play a role in pro-
teasomal degradation of AICD. We next substituted all five lysine residues
within the C-terminal domain of APP by arginine residues—APP(KKK649-
651RRR, K676R, K688R) abbreviated to APP(5KR). Citrine-tagged APP(5KR)
was expressed in HEK cells and treated with epoxomicin (figure 4.4C). Ad-
ditionally, APP-transfected and DAPT-treated, as well as AICD-transfected
protein samples were loaded to western blots to unequivocally identify AICD.
Similar to the observations with APP(KKK649-651RRR), APP(5KR)-derived
AICD accumulated after treatment with epoxomicin.
Formally, the fluorescence-tag of APP used in the experiments could be
ubiquitinated and mediate proteasomal degradation of AICD. Dantuma et al.
(2000) have previously shown that GFP accumulates after inhibition of the
proteasome, and GFP and derivatives (e.g., citrine) carry multiple lysine
residues that could theoretically be ubiquitinated. An Ub-fusion construct of
GFP, similar to that used by Dantuma et al. (2000), was expressed in HEK cells
and treated with epoxomicin (figure 4.4D). However, we could not observe
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accumulation of GFP after inhibition of the proteasome. Further, no higher
molecular weight forms of GFP—that could be indicative of ubiquitination—
were detected, together arguing against a degradation of GFP and derivatives
by the UPS. To conclusively exclude that AICD derived from wildtype APP
and APP(5KR) is degraded by the proteasome due to an ectopic ubiquitination
in the fluorescence-tag, citrine was replaced by an HA-tag, which does not
carry lysine residues. HA-tagged APP(5KR) was expressed in HEK cells and
treated with two different proteasome inhibitors. Proteins samples were loaded
on western blot together with APP-transfected and DAPT-treated samples to
identify AICD (figure 4.4E). Similar to our observation with citrine-tagged
APP(5KR), inhibition of the proteasome resulted also in accumulation of AICD
levels derived from HA-tagged APP(5KR), which is not carrying any lysine
residues.
The most prominent function of lysine ubiquitination is to mark proteins
for degradation by the proteasome. However, lysine ubiquitination can also
modify functions and localization of a protein. For APP, Morel et al. (2013)
have shown that ablation of ubiquitination by the KKK649RRR substitution
resulted in altered subcellular sorting of APP. Whether these changes in APP
localization, subsequently also result in different localization of AICD is not
known. Therefore, we asked whether localization of AICD to nuclear AFT-
complexes is dependent on a potential ubiquitination on lysine residues. HEK
cells were transfected with Fe65, Tip50, and APP(5KR) or wildtype APP and
formation of AFT-complexes was analyzed by confocal microscopy (figure 4.5).
Similar to wildtype APP-derived AICD, AICD derived from APP(5KR) formed
nuclear AFT-complexes and no overt differences in localization were observed.
Figure 4.4 Lysine residues of AICD are dispensable for its proteasomal degradation.
A: Schematic diagram of AICD peptide sequence and potential ubiquitination sites. Lysine
residues are indicated in red. Non-lysine residues and N-terminal residues that can potentially
be ubiquitinated are indicated in yellow and green, respectively. B:Western blot analysis of
HEK cells transfected with citrine-tagged wildtype APP or APP(KKK649RRR) and treated with
epoxomicin (EPX) or DMSO-control (−). C:Western blot analysis of HEK cells transfected with
citrine-tagged wildtype APP and APP(5KR) and treated with epoxomicin or DMSO-control (−).
DAPT-treated APP and AICD-Cit samples were loaded to unequivocally identify AICD bands.
D:Western blot analysis of HEK cells transfected with Ub-fusion construct of GFP and treated
with epoxomicin or DMSO-control (−). E:Western blot analysis of HEK cells transfected with
HA-tagged wildtype APP and APP(5KR) and treated with epoxomicin, MG132, or DMSO-control
(−). 16% Tricine gel was used. Dashed line indicates removal of western blot lanes; depicted
lanes derive from same western blot and same exposure times are displayed. Epoxomicin
(0.1µM) and MG132 (1µM) treatment was done for six hours.
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Fe65 Tip60 merge
APP
APP(5KR)
Figure 4.5 Lysine residues of AICD are dispensable for formation of AFT-complexes. Con-
focal ﬂuorescence images of HEK cells transfected with HA-Fe65, CFP-Tip60, and APP-Cit (top
row) or APP(5KR)-Cit (bottom row). Note the formation of spherical AFT-complexes in the
nucleus of cells transfected with APP or APP(5KR). Scale bars represent 13µm.
In summary, our results from lysine-to-arginine substitutions show that
lysine residues of AICD are dispensable for its proteasomal degradation,
overall localization and the formation of AFT-complexes. Our results explicitly
exclude that the mechanism of proteasomal degradation of AICD takes place
by ubiquitination of lysine residues.
Ubiquitinated forms of AICD
Ubiquitination of lysine residues is the predominant signal for substrate recogni-
tion and degradation by the proteasome (Kravtsova-Ivantsiv and Ciechanover,
2012). However, also other residues have been shown to act as ubiquitin
acceptor sites. Described non-lysine ubiquitination sites are cysteine, serine,
and threonine residues as well as the α-NH2 group of the N-terminal amino
acid of a protein. Although only few reports of non-lysine ubiquitination
exist and it is therefore thought to play only a minor role, the possibility of
non-lysine-mediated proteasomal degradation of AICD species must be taken
into account. AICD harbors five potential non-lysine ubiquitination sites,
which are three threonine residues and two serine residues (figure 4.4A). Most
of these residues are embedded in the conserved motifs of AICD that mediate
several functions of AICD and APP (see section 1.3 for AICD motifs and their
function). An arginine replacement approach would likely interfere or disturb
these functions and impede result interpretation. Therefore, we decided to
64
Results 4.2
B CA
− HA-Ub
H
A
-ta
g
105
MW
[kDa]
78
55
45
34
16
7
H
A
-ta
g
IP:GFPLysate
Ub-AICD51-Cit, Ub-HA
105
MW
[kDa]
78
55
45
34
16
7
G
FP
IP:GFPLysate
105
MW
[kDa]
78
55
45
34
16
7
H
A
-ta
g
APP-Cit, Ub-HA
A
IC
D
ne
o
IP:AICDLysateIP:AICDLysate
105
MW
[kDa]
78
55
45
34
16
7
105
MW
[kDa]
78
55
45
34
16
7
Figure 4.6 AICD is not ubiquitinated. A: Western blot analysis of HEK cell lysates trans-
fected with N-terminally HA-tagged ubiquitin (HA-Ub). HA-tagged monoubiquitin is detected at
approximately 10 kDa. HA positive bands indicate that HA-tagged ubiquitin is used for protein
ubiquitination. B: Western blot analysis of HEK cell lysates transfected with citrine-tagged
Ub-fusion construct expressing AICD51 and HA-Ub and subjected to immunoprecipitation with
GFP antibody. Cells were treated for four hours with MG132 prior to harvest. C: Western
blot analysis of HEK cell lysates transfected with citrine-tagged APP and HA-Ub and subjected
to immunoprecipitation with AICDneo antibody. Cells were treated for four hours with 1µM
epoxomicin prior to harvest. Dashed line indicates removal of western blot lanes; depicted
lanes derive from same western blot.
analyze overall AICD ubiquitination—assessing both lysine and non-lysine
residue ubiquitination—by immunoprecipitation.
Ubiquitin is bound to substrates by covalent attachment and is thus not
removed in SDS-PAGE-based western blots. A plasmid encoding ubiquitin
with N-terminal HA-tag (HA-Ub) was used for convenient detection of ubiquiti-
nation. Western blot analysis of HA-Ub expressed in HEK cells revealed a band
at approximately 10 kDa, corresponding to HA-tagged soluble monoubiquitin
(figure 4.6A). Additionally, an HA-tag positive smear, typically observed for
protein ubiquitination, was detected, indicating effective expression of HA-Ub
and its attachment to target proteins.
Citrine-tagged AICD51 was co-expressed with HA-Ub and treated with
MG132 to inhibit proteasomal degradation and accumulate potential ubiquiti-
nated forms of AICD. Samples were harvested in lysis buffer supplemented
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with inhibitors of DUBs and the proteasome (RIPA-Ub) to prevent ubiquitin
removal and degradation of ubiquitinated forms. AICD51 was immunopre-
cipitated with an antibody recognizing the fluorescence-tag. Analysis of
lysates clearly shows that both proteins, AICD51 and HA-Ub were expressed
(figure 4.6B). Eluate probed against AICD51 clearly indicated its successfull
immunoprecipitation. However, no HA-tag positive signal was detected in the
eluate, indicating that AICD51 is not ubiquitinated.
It is possible that localization and/orproximity to themembrane are necessary
for ubiquitination of AICD. To exclude that localization of Ub-fusion construct–
derived AICD prevents its ubiquitination, immunoprecipitation was also
done with APP-derived AICD. APP-Cit and HA-Ub were expressed in HEK
cells and AICD50neo antibody, exclusively recognizing AICD50, used for
immunoprecipitation. Although eluate probed with AICD50neo detected a
protein smear, no HA-positive signal was observed (figure 4.6C).
In summary, no ubiquitinated forms of AICD were detected in immunopre-
cipitation experiments. These result suggest that proteasomal degradation of
AICD is independent of ubiquitination. However, it should be noted that only
minor fractions of a protein are normally ubiquitinated and proteasomal degra-
dation of ubiquitinated proteins is very fast. Therefore, levels of ubiquitinated
forms of a protein are often marginal and difficult to detect. Thus the absence
of detected ubiquitinated forms is suggestive but not sufficient to refuse a role
of ubiquitination and further experiments are required.
The role of E1 ubiquitin-activating enzymes for AICD degradation
To corroborate our findings from immunoprecipitation, we aimed to investigate
the role of the ubiquitination machinery in the regulation of AICD. Protein-
ubiquitination is mediated by the concerted actions of E1 Ub-activating, E2
Ub-conjugating, and E3 Ub-ligase enzymes. In humans more than fifty E2
Ub-conjugating and more than 500 E3 Ub-ligase enzymes are encoded. In
contrast, only eight E1 Ub-activating enzymes are described and, importantly,
only two of those activate ubiquitin, while the others activate ubiquitin-like
proteins (Schulman and Harper, 2009). UBA1 is the major ubiquitin activating
enzyme but in particular in development a second enzyme, UBA6, can activate
ubiquitin. The low numerical redundancy of E1 Ub-activating enzymes (in
contrast to E2 Ub-conjugating and E3 Ub-ligase enzymes), makes them a
suitable target for our investigations. Additionally, previous studies have
shown the utility of siRNA-mediated knockdown of E1 Ub-activating enzymes.
Lee et al. (2011) for example have shown that siRNA-mediated knockdown of
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UBA1/UBA6 results in accumulation of proteins that would otherwise undergo
degradation by the UPS.
We have ordered siRNA against UBA1 and UBA6 and transfected them into
HEK cells (figure 4.7A). Efficient knockdown of both enzymes, individually
and in combination, was observed and reached approximately 94% and 85%
for UBA1 and UBA6, respectively (figure 4.7A). To test a role of UBA1 and
UBA6 in the regulation of AICD, siRNA were transfected into HEK cells
transiently expressing different AICD species (figure 4.7B). We reasoned that if
proteasomal degradation of AICD is ubiquitin-dependent, knockdown of the
E1 Ub-activating enzymes would result in an increase in AICD levels. However,
we did not observe an increase for either AICD species, rather a slight reduction
of AICD levels after E1 Ub-activating enzyme knockdownwas observed, which,
however, did not reach significance (figure 4.7C). Our results thus suggest that
proteasomal degradation of AICD species is ubiquitination-independent.
To complement genetic ablation of E1 Ub-activating enzymes, pharmacolog-
ical inhibition was envisaged with the commercially UBA1 inhibitor PYR41
(Yang et al., 2007). However, paradoxically, previous studies have reported
an increase in total protein ubiquitination upon PYR41 treatment, which is
probably due to off-target inhibition of DUBs (Kapuria et al., 2011). Unfortu-
nately, accumulation of total protein ubiquitination was also observed in our
experimental system (figure 4.7D). Because normal function of DUBs is essential
for processing of Ub-fusion constructs—used to express AICD species—PYR41
is not suitable for our experiments and hence experiments using this inhibitor
were aborted.
4.2.4 The role of N-domain-containing N-recognins in proteasomal
degradation of AICD
N-recognins are the central enzymes in theN-end rule pathway. They recognize
theN-terminal residues of N-end rule substrates andmediate their proteasomal
degradation. N-recognins contain specific domains for substrate recognition,
that are the UBR box and the N-domain, which recognize type 1 and type 2
destabilizing residues, respectively (see also table 4.1). The N-domain, which
recognizes type 2 destabilizing residues is only conserved in UBR1 and UBR2.
To test whether N-recognins mediate proteasomal degradation of AICD species,
we obtained UBR1/2 dKO MEFs from Yong Tae Kwon. Lentivirus expressing
a Ub-fusion construct of AICD51 was prepared and used for infection of
wildtype and UBR1/2 dKO MEFs (figure 4.8A). Cycloheximide was used to
inhibit protein synthesis for indicated times and, thus, permit calculation of
67
4 Characterization of Proteasomal Degradation of AICD Species
B
16
7
105
78
55
45
105
78U
B
A
1
U
B
A
6
H
A
-ta
g
α-
tu
b.
AICD50 AICD51
siRNA:siRNA: Ctrl UBA1+6 Ctrl UBA1+6
0 
AICD50 AICD51 
C
20 
40 
60 
80 
100 
120 
A
IC
D
 le
ve
ls
 [A
U
]
A
Ctrl UBA1 UBA6 UBA1+6
U
B
A
1
U
B
A
6
105
78
55
105
78
55
45
α-
tu
b. 55
45
Ctrl siRNA
UBA1+6 siRNA
MW
[kDa] MW
[kDa]
D
U
bi
qu
iti
n
α-
tu
b.
PYR41−
55
105
MW
[kDa]
78
Figure 4.7 Knockdown of E1 Ub-activating enzymes does not stabilize AICD species.
A:Western blot analysis of HEK cells transfected with siRNAs directed against UBA1 and UBA6 or
control siRNA (Ctrl). Both E1 Ub-activating enzymes, UBA1 and UBA6, are eﬃciently decreased
by siRNA-mediated knockdown, individually and combined. B:Western blot analysis of HEK
cells transfected with Ub-fusion constructs expressing AICD50 and AICD51 and siRNA directed
against UBA1 and UBA6 or control-siRNA (Ctrl). C: Quantiﬁcation of AICD levels from B. No
signiﬁcant change in AICD50 and AICD51 was observed after combined knockdown of UBA1
and UBA6. Mean ± SEM of n = 3 are shown (∗p < 0.05, t-test). D:Western blot analysis of HEK
cells treated with the E1 Ub-activating enzyme inhibitor PYR41 or DMSO-control (−). Treatment
with PYR41 increased total ubiquitinated protein, likely because of inhibitory function on DUBs.
Dashed line indicates removal of western blot lanes; depicted lanes derive from same western
blot and same exposure times are displayed.
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Figure 4.8 Knockdown of N-domain-containing N-recognins does not stabilize AICD
species. A: Western blot analysis of wildtype and UBR1/2 dKO MEF lysates infected with
Ub-fusion construct expressing AICD51 and treated with cycloheximide (CHX) for the indicated
time. AICD51 was detected with HA-tag antibody. α-tubulin and GAPDH were probed to
show equal protein loading and are detected at approximately 50 kDa and 40 kDa, respectively.
B: Quantiﬁcation of AICD51 levels from A. Mean ± SEM of n = 3 are shown for each time point.
Data was ﬁtted to exponential functions by the least square approach. R2(WT) = 1.0; R2(UBR1/2
dKO) = 0.99.
the half-live of AICD51 in both cell lines. Wildtype and UBR1/2 dKO cells
did not display different half-live of AICD51, which was approximately 38min
in wildtype and approximately 38min in UBR1/2 dKO cells (figure 4.8B). We
could also not detect differences in steady-state levels of AICD51 in wildtype
and UBR1/2 dKOMEFs—though steady-state comparison between different
cell lines have to be considered with caution, because infection efficiency
between cell lines could vary considerably. Together, our data suggest that
different proteasomal degradation is not mediated by N-domain-containing
N-recognins. From the data presented here, we can not exclude that other
N-recognins are involved in the degradation of AICD species. Interestingly,
Tasaki et al. (2005) show that, in addition to UBR1/2, UBR4 might have a role
in degradation of proteins with type 2 destabilizing residues, though UBR4
does not contain an N-domain. Therefore, it is likely that the N-domain is not
the only domain mediating degradation of proteins with type 2 destabilizing
residues.
4.2.5 The role of AICD binding proteins in AICD degradation
Theoretically, the accumulation of AICD upon proteasomal inhibition that we
observed could be a result of decreased proteasomal degradation of a AICD-
stabilizing factor. Therefore, we aimed to show that AICD itself is degraded
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Figure 4.9 Binding of proteins to the YENPTY-domain of AICD is dispensable for its pro-
teasomal degradation. Western blot analysis of HEK cells transfected with HA-tagged wildtype
APP or APP(NPTY–NATA) and treated with epoxomicin (EPX; 0.1µM) or DMSO-control (−) for six
hours. Non-transfected sample (n.t.), DAPT-treated APP, and AICD (Ub-AICD50-HA construct)
samples were loaded to unequivocally identify CTF and AICD bands. Dashed line indicates re-
moval of western blot lanes; depicted lanes derive from same western blot and same exposure
times are displayed.
by the proteasome. Within the C-terminal domain of APP, the majority of
described protein interactions takes place at the YENPTY domain harboring
the NPxY motif (for a review of AICD binding partners see Muller et al., 2008).
These interactions at the YENPTY domain include Fe65 and Fe65-like proteins,
which were shown to be ubiquitinated and are suggested to be degraded by the
proteasome (Lee et al., 2009). But also other proteins, which were suggested to
mediate a function of AICD, as for example the Mint and JIP protein families
bind to the YENPTY domain.
To abrogate protein binding and thus investigate a potentially stabilizing
function of binding partners, we used a mutation of the NPxY motif. Previ-
ous publications have shown that the APP(NPTY-NATA) mutation abrogates
protein binding to this site (Cao and Sudhof, 2001; see also figure 3.8A for
immunocytochemical analysis of Fe65.) HA-tagged APP(NPTY-NATA) and
wildtype APP were transfected into HEK cells and treated with proteasomal
inhibitor (figure 4.9). DAPT-treated APP and AICD samples were loaded to
identify AICD bands. Similar to wildtype APP, AICD derived from APP(NPTY-
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Figure 4.10 APP FADmutations dramatically decrease AICD levels. A:Western blot anal-
ysis of HEK cells transfected with wildtype APP (WT) or APP harboring the T639I (Austrian, AT),
V639F (Indiana, IN), or K649N (Belgian, BE) mutation (all HA-tagged) and treated with epoxomicin
(EPX) or DMSO control (−) for four hours. DAPT-treated APP sample was loaded to identify CTF
and AICD bands. Dashed line indicates removal of western blot lanes; depicted lanes derive
from same western blot and same exposure times are displayed. B: Quantiﬁcation of AICD
levels from A. AICD levels from epoxomicin-treated samples were normalized to AICD levels the
from the respective DMSO-control–treated samples. Mean ± SEM of n = 3 are shown (∗p < 0.05,
t-test).
NATA) displayed accumulation after inhibition of the proteasome. Our results
do not permit to exclude stabilization of AICD by binding to other regions.
However, considering that most identified binding takes place at the YENPTY
domain, a stabilization of AICD by a binding protein that undergoes proteaso-
mal degradation is unlikely. In turn these results suggest that AICD itself is
subject to proteasomal degradation.
4.2.6 AICD levels in AD-causing APP mutations
To evaluate a potential role of AICD species in AD, we assessed proteasomal
degradation in selected FAD mutants. The T639I (Austrian), V639F (Indiana),
and K694N (Belgian) mutations were selected due to their proximity to the
-site. The T639I (Austrian) and V639F (Indiana) mutations were previously
also reported to shift processing towards the 48-site, thus increasing the
AICD51-to-AICD50 ratio (Chávez-Gutiérrez et al., 2012). APP-expressing
plasmids harboring the mutations were cloned, expressed in HEK cells, and
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treated with proteasomal inhibitor. DAPT-treated APP sample was loaded
to identify AICD bands. Western blot analysis of protein samples revealed
strongly decreased steady-state levels of AICD derived from all three mutations
under control conditions (figure 4.10A, compare lane three, five, and seven
to lane one). This reduction could be due to partial loss-of-function of γ-
secretase processing of mutant APP. These different efficiencies of γ-secretase
processing should display same fold-changes of AICD levels by inhibition
of degradation. Wildtype and FAD mutant–derived AICD levels increased
strongly after inhibition of the proteasome. All three FAD mutants displayed
increased fold-change of AICD upon inhibition of the proteasome, which can
not be explained by decreased γ-secretase cleavage (figure 4.10B). Our data
thus point towards an increased proteasomal degradation of AICD from FAD
APP mutants, possibly because of a shift of AICD production towards AICD51
that undergoes faster proteasomal degradation.
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4.3 Discussion
We have investigated proteasomal degradation of different AICD species. Our
data clearly demonstrates that AICD species are degraded by the proteasome
and, importantly, that AICD51 displays a faster proteasomal degradation
than AICD50. Analysis of the mechanism of degradation points towards
an ubiquitination-independent proteasomal degradation of AICD species.
Although the different proteasomal turnover of AICD species is reminiscent
of N-end rule proteasomal degradation, we could not identify a role of this
pathway in AICD species degradation. We further show that AICD levels
derived from FAD APP mutations are consistently decreased, possibly due to
increased production of unstable AICD species.
4.3.1 Mechanism of different proteasomal degradation of AICD
species
Expression of AICD species using Ub-fusion constructs in HEK cells revealed
significantly lower levels of AICD51 than AICD50. Inhibition of the proteasome
restored AICD51 levels to those of AICD50, clearly indicating that different
levels of AICD species are due to different proteasomal degradation. Since
AICD50 carries a stabilizing and AICD51 destabilizing residues—while the
remaining properties of the proteins are identical—we hypothesized that AICD
species undergo N-end rule proteasomal degradation, a specific ubiquitination-
dependent branch of proteasomal degradation.
However, our analysis from independent experimental lines argue against an
involvement of ubiquitination in the degradation of AICD species. Firstly, we
could not detect any ubiquitinated forms of AICD in immunoprecipitation of
APP-derived AICD50 and Ub-fusion construct-expressed AICD51. However,
enrichment of ubiquitinated forms by inhibition of the proteasome might be
counteracted by deubiquitinating activity of DUBs—for which, unfortunately,
no broad band inhibitor for cell culture is available. As Jariel-Encontre et al.
(2008) pointed out, “ubiquitylation (ubiquitination) usually concerns small
fractions of proteins and the assay used may meet with problems of sensitivity”
and, thus, absence of detection of ubiquitinated forms is not sufficient to
reject ubiquitination of a given protein. Therefore, in a second experimental
line, AICD levels were assessed after siRNA-mediated knockdown of E1 Ub-
activating enzymes. Combined depletion of both Ub-activating enzymes, UBA1
and UBA6, did not result in increased AICD levels. Given the importance
of ubiquitination in multiple cellular processes, an abundance of E1 Ub-
activating enzymes is likely and therefore residual enzyme levels could be
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sufficient to maintain protein ubiquitination. However, it should be noted that a
previous study, which used a similar experimental scheme and achieved similar
knockdown efficiencies of E1 Ub-activating enzymes, observed accumulation of
proteins that are otherwise degraded by theUPS (Lee et al., 2011). Similar to our
results from immunoprecipitation and E1 Ub-activating enzyme knockdown,
our investigations concerning a possible ubiquitination site argue against a
classical ubiquitin-dependent degradation of AICD. We conclusively show, by
lysine-to-arginine substitutions, that lysine residues are dispensable for the
proteasomal degradation ofAICD.Although, the vastmajority of ubiquitination
takes place on lysine residues, lysine-independent ubiquitination on cysteine,
serine, and threonine residues, as well as on the α-NH2 group of N-terminal
amino acids has been described (Kravtsova-Ivantsiv and Ciechanover, 2012).
Although, these reports are very rare, and non-lysine dependent ubiquitination
has only been described for a handful of proteins, we can formally not exclude
ubiquitination on non-lysine residues. Together, our results from AICD
immunoprecipitation, E1 Ub-activating enzyme knockdown, and lysine-to-
arginine substitutions failed to uncover a involvement of ubiquitination in
AICD degradation. Therefore, this combined evidence suggests that AICD
undergoes proteasomal degradation independent of ubiquitination. It is worth
mentioning that our results are not contradictory to previous studies that have
shown ubiquitination of C-terminal lysine residues of APP (Watanabe et al.,
2012; El Ayadi et al., 2012; Morel et al., 2013). These studies have only detected
ubiquitination of full-length APP and thus allow no conclusion about the
ubiquitination status of AICD. Ubiquitinated APP could possibly be degraded
or ubiquitin be removed before release of AICD by γ-secretase cleavage. Since,
we observe formation of nuclear AFT-complexes with AICD devoid of lysine
residues, our results also suggest that the transcriptional function of AICD is
no influenced by ubiquitination.
The bulk of proteins that are degraded by the proteasome undergoes prior
polyubiquitination, which serves as a recognition signal for the proteasome.
However, it must be noted that ubiquitination is not the only way to mark
proteins for proteasomal degradation. Two major ubiquitin-independent
proteasomal degradation mechanism are known, which are (i) ubiquitin-like
protein (UBL)-mediated degradation and (ii) direct substrate recognition by
the proteasome without prior PTM (Erales and Coffino, 2014).
UBLs are a family of nearly twenty proteins, which are involved in PTMs and
are characterized by a common structural element, the ubiquitin-superfold.2
2 To date known UBLs are—sorted according to van der Veen and Ploegh (2012) in decreasing
similarity to ubiquitin: Nedd8, Fub1, Isg15, Fat10, Hub1, Sumo1–3, Ufm1, Urm1, Atg8, and
Atg12.
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UBLs were shown to be involved in diverse cellular processes such as protein
transport, autophagy, and protein translation (for a review see van der Veen
and Ploegh, 2012), but presumably many functions remain unexplored. At least
three ubiquitin-like modifications—neddylation, fatylation, and sumoylation—
were shown to be involved in proteasomal degradation (Schulman and Harper,
2009). Interestingly, AICD can be neddylated at all five lysine residues, which
might influence bindingof adaptor proteins (Chen et al., 2012). However, among
the UBL modification, only attachment of Fat10 was shown to be independent
of ubiquitination, while attachment of Nedd8 and Sumo proteins is believed
to function as a basis for subsequent ubiquitination. Similar to ubiquitin,
absence of detection is not sufficient for denial of PTM by UBL modification,
which applies particularly to Fat10, which is rapidly removed from proteins
(Buchsbaum et al., 2012). Although, UBLs have their individual E1s (i.e.,
activating enzymes), UBA6 has dual function in activating ubiquitin and FAT10.
In light of the dependency of neddylation and sumoylation on subsequent
ubiquitination for proteasomal degradation, the combined knockdown of
UBA1 and UBA6 employed here should prevent any described ubiquitin or
ubiquitin-like modification that eventually results in proteasomal degradation.
Additionally, UBL modification, as ubiquitination, are predominantly taking
place on lysine residues. Therefore, lysine-to-arginine substitutions would
have equally uncovered a role of UBLs in AICD degradation. Our results thus
argue also against a involvement of UBL modification in AICD degradation.
The described evidence thus suggest that AICD undergoes proteasomal
degradation independent of modification of ubiquitin or UBL. An increasing
number of proteins has been discovered that undergo proteasomal degrada-
tion without PTM as recognition signal (see Ben-Nissan and Sharon, 2014 for
review and list of proteins). Additionally, multiple proteins (e.g., c-jun and
the transcriptional factor Rpn4) can undergo both ubiquitin-dependent and
ubiquitin-independent proteasomal degradation (Ju and Xie, 2004). General
mechanistic insight how proteins are degraded independent of ubiquitination
is missing. Analysis of proteins that undergo ubiquitin-independent protea-
somal degradation has revealed that they share a common feature, which are
intrinsically disordered regions (IDR; Erales and Coffino, 2014). Whether the
IDR is directly recognized by the proteasome or whether IDR folding and
binding to interaction partner mediates their proteasomal degradation is not
clear. For some proteins experimental evidence has suggested that ubiquitin-
independent proteasomal degradation is mediated by the 20S proteasome
(Ben-Nissan and Sharon, 2014). Interestingly, NMR and CD experiment have
revealed that AICD is intrinsically disordered (Ramelot et al., 2000). Although
this feature of AICD has been suggested to play a role for molecular recognition
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in intracellular signaling events, investigations of proteasome recognition are
missing.
N-end rule degradation is a specific branch of proteasomal degradation. It
is distinct from other proteasomal branches in two major points: Firstly, in
N-end rule degradation proteins are directly recognized at N-terminal residues
by specific E3 Ub-ligase enzymes, the N-recognins, which then ubiquitinate
the proteins. In contrast, in other branches of proteasomal degradation, other
parts of the protein sequence or a PTM of the protein is recognized by E3
Ub-ligase enzymes (e.g. recognition of phosphorylation by F-box proteins
of the SCF E3 Ub-ligase; Winston et al., 1999). Secondly, the identity of
the N-terminal amino acids, determines the kinetics of ubiquitination and
thus the rate of degradation (Bachmair et al., 1986).3 Accordingly, the twenty
naturally-occurring amino acids have either stabilizing or destabilizing function
(see table 4.1), presumingly because of binding specificity of the recognition
domains of the N-recognins (Varshavsky, 1992; Choi et al., 2010). Destabilizing
residues are further subdivided in type 1 and 2. Type 1 residues are basic amino
acids that are recognized by the UBR box of N-recognins. Type 2 residues in
contrast are bulky and hydrophobic amino acids and experimental evidence
suggest that these residues are recognized by the N-domain, which is present
only in the N-recognins UBR1 and UBR2 (Tasaki et al., 2005). Strikingly, we
observe a significantly faster proteasomal degradation of AICD51, harboring a
type 2 destabilizing N-terminal residue, than AICD50, harboring a stabilizing
N-terminal residue. Therefore, we have analyzed AICD species degradation in
MEFs deficient for the N-recognins UBR1 and UBR2. Tasaki et al. (2005) have
created and used these MEFs to show that N-domain-containing UBRs mediate
degradation of proteins bearing type 2 destabilizing residues. However, we
could not observe an influence of theses N-recognins on the degradation of
AICD51 that has a N-terminal type 2 destabilizing residue. Formally, we can
not exclude that other N-recognins play a role in AICD degradation. Indeed, for
UBR4 Tasaki et al. (2005) show that, although it does not contain anN-domain, it
can contribute to the degradation of proteins with type 2 destabilizing residues,
thus suggesting that also other domains than the N-domain mediate the
degradation of proteins with type 2 destabilizing residues (Dougan et al., 2012).
However, in light of our data that demonstrates that AICD is not ubiquitinated,
it is unlikely that proteasomal degradation takes place by N-recognin-mediated
N-end rule proteasomal degradation.
3 Recent studies have shown that in addition to the N-terminal residue, the identity of the
following residues can also influence binding to N-recognins and are thus important for the
N-end rule pathway (Sriram et al., 2013). Choi et al. (2010) provide also structural inside
how residues at the second position of a protein can modulate this binding specificity.
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How can the different proteasomal degradation, reminiscent of N-end rule
degradation, be explained without the involvement of ubiquitination and N-
recognins? It is unlikely that different AICD species adopt different structures,
and our experiments, using the expression from Ub-fusion constructs, should
also exclude a different localization of AICD species. A direct role of the
N-terminal amino acids is more likely and possible mechanisms include: (i)
preferential binding of destabilizing factors or the proteasome itself to AICD51
and (ii) preferential binding of stabilizing or shielding factors to AICD50.
Preferential binding of destabilizing factors to AICD51 could involve a direct
transport to the proteasome. In this respect, a role of the N-terminal region
in ubiquitin-independent proteasomal degradation was shown for multiple
proteins. Ju and Xie (2004) for example show that ubiquitin-independent degra-
dation of the transcription factor Rpn4 is dependent on its tenN-terminal amino
acids, while ubiquitin-dependent degradation depends on a more C-terminal
region of the protein. Peña et al. (2006) show that the thymidylate synthase (TS)
exclusively undergoes ubiquitin-independent proteasomal degradation and
that deletion of the N-terminal residues prevents TS degradation. Whether the
identity of the N-terminal residues influences turnover of degradation was not
investigated in these studies and also the mechanism how proteins find their
way to the proteasome without the ubiquitin-tag remains elusive. Interestingly,
in E.coli, which lack ubiquitin or ubiquitin-like modifications a N-end-rule-like
mechanism mediated by ClpS is well described. Strikingly, the short ClpS
protein is homologous to the N-domain, responsible for recognition of type 2
destabilizing residues and sequence relationship analysis between ClpS and
N-recognins suggests that they share a common origin (Lupas and Koretke,
2003). In contrast to N-recognins, ClpS mediates N-end rule degradation
without prior PTM, by directly escorting a N-terminal bound substrate to
the bacterial equivalent of the 26S proteasome (Tasaki et al., 2012). Whether
similar, direct degradation mechanism exist also in mammalian cells is not
known—at least the two N-domain-containing N-recognins, UBR1 and UBR2,
mediate proteasomal degradation via ubiquitination. A potential candidate
is the ribosomal protein L7/12, which has substantial structural similarity to
ClpS (Lupas and Koretke, 2003). However, experimental evidence whether
this structural feature of L7/12 allows recognition of proteins’ N-termini and
whether L7/12 is involved in proteasomal degradation ismissing. In light of the
remarkable structural and functional similarities between bacterial proteasome
and the mammalian 26S proteasome, it is imaginable that similar or conserved
transport mechanism to the proteasome exist (Verma and Deshaies, 2000).
Preferential binding of a stabilizing factor to AICD50 is a second possibility
to explain the observed different degradation of AICD species. In this respect
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the nanny model for proteins containing intrinsically disordered regions (IDRs)
developed by Tsvetkov et al. (2009) is highly interesting. IDRs are often
functional domains that allow binding to different binding partners with
high specificity and low affinity. Indeed, many IDR-containing proteins are
transcription factors or play a role in transcription. At the same time, the
IDR-containing proteins are designated to “degradation by default” since the
IDR allows a ubiquitination-independent degradation (Tsvetkov et al., 2009).
To overcome the paradoxical situation that the functional region of a protein
also destines the protein to degradation, and thus prevents its function, a
stabilization mechanism—the nanny—is required. The nanny protein shields
degradation of the protein after binding to the IDR. Examples for blockage of
proteasomal degradation of transcriptional factors include Hdmx binding to
N-terminal IDR of p53 and NF-κB shielding of NF-κBα (Tsvetkov et al., 2009).
The IDR of AICD, lack of ubiquitination and its role in transcription make a
AICD a candidate for nanny model. But—who’s AICD’s nanny? The only
described protein binding to theN-terminus of AICD is SET and an involvement
of this complex in apoptosis has been described (Madeira et al., 2005). However,
data of differential binding and putative stabilizing (or destabilizing) function
is not available. Another interesting candidate, for targeting AICD to the
proteasome is ubiquilin-1. Ubiquilin-1 was shown to modulate degradation
of proteasome substrates, such as p53 and also to physically interact with the
proteasome (Kleĳnen et al., 2000; Takalo et al., 2013). Further, ubiquilin-1 can
bind to AICD andmodulate its aggregation in in vitro assays (Stieren et al., 2011)
and influence APP processing (Viswanathan et al., 2013). Ubiquilin-1 could
be a missing link, by differently shielding AICD species from degradation or
transporting them differently to the proteasome.
4.3.2 Function and degradation of AICD species in Alzheimer’s
disease
Mutations in the genes encoding APP as well as the γ-secretase subunits
PSEN1 and PSEN2 result in the development of AD. However, the molecular
mechanism bywhich FADmutations cause the disease remains heavily debated.
A vast number of studies have assessed Aβ production and have revealed that
the Aβ42-to-Aβ40 ratio is increased (Wolfe, 2007). In contrast, only few studies
have investigated the effects of FAD mutations on the generation of AICD
species, although it became evident that FAD mutations affect APP processing
in different and multiple ways. The two alterations observed that directly effect
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AICD species levels are partial loss-of-function of γ-secretase processing as
well as a shift in processing at the -site.
Loss-of-function of processing at the -site and hence reduction in AICD
levels, has been found for the majority of FAD mutations investigated (for a
review see Shen and Kelleher, 2007). All studies have, probably because of
the technical difficulties to detect AICD, employed in vitro γ-secretase cleavage
assays andmost have relied on investigation of steady-state levels. To overcome
limitations of in vitro γ-secretase assays, such as different substrate and/or
enzyme concentrations, Chávez-Gutiérrez et al. (2012) have performed detailed
kinetic analysis of γ-secretase cleavage with FAD mutations in PSEN1, PSEN2,
and APP. Six PSEN1 mutations (Y115H, L166P, ∆E9, I213T, and G384A) and
one PSEN2 mutation (N141I) displayed a partial loss-of-function at the -site
as indicated by reduced AICD levels. M139V, was the only PSEN mutation
that showed no alteration. Loss-of-function (and hence reduced AICD levels),
was also observed for three APP FAD mutations (T639I (Austrian), V640T
(German), and I641T). In contrast, no change was observed for the mutations
V642F (Indiana) and V644I (London). Overall, this study reflects previous
works which show that a partial loss-of-function of γ-secretase activity at -site
and thus corresponding reduction in AICD levels is common in FADmutations
(Moehlmann et al., 2002; Hecimovic et al., 2004; Guardia-Laguarta et al., 2010;
Svedružić et al., 2012). In particular FAD mutations in the presenilins show
predominantly a partial loss-of-function of γ-secretase activity. However, it
is important to emphasize that loss-of-function of γ-secretase activity is not
observed in all FAD mutations.
The second observed route how FAD mutations affect AICD species is a shift
of γ-secretase cleavage position at the -site. Sato et al. (2003) were the first to
observe an increase in AICD51 while total AICD levels were unchanged for
two PSEN1 mutations (M233T and G384A) and the N141I PSEN2 mutation.
A shift of γ-secretase cleavage from the 49- to the 48-site was confirmed for
PSEN1 G384A mutation and further shown for the mutations Y115H, L166P,
and M139V (Chávez-Gutiérrez et al., 2012). However, shifting γ-secretase
cleavage at the -site is not a compulsive property of PSEN mutations since
it was not observed for M146L (Sato et al., 2003), ∆E9, and I213T mutations
(Chávez-Gutiérrez et al., 2012). For mutations in APP, Chávez-Gutiérrez
et al. (2012) observed a shift in all four mutations tested which are T639I
(Austrian), V640A (German), V642F (Indiana), and V642I (London). Recent
and independent studies have confirmed these results and shown shifts also
for the T639A (Iranian), I641V (Florida), and L648P (Australian) mutations
(Dimitrov et al., 2013; Olsson et al., 2014). In contrast, APP FAD mutations
more distant to the -site —A617G (Flemish) , E618G (Arctic), and D619N
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(Iowa)—did not show a shift (Dimitrov et al., 2013). Similar to the described
partial loss-of-function, shifting of cleavage at -site is no necessary property of
FAD mutations. However, it can be excluded that partial loss-of-function and
-site shifting are mutually dependent or exclusive since mutations that result
in both but also those which result only in one are described. Interestingly, all
mutations that were examined for both properties displayed at least one.
The described studies assessing AICD levels in FAD mutations have almost
exclusively relied on in vitro systems. Although these approaches are infor-
mative, in particular about the kinetics of processing, they do not reflect the
physiological situation in the cell. Differences in trafficking and localization
and in particular in degradation are not taken into account. Therefore, we have
analyzed, for the first time, AICD levels from APP FAD mutations expressed
in cells. We placed a particular focus on a possible divergent proteasomal
degradation of AICD species due to the described shift in cleavage at -site.
For the three selected APP FADmutations —T639I (Austrian), V639F (Indiana),
and K649N (Belgian)— we observed dramatic decrease in steady-state AICD
levels under control conditions. Treatment with epoxomicin levels increased
AICD levels in all cases, excluding a complete loss-of-function of γ-secretase
processing. If different efficiencies of γ-secretase processing alone were to ex-
plain the reduced AICD levels, same fold-changes of AICD levels by inhibition
of the proteasome would be expected. However, analysis of fold-changes of
AICD levels revealed consistent increases in all three FADmutations. Thus, our
results suggest that FAD APP mutants result in decreased AICD levels by two
mechanism, which are a partial loss-of-function of γ-secretase function and a
increased degradation by the proteasome. In light of the described processing
shift at the -site for the T639I (Austrian) and V639F (Indiana) mutations—the
K649N (Belgian) was not investigated so far—it is tempting to speculate that
faster proteasomal degradation of AICD51 contributes to the observed decrease
in total AICD levels. However, further analysis, in particular separate and
reliable detection of AICD species, are needed to conclusively demonstrate a
potential role of different AICD species degradation in FAD mutations.
4.3.3 Conclusion
In summary, the data presented here clearly show for the first time proteasomal
degradation of AICD species. We show further that different AICD species
undergo different proteasomal degradation and that proteasomal degradation
is independent of prior ubiquitination. As discussed, our data suggest a
ubiquitination-independent proteasomal degradation of AICD species that
is modulated by stabilizing or destabilizing factors in an N-end rule-like
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manner. We further analyze for the first time AICD levels from APP FAD
mutants from cell culture experiments and show that APP FAD mutations
result in consistent reduction of AICD levels. Our results suggest that decreased
efficiency of γ-secretase cleavage and shift in processing towards AICD species
that is degraded faster by the proteasome results in overall decreased AICD
levels. Thus our results imply that alteration in the production of Aβ42/40 is
inherently correlated with alterations in the transcriptional regulator AICD.
Interestingly, recent genetic analyses have revealed that the UPS is one of
four biological network modules with increased genetic association to AD
(International Genomics of Alzheimer’s Disease Consortium (IGAP), 2014) and
multiple studies have shown that the UPS is impaired in AD (Keller et al., 2000;
Lam et al., 2000; Riederer et al., 2011). A possible contribution of AICD to the
pathological events of FAD—via transcriptional regulation or other— needs
therefore further investigations.
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5 Towards an in vivoModel of AICD
Transcriptional Function
In this chapter, we present and analyze a novel mouse model of the transcrip-
tional function of AICD.
5.1 Introduction
Since the first description of the involvement of AICD in gene regulation,
the transcriptional function of AICD was repeatedly confirmed in vitro (Cao
and Sudhof, 2001; Pardossi-Piquard and Checler, 2012). Recent studies have
begun to investigate the functional role of AICD also in vivo. Using APP
knockout as well as knock-in mouse lines, multiple publications, particularly
from the laboratories of Luciano D’Adamio and Hui Zheng, have revealed
essential functions of APP. Interestingly, binding of Fe65 to the APP C-terminus
emerged as particularly important for the role of APP. Tyrosine-to-glycine
substitution of the first tyrosine within the YENPTY domain in the C-terminus
of APP (APP(Y682G)) abolished binding to Fe65 in an APP knock-in mouse line
(Barbagallo et al., 2010). Phenotypical analyses of APP(Y682G) mice revealed
an age-dependent cognitive decline and progressive reduction in dendritic
spines (Matrone et al., 2012). APP(Y682G) mice crossed to an APLP2 knockout
background even displayed postnatal lethality and defects in formation of
the neuromuscular junction similar to mice completely deficient in APP and
APLP2 (Barbagallo et al., 2011). In an independent mouse line, Weyer et al.
(2011) show that ablation of the last ninety-nine amino acids of APP on an
APLP2 knockout background resulted in cognitive dysfunction and similar
defects at the neuromuscular junction. Although, these mice—in contrast
to the APP(Y682G) mice—survived early development, additional defects in
hippocampus-dependent learning and memory as well as impaired long-term
potentiationwere observed. Together, these results demonstrate the importance
of the C-terminal domain of APP and its binding to Fe65. Formally, it can not be
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excluded that the observed phenotypes are due to other functions of Fe65 than
mediating AICD transcriptional signaling (discussed below). However, in light
of the well described function of Fe65 for nuclear signaling and transcriptional
function of AICD, a role of AICD in the described phenotypes is very likely.
The describedmouse lines with ablatedAICD signaling have greatly enriched
our understanding of the function of AICD in vivo. However, no study has so
far addressed how the transcriptional function of AICD is regulated in vivo.
Multiple studies have shown that APP processing as well as Aβ secretion
and toxicity are regulated by neuronal activity.1 Using hippocampal slice
cultures, Kamenetz et al. (2003) for example, show that increased neuronal
activity increases secreted Aβ levels. They show further, that neuronal activity
increases the levels of C83, suggesting that β-cleavage of APP by BACE1 is
activity-dependent. In primary cortical neurons, Hoey et al. (2009) observe that
activation of synaptic NMDA receptors increased α-secretase processing of
APP and decreased Aβ release. Imaging studies indicate that neuronal activity
modulates APP processing and/or Aβ deposition also in humans. Buckner
et al. (2005) used FDG-PET, to measure glucose metabolism, and PiB-PET, to
measure Aβ deposition. Interestingly, highest Aβ plaque levels are found in
brain regions with highest synaptic activity reflected by highest metabolic rate.
Together, these studies also suggest that AICD—as it is produced hand in hand
with Aβ—is regulated by neuronal activity. However, secretion and possible
functions of AICD in response to neuronal activity have been hardly addressed.
In particular the technical difficulties in detecting AICD, due to its lability
but also lack of specific antibodies, have so far not allowed to unequivocally
identify nuclear AICD and thus prevented an analysis of AICD regulation in
response to neuronal activity. A novel approach to visualize AICD activity is
therefore required.
The aim of this project is to establish and analyze an in vivomodel of AICD
transcriptional function. The UAS/Gal4 system allows to study and visualize
transcriptional function and has been successfully used for gene expression
analysis in vitro as well as in animals, such as Drosophila and mice (Halpern
et al., 2008). The system is based on the modular character of the yeast Gal4
transcription factor. The N-terminal domain of Gal4 contains the DNA binding
domain (DBD), which binds to specificDNA sequences, the upstream activating
sequence (UAS) elements. Its C-terminal domain contains an acidic domain
which activates transcription by interaction with the transcription complex,
therefore also called acivation domain (here abbreviated AcD). Binding of
complete transactivator Gal4 (i.e., DBD and AcD) to the UAS elements can thus
1 For a comprehensive review of activity-dependent processing of APP see Haass et al., 2012.
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activate expression of a reporter gene of choice present downstream of the
UAS elements. Cao and Sudhof (2001) have shown that fusion of AICD to the
Gal4-DBD regulates reporter gene expression, thus suggesting that AICD is a
transcriptional activator. We reasoned that the UAS/Gal4-system could also be
a valuable system for visualization of transcriptional function of AICD in vivo.
Therefore, we transferred the UAS/Gal4-based AICD transcription assay to an
in vivo context and describe here the generation of the APPGal4 mouse line.
The APPGal4 mouse line promises to allow visualization of the spatiotemporal
pattern of the transcriptional function of AICD in vivo.
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5.2 Results
5.2.1 Characterization of the APP-Gal4 chimeric protein
For the creation of a in vivo model for transcriptional activity of AICD, we
intended to use a chimeric APP-Gal4 construct. Cao and Sudhof (2001) have
cloned and used the APP-Gal4 construct to show that AICD is transcriptionally
active in a UAS/Gal4 assay. The construct comprises the insertion of the 147
amino acid long Gal4-DBD (Gal4 residues 1–147) at position 651 of human
APP, which is six amino acids C-terminal to the -site (see also figure 5.1A
and section 2.3). Ectodomain shedding of the APP-Gal4 construct produces
CTF-Gal4, which is then supposed to be cleaved by γ-secretase to produce
AICD-Gal4 (and Aβ). The close proximity of the Gal4-DBD to the γ-secretase
cleavage sites have raised concerns about proper cleavage of CTFs (because
of e.g., sterical hindrance). Therefore, HEK cells were transfected with APP-
Gal4, treated with the γ-secretase inhibitor DAPT, and subjected to western
blotting with an antibody recognizing the C-terminus of APP (figure 5.1B).
Full-length APP-Gal4 was detected as major band at the expected height of
approximately 100 kDa. CTF-Gal4 and AICD-Gal4 were detected in control-
treated cells at approximately 30 kDa—the theoretical molecular weight of
the primary sequence of α-CTF-Gal4 and AICD-Gal4 are 28 kDa and 24 kDa,
respectively. AICD-Gal4 disappeared upon inhibition ofγ-secretase, while CTF-
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Figure 5.1 The APP-Gal4 chimeric protein undergoes normal APP processing.
A: Schematic illustration of the APP-Gal4 construct. Cleavage of APP-Gal4 by either α- or
β- secretase followed by γ-secretase cleavage at the -site produces AICD-Gal4. B:Western
blot analysis of HEK cells transfected with APP-Gal4 and treated with γ-secretase inhibitor
DAPT or DMSO-control (−). An antibody recognizing the C-terminus of APP was used to detect
APP-Gal4 and its cleavage products.
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Gal4 concomitantly accumulated. These results clearly show that γ-secretase is
able to cleave APP-Gal4, resulting in the release of AICD-Gal4.
To confirm transcriptional activity of AICD-Gal4 we established a novel, cell
based UAS/Gal4 assay. A plasmid expressing citrine under the control of a
minimal promoter and nine UAS repeat elements was cloned. Figure 5.2A
shows that UAS-Cit construct is only allowing the expression of citrine in the
presence of a complete transactivator (i.e., Gal4-DBD fused to an activation
domain). To overcome limitations of transient transfection, we prepared a
HEK cell line with stable integration of the UAS-Cit element (see section 2.2 for
details of preparation of stable cell lines). The HEK(UAS-Cit) cell line displays
expression of the citrine reporter gene only upon transfection with a complete
transactivator (figure 5.2B). To test transcriptional activity of AICD-Gal4, APP-
Gal4 was transfected into the HEK(UAS-Cit) cell line and citrine reporter signal
was amplified by immunostaining (figure 5.3). However, no fluorescence signal
was observed. Binding of AICD to adaptor proteins such as members of the
Fe65 and Jip family of proteins is known to be necessary for nuclear transport
of AICD (see e.g., von Rotz et al., 2004). However, Fe65 for example is strongly
expressed in neurons, while expression in other cell types is rather low (Sabo
et al., 2003). Therefore, nuclear signaling and transcriptional activity of AICD
in HEK cells could be limited by low levels of adaptor proteins. Co-transfection
of APP-Gal4 and Fe65 into the HEK(UAS-Cit) cell line showed prominent signal
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Figure 5.2 The HEK(UAS-Cit) cell line shows reporter activity with a transactivator.
A: Fluorescence and bright-ﬁeld (BF) images of HEK cells transfected with the UAS-Cit plas-
mid and co-transfected with the complete transactivator Gal4(DBD)-Gal4(AcD) or Gal4-DBD
alone. B: Fluorescence images of HEK(UAS-Cit) cells mock transfected or transfected with or
Gal4(DBD)-Gal4(AcD). Nuclei were stained with DAPI.
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Figure 5.3 APP-Gal4 shows nuclear transcriptional activity with co-transfection of Fe65.
Confocal ﬂuorescence images of HEK(UAS-Cit) cells mock transfected (−), transfected with APP-
Gal4, or co-transfected with APP-Gal4 and Fe65. Citrine signal was enhanced by immunostaining.
Nuclei were stained with DAPI. Merge is DAPI and citrine. Scale bar represents 200µm.
of reporter activity, indicating that indeed levels of Fe65 are a rate-limiting
factor for transcriptional activity of AICD in non-neuronal cells (figure 5.3). In
summary, our results from a novel cell-based UAS/Gal4 assay confirm that
AICD-Gal4 derived from APP-Gal4 is transcriptionally active. In addition, it
is important to note, that because of the stable integration of UAS-Cit in the
HEK(UAS-Cit), we show here for the first time unequivocally that nuclear
localization of AICD is necessary for its transcriptional activity.
5.2.2 Construction and analysis of the APPGal4 mice
APP-Gal4 was cloned into a pMoPrp plasmid, previously used successfully
in our laboratory to generate the ArcAβ mice, a APP transgenic mouse line
(Knobloch et al., 2007). Transgenic mice were generated by the Institut für
Labortierkunde (University Zurich) by embryo transfer of the APP-Gal4 con-
struct and three different founder lines were provided. Whole brain lysates of
founder lines were prepared and probed for expression of the transgenewith an
antibody recognizing human but not mouse APP (figure 5.4). All three founder
lines showed expression of APP-Gal4, however, levels were considerably lower
than APP levels in ArcAβmice. Founder line #3, subsequently called APPGal4
mice, was chosen for subsequent experiments because of highest expression
levels.
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Figure 5.4 APPGal4 founder lines showedmoderate expression of the APP-Gal4 protein.
Western blot analysis of whole brain lysates were probed with an antibody recognizing ex-
clusively human (here i.e., transgenic) APP. Note that AICD is not recognized by this antibody.
Founder line #3 was chosen for subsequent experiments, and hereafter called APPGal4 mice.
For in vivo analysis of AICD transcriptional activity, APPGal4 mice were
cross-breed with UAS-lacZ mice, which were previously used in Govindarajan
et al. (2005) and Smith et al. (2012). UAS-lacZ mice carry the β-galactosidase-
encoding gene lacZ under the control of a minimal promoter and six UAS
elements. In absence of a complete transactivator that is able to bind to
the UAS repeats no expression of β-galactosidase takes place. Due to the
transcriptional activity of AICD, binding of AICD-Gal4 to the UAS element
repeats should induce expression of β-galactosidase. β-galactosidase in-turn
can be detected by X-Gal staining, a colorimetric staining of a synthetic product
of β-galactosidase enzyme activity. To analyze expression of β-galactosidase
by transcriptional activity of AICD, cryosections of wildtype, UAS-lacZ, and
APPGal4/UAS-lacZ double transgenic mouse brains were prepared. Sections
were fixed with PFA, methanol, or fixative solution (provided by the X-Gal
staining Invitrogen kit) and stained for β-galactosidase activity. Sections were
analyzed one hour and longer durations of incubation at 37 ◦C by regular light
microscopy. However, we could not detect any formation of insoluble, blue
precipitate which is suppose to form by β-galactosidase activity. Due to poor
quality of sections after extended incubation with X-Gal (more than forty-eight
hours incubation) no images of sections were taken.
We reasoned that detection of potentially low β-galactosidase levels in
APPGal4/UAS-lacZ mice could be enhanced by immunohistochemical stain-
ing. Free-floating brain sections were prepared from adult wildtype and
APPGal4/UAS-lacZ double transgenic mice and stained with an antibody rec-
ognizing β-galactosidase. Brain sections of embryonic BATGal transgenic mice
were obtained from Bruno Fischer and Olivier Raineteau (University Zurich)
and used as positive control for β-galactosidase antibody staining. BATGal
mice express nuclear β-galactosidase under the control of β-catenin/T-cell
factor responsive elements (Maretto et al., 2003; Al Alam et al., 2011; Azim et al.,
2014). Staining of BATGal brain sections displayed clear nuclearβ-galactosidase
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Figure 5.5 β-galactosidase is not detectable in brain sections of APPGal4/UAS-lacZ dou-
ble transgenic mice. Fluorescence images of brain sections from E14 BATGal (left panel), adult
APPGal4/UAS-lacZ double transgenic (middle panel), or adult wildtype mice (right panel) stained
with β-galactosidase primary and Cy3-coupled secondary antibody. Nuclei were stained with
DAPI. Scale bar represents 150µm.
staining, demonstrating usability of the employed β-galactosidase staining
protocol (figure 5.5). In contrast to sections of BATGal mice, we could not
observe β-galactosidase positive cells in sections from APPGal4/UAS-lacZ
double transgenic mice (figure 5.5). The weak observed signal observed in
APPGal4/UAS-lacZ sections was equally present in sections from wildtype
mice and accounts thus as background signal. Together, our results from
enzymatic and immunohistochemical staining show no detectable levels of
β-galactosidase in APPGal4/UAS-lacZ double transgenic mice. Possible reason
for the absence of reporter protein include low sensitivity of the used assays,
absence of transcriptional activity of AICD in vivo, and dysfunction of the
UAS-lacZ reporter mice.
To explore the underlying reason for absence of β-galactosidase signal in
APPGal4/UAS-lacZ mice, we envisaged analysis of primary neurons that
allow manipulations that are not possible with brain sections. To this end,
a β-galactosidase staining protocol for cultured cells was developed. HEK
cells were transfected with a plasmid encoding the lacZ gene under the control
of a CMV promoter, which allows constitutive gene expression. Cells were
fixed and stained for enzymatic activity of β-galactosidase as described in
section 2.4. A clear β-galactosidase signal was observed in lacZ transfected
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Figure 5.6 β-galactosidase activity can be detected in cultured cells. Bright-ﬁeld (BF)
images of HEK cells transfected with constitutively-expressed lacZ or mock transfected (−) and
stained for β-galactosidase activity with X-Gal.
cells that was absent in stained but non-transfected control cells (figure 5.6).
Next, we prepared primary neurons from one-day-old wildtype, APPGal4,
UAS-lacZ, and APPGal4/UAS-lacZ mice. Plasmid transfection of primary
neurons was done at DIV 7 and cells fixed and stained for β-galactosidase at
DIV 11. Primary neurons from wildtype mice transfected with lacZ showed
clear and abundant staining of β-galactosidase, confirming the utility of the
staining protocol and efficient plasmid transfection also in primary neurons
(figure 5.7). Of note, β-galactosidase signal was almost exclusively detected in
the cell soma and no signal was observed in dendrites. Similar to the reported
observations from brain sections, primary neurons from APPGal4/UAS-lacZ
did not show a positive signal. Next, we aimed to analyze functionality of
APPGal4 and UAS-lacZ mice separately. For this purpose, the Gal4(DBD)-
VP16 plasmid, expressing the potent activation domain VP16 fused to the
Gal4-DBD, and the UAS-lacZ plasmid harboring a reporter construct similar
to the transgene of UAS-lacZ mice were obtained. Wildtype primary neurons
CMV-lacZ
WT mice
−
APPGal4/
UAS-lacZ mice
UAS-lacZ
WT mice
UAS-lacZ + 
Gal4-VP16
WT mice
UAS-lacZ
APPGal4 mice
Gal4-VP16
UAS-lacZ mice
B
F
Figure 5.7 UAS-lacZ primary neurons do not show β-galactosidase expression after
transfection with a strong transactivator. Representative bright-ﬁeld (BF) images of pri-
mary neurons stained for β-galactosidase with X-Gal staining at DIV 11. Primary neurons were
prepared from P1 embryos and transfected with plasmids at DIV 7. Genotypes of mice are
indicated above the bar. Plasmid used for transfection are indicated below the bar.
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Figure 5.8 Transcriptional activity of AICD-Gal4 in APPGal4 primary neurons is en-
hanced by expression of Fe65. Representative ﬂuorescence images of primary neurons
immunostained for β-galactosidase at DIV 11. Nuclei were stained with DAPI. Primary neurons
were prepared from P1 embryos and transfected with plasmids at DIV 7. Genotypes of mice are
indicated above the bar. Plasmid used for transfection are indicated below the bar.
transfected with UAS-lacZ and Gal4-VP16 plasmids showed clear positive
signal (figure 5.7). No signal in contrast was observed in primary neurons
transfected with UAS-lacZ alone , demonstrating that the UAS-lacZ plasmid
is not expressing β-galactosidase without complete transactivator. APPGal4
neurons transfected with UAS-lacZ showed any positive signal, albeit in very
few cells. In contrast, UAS-lacZ neurons did not show a positive signal when
transfected with the strong transactivator Gal4(BDB)-VP16.
As mentioned earlier, immunohistochemical staining for β-galactosidase
might display higher sensitivity than enzymatic staining for β-galactosidase
activity. Therefore, primary neurons were also analyzed by immunostaining of
β-galactosidase. Immunohistochemical staining of wildtype primary neurons
showed no signal, indicating very low off-target recognition of both primary
and secondary antibody (figure 5.8). In contrast primary neurons transfected
with lacZ showed strong and abundant fluorescence signal. Similar to staining
of enzymatic activity, primary neurons from APPGal4 mice transfected with
UAS-lacZ displayed a clear positive signal, albeit in only few cells. As shown
earlier, binding of adaptor proteins, such as Fe65, are a rate-limiting factor for
transcriptional activity of AICD in non-neuronal cells. We reasoned that levels
of adaptor proteins could also be a rate-limiting factor in primary neurons.
Co-transfection of UAS-lacZ and Fe65 in APPGal4 primary neurons clearly
increased the number of β-galactosidase positive cells compared to transfection
with UAS-lacZ alone (figure 5.8). We also transfected APPGal4/UAS-lacZ
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primary neurons with Fe65 to test whether increasing nuclear transport of
AICD-Gal4 could result in enhancement of its transcriptional activity. However,
transfection of Fe65 did also not result in detectable levels of β-galactosidase.
In summary the analysis of primary neurons from APPGal4 and UAS-lacZ
mice revealed several interesting findings. Firstly, transfection of UAS-lacZ
primary neurons with the strong transactivator Gal4(DBD)-VP16 did not result
in expression of β-galactosidase. This observation strongly suggest that the
UAS-lacZ element of UAS-lacZ mice is non-functional. Secondly, transfection
of APPGal4 primary neurons with a UAS-lacZ plasmid showed positive, albeit
little, signal. Further, we show that transcriptional activity of AICD-Gal4 in
APPGal4 primary neurons can be strongly increased by transfection of Fe65.
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5.3 Discussion
We have generated a novel transgenic mouse line, the APPGal4 line, for
analysis of the transcriptional function of AICD in vivo. APPGal4 mice were
crossed to the UAS-lacZ reporter line and brain lysates, brain sections, and
primary neurons analyzed. However, no reporter activity was observed in
APPGal4/UAS-lacZ double transgenic mice. By analysis of transgenic mice
separately, we discovered that the reporter element of UAS-lacZ mice is non-
functional, while APPGal4 mice displayed transcriptional activity as intended
by their design.
Our analysis of UAS-lacZ mice demonstrated that the reporter construct is
not functional. Primary neurons from UAS-lacZ mice were transfected with
the potent transactivator Gal4-VP16 but no reporter activity was detected.
It remains unclear why the UAS-lacZ transgene is not functional. Previous
studies have successfully used the UAS-lacZ mouse line as a reporter of Notch
transcriptional activity (Smith et al., 2012). It is unlikely that UAS-lacZ site
is placed in a loci that hinders its accessibility in the here investigated brain-
derived tissue because similar tissue was analyzed previously (Smith et al.,
2012). Aparticular difficulty in themaintenance of thesemice is that the reporter
gene is not expressed, unless crossed to an activator line. Additionally, the
number of UAS-lacZ transgene integrations and the actual sites of integration
are not known. Therefore, genotyping of mice can only be done by intra-
transgenetical PCR and length of the PCR product is the only criterion for
selection of offspring. It is possible that UAS-lacZ mice acquired mutations
in the UAS regulatory region or lacZ coding region that ablate binding of the
Gal4(BDB) or impede proper gene expression, respectively.
APPGal4 is a novel mouse line for studying the transcriptional activity of
AICD. APP-Gal4 transgene expression is approximately ten fold lower than
APP expression in the ArcAβ mouse line, which was established using the
same promoter for transgene expression (Knobloch et al., 2007). Because the
APPGal4 mouse line is based on the UAS/Gal4 activator/reporter system,
its utility is fully dependent on a functional reporter mouse line. In light of
the non-functioning of the UAS-lacZ mouse line, analysis of APPGal4 mice
was only possible in primary neurons, which can be transfected with UAS-
reporter plasmids. Generation of a novel reporter line is therefore obligatory
for further investigations using the APPGal4 mouse line. A second critical
point of the APPGal4 mouse line are the levels of adaptor proteins that
mediate nuclear translocation of AICD-Gal4. We showed that primary neurons
from APPGal4 mice transfected with UAS-lacZ plasmid displayed sporadic
positive cells, which were greatly increased in number by co-transfection of
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the AICD-binding protein Fe65. Though we have not evaluated endogenous
Fe65 levels itself, our results suggest that levels of Fe65 are rate-limiting for the
transcriptional function of AICD-Gal4 in non-neuronal cells and also primary
neurons. However, it is important to emphasize that the data presented here
does not allow to claim that AICD has no transcriptional function in these cells
at all. Sensitivity of endogenous AICD-binding regulatory elements could
be higher than the one of the UAS/Gal4 system. It has also to be kept in
mind that AICD levels from transgene expression are probably a multitude
higher than endogenous AICD levels. Therefore, levels of Fe65 and other
adaptor proteins could be largely sufficient to mediate transcriptional function
of endogenous AICD. The observation that APP(Y682G) on a APLP2 knockout
background, which have disrupted AICD–Fe65 binding, die perinatally, also
emphasizes a important role of this protein complex in mouse development.
Therefore, the important question for the utility of the APPGal4 mouse line is,
whether levels of adaptor proteins are always the rate-limiting factor for the
transcriptional function of transgene-derived AICD-Gal4. Kesavapany et al.
(2002) demonstrate that Fe65 levels in late embryonic development and at a
birth of mice are barely detectable. However, since Fe65 strongly increases
postnatally, we have good reason to believe that levels of adaptor proteins are
not generally rate-limiting for the transcriptional function of AICD-Gal4. In
summary, our results thus provide proof-of-principle of the APPGal4 mouse
line for studying the transcriptional function of AICD. Under the assumption
that a functional UAS-reporter mouse can be established, the APPGal4 mouse
line constitutes a promising tool for the investigation of transcriptional function
of AICD in vivo.
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6 Conclusions and Outlook
In the first results part of this thesis, we aimed to better understand the
mechanism and constraints of nuclear signaling of AICD. We discovered
different nuclear signaling and AFT-complex formation capability of ICDs
derived from different APP family members. In summary, our subsequent
analyses revealed sequence determinants for AFT-complex formation and
displays, for the first time, that ICDs from APP family members are subject to
proteasomal degradation. Our results suggest a function of APP and APLP2 in
transcriptional regulation, which is absent in APLP1. The uncovered sequence
determinants for nuclear signaling of AICD can be of great benefit for future
analyses of the physiological function of AICD.
APP knockout mice display a variety of phenotypes, including decreased
body and brain weight, behavioral deficits, and defects at the neuromuscular
junction, which are further aggravated by additional knockout of APLP2 (see
also Müller and Zheng, 2012). Whereas these phenotypes first of all clearly
demonstrate that APP and its proteolytic products have important physiological
functions, they secondly raise the questions which function is mediated by
which APP fragment. A prime function of AICD among APP proteolytic
fragments was highlighted by the analysis of an APP knock-in mouse line
with a single amino acid mutation in vicinity to the NPxY motif (APP(Y682G)
mice), which abolished binding of Fe65 (Barbagallo et al., 2010, 2011; Matrone
et al., 2012). APP(Y682G) mice crossed to an APLP2 knockout background
displayed severe defects in the formation of the neuromuscular junction and
perinatal lethality similar to mice completely deficient in APP and APLP2.
Binding of Fe65, in addition to its role in nuclear translocation of AICD, was
also shown to influence APP processing, which is reflected by clearly increased
levels of sAPPα in the brains of APP(Y682G) mice. The observed phenotypes
in these mice can therefore not be attributed exclusively to the lack of AICD-
mediated transcriptional activity. The discovery of sequence determinants
for nuclear signaling of AICD presented here, offers in this respect a unique
possibility to investigate the function of AICD. Exchange of the N-terminal
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amino acids of AICD VML646 with LLR, did not disrupt binding of Fe65 and,
importantly, no differences in APP processing were observed, except for a
dramatic reduction in AICD levels. We therefore propose the generation of
an APP(VML646LLR) knock-in mouse line. This mouse line—which from a
physiological perspective could represent an AICD knockdown model—could
allow to investigate unambiguously the physiological functions of AICD in
vivo. To allow investigation of redundant functions of AICD and AL2ICD, we
propose also the construction of a conditional APP(VML646LLR) mouse line to
circumvent possible (and likely) perinatal lethality of APP(VML646LLR) mice
on an APLP2 knockout background.
In the second results part of this thesis, we aimed to decipher the molecular
mechanism of AICD proteasomal degradation. In this analysis, a particular
focus was placed on the regulation of different AICD species, generated by vari-
able cleavage of γ-secretase at the -site, and a possible contribution of AICD
to AD pathology. We clearly show that AICD51 undergoes faster proteasomal
degradation than AICD50. This different regulation is reminiscent of the N-end
rule proteasomal pathway, a specific ubiquitin-dependent branch of proteaso-
mal degradation, in which the identity of the N-terminal residue of a substrate
determines its proteasomal turnover. In summary, our mechanistic analyses,
however, show that proteasomal degradation of AICD species is independent
of ubiquitination or modification by ubiquitin-like proteins, and we could also
not detect any regulation of AICD levels by N-end rule specific E3 Ub-ligase
enzymes. Therefore, we suggest that different proteasomal degradation of
AICD species is mediated by stabilizing or destabilizing factors in a N-end rule-
like manner. Identification of the proposed stabilizing or destabilizing factors
that mediate the different degradation of AICD species should, therefore, be a
main aim for future experiments. Experiments employing comparative mass
spectrometry analysis to identify binding partners of AICD species could build
on the already established and efficient immunoprecipitation of AICD species.
In the course of our investigations, we also analyzed, for the first time, AICD
levels derived from FAD APP mutants in cell culture experiments and revealed
a dramatic reduction of AICD levels. FAD mutants display two well-described,
independent phenomena of altered γ-secretase processing, which are partial
loss-of-function of γ-secretase activity and shift of γ-secretase cleavage at the
-site. It is well established that partial loss-of-function results in decreased
AICD levels. We suggest that shift of γ-secretase cleavage at the -site, by
the production of unstable AICD species, similarly results in decreased total
AICD levels. Interestingly, such a regulation would imply that production of
the principal toxic agent of AD, Aβ42, would be inherently correlated with
decreased total levels of AICD,which could in turn point towards a role of AICD
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in AD pathology. However, a clear analysis of possible different degradation
of AICD species derived from APP, and in particular APP with FAD mutations,
is clearly limited by the lack of techniques to separately detect AICD species.
Developing means to separately detect AICD species should, therefore, obtain
highest priority for future experiments. Two promising techniques that could
be employed are usage of urea-based SDS-PAGE, which has been shown to
provide higher resolution than regular SDS-PAGE, and detection of AICD by
mass spectrometry as performed by Dimitrov et al. (2013) for AICD generated
from in vitro assays. A better understanding of the regulation of AICD species
promises to contribute to our understanding of AD pathology, but will also be
essential for developing efficient and save therapeutics.
In the third results part of this thesis, we aimed to explore the regulation and
function of AICD in vivo. To this end, the APPGal4 mouse line, which harbors a
transgenic APPwith aGal4-DBDwithin theAICD sequence, was generated and
analyzed. The APPGal4 mouse line is designed to monitor the transcriptional
activity of AICD, after crossing APPGal4 mice with a UAS-reporter mouse line.
Our combined analysis from mouse brains and primary neurons revealed a
general functionality of the APPGal4 mouse line, but showed, unfortunately,
that the UAS-reporter mouse line is not functional. We also showed that the
adaptor protein Fe65 is critical for the transcriptional function of AICD in
APPGal4 mice. The importance of Fe65 was further underlined in cell-culture
basedUAS/Gal4 assays. Generation of a novel reporter mouse line is obligatory
for future analysis of transcriptional function of AICDwith the APPGal4mouse
line. A major problem of the currently available reporter mouse line is the
difficulty to monitor integrity of the transgene since it is not expressed unless
mice are crossed to activator mice. To ensure better monitoring of transgene
integrity in a novel reporter mouse line, we recommend site specific integration
of the UAS-reporter element. Usage of fluorescence proteins as reporter—in
lieu of β-galactosidase—to allow live in vivo analysis of the spatiotemporal
patterns of AICD transcriptional activity, should be considered to tap the full
potential of the APPGal4 mouse line.
The main challenge to the role of AICD as a transcriptional regulator is the
identification of reliable target genes. Regulation of transcription is the most
prominent function described for AICD and to date approximately thirty target
genes have been identified. However, AICD regulation of several of these genes
have been challenged, while other completely lack independent confirmation.
Part of these difficulties can be attributed to usage of different biological
systems and technical difficulties to manipulate AICD. However, it seems that
transcriptional activity by AICD is itself regulated or modulated by hitherto
unknown mechanism. This may comprise—but is certainly not restricted
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to—regulation by direct binding partners of AICD. Multiple experiments,
including results from this thesis, have shown the importance of binding
partners, such as Fe65, for nuclear signaling and transcriptional activity, but
the identity of these facilitators remain partly unknown and their regulation
poorly described. The work presented here will be instrumental to decipher
regulation of AICD transcriptional activity and identification of target genes
itself. On the one hand, the promises of the APPGal4 mouse line, to uncover
the spatiotemporal pattern of transcriptional activity of AICD, could allow us
determine constraints of AICD nuclear signaling. Brain regions and cellular
networks for example that show transcriptional activity could be identified.
On the other hand, identification of nuclear signaling constraints sets the
groundwork for a knock-in mouse line that has the physiological properties
of a AICD knockout model, and could thus allow the identification of AICD
regulated genes.
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pUKBK-C-APP-Cit
6459 bp
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Figure A.1 Plasmid map of pUKBK-C-APP-Cit as representative plasmid for the pUKBK
plasmid series. The promoter region (here CMV promoter) of pUKBK plasmids is ﬂanked by
a SspI and SﬁI cleavage sites for exchange of promoters by restriction-based cloning. The
coding sequence (here APP-Cit) is similarly ﬂanked by SﬁI and PmeI cleavage sites. An AscI
cleavage site is present in the forty-eight bp linker between APP and citrine, which allows simple
exchange of the ﬂuorescence proteins or replacement with protein-tags by AscI-PmeI-mediated
restriction-based cloning.
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APLP1 residue conserved in APP or APLP2 APLP1 residue not conserved
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APLP1
APLP2
caspase c.s. Fe65 b.s.
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Figure A.2 Schematic presentation of APP family ICD sequences and APP-to-APLP1 sub-
stituions used in this study. c.s.: cleavage site; b.s.: binding site.
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(2xMut)
APP
(QMQN692ERP)
APP
(P669L)
APP
(RH672QQ)
APP
(S675R)
APP
(KM676EL)
DIC Citrine Fe65 Tip60 merge
Figure A.3 DIC and confocal ﬂuorescence images of APPwith substituted residues, part
I. HEK cells were transfected with HA-Fe65, CFP-Tip60 and the indicated citrine-tagged APP-
to-APLP1 mutants. See ﬁgure A.2 in the appendix for abbreviation of APP-to-APLP1 mutation
constructs. Scale bar represents 13µm.
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APP
(3xMut)
APP
(4xMut)
APP
(5xMut)
APP
(Q652P,S655A)
APP
(6xMut)
DIC Citrine Fe65 Tip60 merge
Figure A.4 DIC and confocal ﬂuorescence images of APPwith substituted residues, part
II. HEK cells were transfected with HA-Fe65, CFP-Tip60 and the indicated citrine-tagged APP-
to-APLP1 mutants. See ﬁgure A.2 in the appendix for abbreviation of APP-to-APLP1 mutation
constructs. Scale bar represents 13µm.
104


Acknowledgments
I thank Uwe Konietzko for his guidance and help throughout my doctoral
studies. Further, I thank Roger Nitsch for giving me the opportunity to work in
his research group and his valuable suggestions and motivation. I am grateful
to Stephan Neuhauss for his participation in my steering committee and his
scientific advice.
I would like to thank all the past and present members of the Division of
Psychiatry Research for help, support, stimulating scientific discussions, and
a memorable time both inside and outside the lab. Particular thanks go to
Zoë Goodger for initiating an interesting scientific project and Sarina Thöni
for excellent technical assistance. Explicitly, I would also like to acknowledge
Annette Trutzel for help with preparation of primary neurons, Sonja Grinschgl
for preparation of lentiviruses, Maria Teresa Ferretti and Christoph Gericke for
help with immunohistochemistry, and Daniel Schuppli for help in preparation,
maintenance, and genotyping of mice. I also would like to thank Nico Dan-
tuma, Bart De Strooper, Bruno Fischer, Wade Harper, Stefan Kins, Yong Tae
Kwon, Patrick May, Michael Potente, Freddy Radtke, Olivier Raineteau, Walter
Schaffner, Thomas Südhof, and Uli Suter for plasmids, cell lines, antibodies,
mice, and tissue. Special thanks go to Florian Rau, Patrick Kuppinger, Deniz
Gökbuget, and Vinod Udayar for their help with preparation of this doctoral
thesis and Doo Yeon Kim for mentorship throughout my doctoral studies.
My deepest gratitude goes to my family and friends. Without the time that I
spend with you and your constant support and encouragement this doctoral
thesis would not have been possible.
107

List of publications
Riese F, Grinschgl S, Gersbacher MT, Russi N, Hock C, Nitsch RM, Konietzko U.
2013. Visualization and quantification of APP intracellular domain-mediated
nuclear signaling by bimolecular fluorescence complementation. PLoS ONE.
8(9):e76094.
Gersbacher MT∗, Goodger ZV∗, Trutzel A, Bundschuh D, Nitsch RM, Konietzko
U. 2013 Turnover of amyloid precursor protein family members determines
their nuclear signaling capability. PLoS ONE. 8(7):e69363.
Kim DY∗, Gersbacher MT∗, Inquimbert P, Kovacs DM. 2011. Reduced sodium
channel Na(v)1.1 levels in BACE1-null mice. J Biol Chem. 286(10):8106-16.
Gersbacher MT∗, KimDY∗, Bhattacharyya R, Kovacs DM. 2010. Identification of
BACE1 cleavage sites in human voltage-gated sodium channel beta 2 subunit.
Mol Neurodegener. 5:61.
Kovacs DM, Gersbacher MT, Kim DY. 2010. Alzheimer’s secretases regulate
voltage-gated sodium channels. Neurosci Lett. 486(2):68-72.
Madec M, Lallement C, Karstens K, Dittman S, Gersbacher M, Sorg R, Wild
M, Muller M, Bourgine P, Donzeau M, Haiech J. 2009. Synthetic biology
and microelectronics: a similar design flow. Circuits and System and TAISA
Conference Paper
∗ denotes equal authorship
109

Curriculum vitae
Personal details
Name: Manuel Tobias Gersbacher
Date of Birth: August 24, 1982 in Lörrach (Germany)
Education
09/1993 – 07/2002 Theodor-Heuss Gymnasium Schopfheim (Germany)
Degree: Abitur (A-levels)
09/2003 – 09/2005 General Biology, Albert-Ludwigs University Freiburg (Germany)
Degree: Vordiplom (Pre-degree)
09/2005 – 09/2006 Neurosciences, University of Leeds (UK)
10/2006 – 10/2009 Biotechnology, Ecole supérieure de Biotechnologie Strasbourg (France)
Thesis title: Characterization of a novel physiological function of BACE1
Degree: M.Sc. Biotechnology
01/2011 – present Doctoral thesis, University Zurich (Switzerland)
Thesis title: Proteasomal Degradation of the APP Intracellular Domain
(AICD) and Regulation of its Nuclear Signaling
Professional Experience
06/2007 – 08/2007 Internship, Roma Tre University (Italy)
12/2008 – 12/2010 Research Assistant, MGH/Harvard Medical School (USA)
111

Bibliography
Aasland R, Abrams C, Ampe C, Ball LJ, Bedford MT, Cesareni G, Gimona M,
Hurley JH, Jarchau T, Lehto VP, Lemmon MA, Linding R, Mayer BJ, Nagai
M, Sudol M, Walter U, Winder SJ (2002) Normalization of nomenclature for
peptide motifs as ligands of modular protein domains. FEBS Lett 513:141–4.
Al Alam D, Green M, Tabatabai Irani R, Parsa S, Danopoulos S, Sala FG, Branch
J, El Agha E, Tiozzo C, Voswinckel R, Jesudason EC, Warburton D, Bellusci S
(2011) Contrasting expression of canonicalWnt signaling reporters TOPGAL,
BATGAL and Axin2(LacZ) during murine lung development and repair.
PLoS One 6:e23139.
Alves da Costa C, Sunyach C, Pardossi-Piquard R, Sevalle J, Vincent B, Boyer
N, Kawarai T, Girardot N, St George-Hyslop P, Checler F (2006) Presenilin-
dependent gamma-secretase-mediated control of p53-associated cell death
in Alzheimer’s disease. J Neurosci 26:6377–85.
Alzheimer’s Association (2014) 2014 Alzheimer’s disease facts and figures.
Alzheimers Dement 10:e47–92.
Alzheimer’s Association (2015) 2015 Alzheimer’s disease facts and figures.
Alzheimers Dement 11:332–84.
An JY, Seo JW, Tasaki T, Lee MJ, Varshavsky A, Kwon YT (2006) Impaired neu-
rogenesis and cardiovascular development in mice lacking the E3 ubiquitin
ligases UBR1 and UBR2 of the N-end rule pathway. Proc Natl Acad Sci USA
103:6212–7.
Azim K, Fischer B, Hurtado-Chong A, Draganova K, Cantù C, Zemke M,
Sommer L, Butt A, Raineteau O (2014) Persistent Wnt/β-catenin signaling
determines dorsalization of the postnatal subventricular zone and neural
stem cell specification into oligodendrocytes and glutamatergic neurons.
Stem Cells 32:1301–12.
113
Bibliography
Bachmair A, Finley D, Varshavsky A (1986) In vivo half-life of a protein is a
function of its amino-terminal residue. Science 234:179–86.
Bachman DL, Wolf PA, Linn R, Knoefel JE, Cobb J, Belanger A, D’Agostino RB,
White LR (1992) Prevalence of dementia and probable senile dementia of
the Alzheimer type in the Framingham study. Neurology 42:115–9.
Barbagallo APM, Wang Z, Zheng H, D’Adamio L (2011) A single tyrosine
residue in the amyloid precursor protein intracellular domain is essential for
developmental function. J Biol Chem 286:8717–21.
Barbagallo APM, Weldon R, Tamayev R, Zhou D, Giliberto L, Foreman O,
D’Adamio L (2010) Tyr(682) in the intracellular domain of APP regulates
amyloidogenic APP processing in vivo. PLoS One 5:e15503.
Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM,
Salloway S, Sperling RA, Windisch M, Xiong C (2011) Autosomal-dominant
Alzheimer’s disease: a review and proposal for the prevention of Alzheimer’s
disease. Alzheimers Res Ther 3:1.
Bayer TA, Cappai R, Masters CL, Beyreuther K, Multhaup G (1999) It all sticks
together–the APP-related family of proteins and Alzheimer’s disease. Mol
Psychiatry 4:524–8.
Belyaev ND, Kellett KA, Beckett C, Makova NZ, Revett TJ, Nalivaeva NN,
HooperNM,TurnerAJ (2010) The transcriptionally active amyloidprecursor
protein (APP) intracellular domain is preferentially produced from the
695 isoform of APP in a beta-secretase-dependent pathway. J Biol Chem
285:41443–54.
Ben-Nissan G, Sharon M (2014) Regulating the 20S proteasome ubiquitin-
independent degradation pathway. Biomolecules 4:862–84.
Bertram L (2011) Alzheimer’s genetics in the GWAS era: a continuing story of
’replications and refutations’. Curr Neurol Neurosci Rep 11:246–53.
Bertram L, Tanzi RE (2009) Genome-wide association studies in Alzheimer’s
disease. HumMol Genet 18:R137–45.
Bittner T, Fuhrmann M, Burgold S, Jung CKE, Volbracht C, Steiner H, Mit-
teregger G, Kretzschmar HA, Haass C, Herms J (2009) Gamma-secretase
inhibition reduces spine density in vivo via an amyloid precursor protein-
dependent pathway. J Neurosci 29:10405–9.
114
Bibliography
Braak H, Braak E (1997) Staging of Alzheimer-related cortical destruction. Int
Psychogeriatr 9 Suppl 1:257–61; discussion 269–72.
Broadstock M, Ballard C, Corbett A (2014) Latest treatment options for
Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy
bodies. Expert Opin Pharmacother 15:1797–810.
Brower CS, Piatkov KI, Varshavsky A (2013) Neurodegeneration-associated
protein fragments as short-lived substrates of the N-end rule pathway. Mol
Cell 50:161–71.
Buchsbaum S, Bercovich B, Ciechanover A (2012) FAT10 is a proteasomal
degradation signal that is itself regulated by ubiquitination. Mol Biol Cell
23:225–32.
Buckner RL, SnyderAZ, ShannonBJ, LaRossaG, Sachs R, FotenosAF, Sheline YI,
Klunk WE, Mathis CA, Morris JC, Mintun MA (2005) Molecular, structural,
and functional characterization of Alzheimer’s disease: evidence for a
relationship between default activity, amyloid, and memory. J Neurosci
25:7709–17.
Buoso E, Biundo F, Lanni C, Schettini G, Govoni S, Racchi M (2012) AβPP in-
tracellular C-terminal domain function is related to its degradation processes.
J Alzheimers Dis 30:393–405.
Buoso E, Lanni C, Schettini G, Govoni S, Racchi M (2010) β-Amyloid precursor
proteinmetabolism: focus on the functions anddegradationof its intracellular
domain. Pharmacol Res 62:308–17.
Bush AI, Pettingell J W H, de Paradis M, Tanzi RE, Wasco W (1994) The
amyloid beta-protein precursor and its mammalian homologues. Evidence
for a zinc-modulated heparin-binding superfamily. J Biol Chem 269:26618–21.
Cao X, Sudhof TC (2001) A transcriptionally [correction of transcriptively]
active complex of APP with Fe65 and histone acetyltransferase Tip60. Science
293:115–20.
Chávez-Gutiérrez L, Bammens L, Benilova I, Vandersteen A, Benurwar M,
BorgersM, Lismont S, Zhou L, Van Cleynenbreugel S, EsselmannH,Wiltfang
J, Serneels L, Karran E, Gĳsen H, Schymkowitz J, Rousseau F, Broersen K,
De Strooper B (2012) The mechanism of γ-Secretase dysfunction in familial
Alzheimer disease. EMBO J 31:2261–74.
115
Bibliography
Chen AC, Selkoe DJ (2007) Response to: Pardossi-Piquard et al., "Presenilin-
dependent transcriptional control of the Abeta-degrading enzyme neprilysin
by intracellular domains of betaAPP andAPLP." Neuron 46, 541-554. Neuron
53:479–83.
ChenY,Neve RL, LiuH (2012) Neddylation dysfunction in alzheimer’s disease.
J Cell Mol Med 16:2583–91.
Choi WS, Jeong BC, Joo YJ, Lee MR, Kim J, Eck MJ, Song HK (2010) Structural
basis for the recognition of n-end rule substrates by the ubr box of ubiquitin
ligases. Nat Struct Mol Biol 17:1175–81.
Ciechanover A (1994) The ubiquitin-proteasome proteolytic pathway. Cell
79:13–21.
Ciechanover A (2013) Intracellular protein degradation: from a vague idea
through the lysosome and the ubiquitin-proteasome system and onto human
diseases and drug targeting. Bioorg Med Chem 21:3400–10.
Coulson EJ, Paliga K, Beyreuther K, Masters CL (2000) What the evolution of
the amyloid protein precursor supergene family tells us about its function.
Neurochem Int 36:175–84.
Cummings JL, Dubois B, Molinuevo JL, Scheltens P (2013) International work
group criteria for the diagnosis of Alzheimer disease. Med Clin North Am
97:363–8.
Cupers P, Orlans I, Craessaerts K, Annaert W, De Strooper B (2001) The
amyloid precursor protein (APP)-cytoplasmic fragment generated by gamma-
secretase is rapidly degraded but distributes partially in a nuclear fraction of
neurones in culture. J Neurochem 78:1168–78.
Cusimano M, Biziato D, Brambilla E, Donegà M, Alfaro-Cervello C, Snider
S, Salani G, Pucci F, Comi G, Garcia-Verdugo JM, De Palma M, Martino
G, Pluchino S (2012) Transplanted neural stem/precursor cells instruct
phagocytes and reduce secondary tissue damage in the injured spinal cord.
Brain 135:447–60.
Dantuma NP, Lindsten K, Glas R, Jellne M, Masucci MG (2000) Short-lived
green fluorescent proteins for quantifying ubiquitin/proteasome-dependent
proteolysis in living cells. Nat Biotechnol 18:538–43.
116
Bibliography
De Strooper B, Annaert W (2010) Novel research horizons for presenilins and
gamma-secretases in cell biology and disease. Annual review of cell and
developmental biology 26:235–60.
Degasperi A, Birtwistle MR, Volinsky N, Rauch J, Kolch W, Kholodenko BN
(2014) Evaluating strategies to normalise biological replicates of western
blot data. PLoS One 9:e87293.
Dimitrov M, Alattia JR, Lemmin T, Lehal R, Fligier A, Houacine J, Hussain I,
Radtke F, Dal Peraro M, Beher D, Fraering PC (2013) Alzheimer’s disease
mutations in APP but not γ-secretase modulators affect epsilon-cleavage-
dependent AICD production. Nat Commun 4:2246.
Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, He
F, Sun X, Thomas RG, Aisen PS, Alzheimer’s Disease Cooperative Study
Steering Committee, Siemers E, Sethuraman G, Mohs R, Semagacestat Study
Group (2013) A phase 3 trial of semagacestat for treatment of Alzheimer’s
disease. N Engl J Med 369:341–50.
Dougan DA, Micevski D, Truscott KN (2012) The N-end rule pathway: from
recognition by N-recognins, to destruction by AAA+proteases. Biochim
Biophys Acta 1823:83–91.
Edbauer D, Willem M, Lammich S, Steiner H, Haass C (2002) Insulin-
degrading enzyme rapidly removes the beta-amyloid precursor protein
intracellular domain (AICD). J Biol Chem 277:13389–93.
Eggert S, Paliga K, Soba P, Evin G, Masters CL, Weidemann A, Beyreuther
K (2004) The proteolytic processing of the amyloid precursor protein gene
family members APLP-1 and APLP-2 involves alpha-, beta-, gamma-, and
epsilon-like cleavages: modulation of APLP-1 processing by n-glycosylation.
J Biol Chem 279:18146–56.
El Ayadi A, Stieren ES, Barral JM, Boehning D (2012) Ubiquilin-1 regulates
amyloid precursor protein maturation and degradation by stimulating K63-
linked polyubiquitination of lysine 688. Proc Natl Acad Sci USA 109:13416–21.
Erales J, Coffino P (2014) Ubiquitin-independent proteasomal degradation.
Biochim Biophys Acta 1843:216–21.
Farris W, Mansourian S, Chang Y, Lindsley L, Eckman EA, Frosch MP, Eckman
CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme
regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid
117
Bibliography
precursor protein intracellular domain in vivo. Proc Natl Acad Sci USA
100:4162–7.
Ferretti MT, Allard S, Partridge V, Ducatenzeiler A, Cuello AC
(2012) Minocycline corrects early, pre-plaque neuroinflammation and in-
hibits BACE-1 in a transgenic model of Alzheimer’s disease-like amyloid
pathology. J Neuroinflammation 9:62.
Fontana L, Kennedy BK, Longo VD, Seals D, Melov S (2014) Medical research:
treat ageing. Nature 511:405–7.
Galvan V, Chen S, Lu D, Logvinova A, Goldsmith P, Koo EH, Bredesen DE
(2002) Caspase cleavage of members of the amyloid precursor family of
proteins. J Neurochem 82:283–94.
Gersbacher MT, Goodger ZV, Trutzel A, Bundschuh D, Nitsch RM, Konietzko U
(2013) Turnover of amyloid precursor protein family members determines
their nuclear signaling capability. PLoS One 8:e69363.
Ghosal K, Vogt DL, Liang M, Shen Y, Lamb BT, Pimplikar SW
(2009) Alzheimer’s disease-like pathological features in transgenic mice
expressing the APP intracellular domain. Proc Natl Acad Sci USA 106:18367–
72.
Goodger ZV (2009) Regulation of Nuclear Signalling Mediated by the APP
Intracellular Domain (AICD) and its Functional Role. Ph.D. thesis, University
Zurich.
Goodger ZV, Rajendran L, Trutzel A, Kohli BM, Nitsch RM, Konietzko U
(2009) Nuclear signaling by the APP intracellular domain occurs predomi-
nantly through the amyloidogenic processing pathway. J Cell Sci 122:3703–14.
Govindarajan V, Harrison WR, Xiao N, Liang D, Overbeek PA
(2005) Intracorneal positioning of the lens in Pax6-GAL4/VP16 transgenic
mice. Molecular vision 11:876–86.
Grimm MOW, Mett J, Stahlmann CP, Haupenthal VJ, Zimmer VC, Hartmann T
(2013) Neprilysin and Aβ clearance: Impact of the APP intracellular domain
in NEP regulation and implications in Alzheimer’s disease. Front Aging
Neurosci 5:98.
GuY,MisonouH, Sato T,DohmaeN, TakioK, Ihara Y (2001) Distinct intramem-
brane cleavage of the beta-amyloid precursor protein family resembling
gamma-secretase-like cleavage of notch. J Biol Chem 276:35235–8.
118
Bibliography
Guarani V, Deflorian G, Franco CA, Krüger M, Phng LK, Bentley K, Toussaint
L, Dequiedt F, Mostoslavsky R, Schmidt MHH, Zimmermann B, Brandes
RP, Mione M, Westphal CH, Braun T, Zeiher AM, Gerhardt H, Dimmeler S,
Potente M (2011) Acetylation-dependent regulation of endothelial Notch
signalling by the SIRT1 deacetylase. Nature 473:234–8.
Guardia-Laguarta C, Pera M, Clarimón J, Molinuevo JL, Sánchez-Valle R,
Lladó A, Coma M, Gómez-Isla T, Blesa R, Ferrer I, Lleó A (2010) Clinical,
neuropathologic, and biochemical profile of the amyloid precursor protein
I716F mutation. J Neuropathol Exp Neurol 69:53–9.
Guenette S, Chang Y, Hiesberger T, Richardson JA, Eckman CB, Eckman EA,
Hammer RE, Herz J (2006) Essential roles for the FE65 amyloid precursor
protein-interacting proteins in brain development. Embo J 25:420–31.
Haass C, Kaether C, Thinakaran G, Sisodia S (2012) Trafficking and proteolytic
processing of APP. Cold Spring Harb Perspect Med 2:a006270.
Halpern ME, Rhee J, Goll MG, Akitake CM, Parsons M, Leach SD
(2008) Gal4/UAS transgenic tools and their application to zebrafish. Ze-
brafish 5:97–110.
Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease:
progress and problems on the road to therapeutics. Science 297:353–6.
Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid cascade
hypothesis. Science 256:184–5.
Harris JA, Devidze N, Halabisky B, Lo I, Thwin MT, Yu GQ, Bredesen DE,
Masliah E, Mucke L (2010) Many neuronal and behavioral impairments in
transgenic mouse models of Alzheimer’s disease are independent of caspase
cleavage of the amyloid precursor protein. J Neurosci 30:372–81.
Heber S,Herms J, Gajic V,Hainfellner J, AguzziA, Rulicke T, vonKretzschmarH,
von Koch C, Sisodia S, Tremml P, Lipp HP, Wolfer DP, Muller U (2000) Mice
with combined gene knock-outs reveal essential and partially redundant
functions of amyloid precursor protein family members. J Neurosci 20:7951–
63.
Hebert SS, Serneels L, Tolia A, Craessaerts K, Derks C, Filippov MA, Muller
U, De Strooper B (2006) Regulated intramembrane proteolysis of amyloid
precursor protein and regulation of expression of putative target genes.
EMBO Rep 7:739–45.
119
Bibliography
Hecimovic S, Wang J, Dolios G, Martinez M, Wang R, Goate AM
(2004) Mutations in APP have independent effects on Abeta and CTFgamma
generation. Neurobiol Dis 17:205–18.
Heckman KL, Pease LR (2007) Gene splicing and mutagenesis by PCR-driven
overlap extension. Nat Protoc 2:924–32.
Herms J, Anliker B, Heber S, Ring S, Fuhrmann M, Kretzschmar H, Sisodia S,
Muller U (2004) Cortical dysplasia resembling human type 2 lissencephaly
in mice lacking all three APP family members. Embo J 23:4106–15.
HoeySE,WilliamsRJ, PerkintonMS (2009) SynapticNMDAreceptor activation
stimulates alpha-secretase amyloid precursor protein processing and inhibits
amyloid-beta production. J Neurosci 29:4442–60.
Huber N, Guimaraes S, Schrader M, Suter U, Niemann A (2013) Charcot-
Marie-Tooth disease-associated mutants of GDAP1 dissociate its roles in
peroxisomal and mitochondrial fission. EMBO Rep 14:545–52.
Huysseune S, Kienlen-Campard P, Octave JN (2007) Fe65 does not stabilize
AICD during activation of transcription in a luciferase assay. Biochem
Biophys Res Commun 361:317–22.
International Genomics of Alzheimer’s Disease Consortium (IGAP)
(2014) Convergent genetic and expression data implicate immunity in
Alzheimer’s disease. Alzheimers Dement .
Jariel-Encontre I, Bossis G, PiechaczykM (2008) Ubiquitin-independent degra-
dation of proteins by the proteasome. Biochim Biophys Acta 1786:153–77.
Jin J, Li X, Gygi SP, Harper JW (2007) Dual E1 activation systems for ubiquitin
differentially regulate E2 enzyme charging. Nature 447:1135–8.
Ju D, Xie Y (2004) Proteasomal degradation of RPN4 via two distinct mecha-
nisms, ubiquitin-dependent and -independent. J Biol Chem 279:23851–4.
Kaden D, Voigt P, Munter LM, Bobowski KD, Schaefer M, Multhaup G
(2009) Subcellular localization and dimerization of APLP1 are strikingly
different from APP and APLP2. J Cell Sci 122:368–77.
Kamenetz F, Tomita T, Hsieh H, Seabrook G, Borchelt D, Iwatsubo T, Sisodia S,
Malinow R (2003) APP processing and synaptic function. Neuron 37:925–37.
120
Bibliography
Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik
KH, Multhaup G, Beyreuther K, Muller-Hill B (1987) The precursor of
Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor.
Nature 325:733–6.
Kapuria V, Peterson LF, Showalter HDH, Kirchhoff PD, Talpaz M, Donato NJ
(2011) Protein cross-linking as a novel mechanism of action of a ubiquitin-
activating enzyme inhibitor with anti-tumor activity. Biochem Pharmacol
82:341–9.
Karran E, Mercken M, De Strooper B (2011) The amyloid cascade hypothesis
for Alzheimer’s disease: an appraisal for the development of therapeutics.
Nat Rev Drug Discov 10:698–712.
Keller JN, Hanni KB, Markesbery WR (2000) Impaired proteasome function in
Alzheimer’s disease. J Neurochem 75:436–9.
Kesavapany S, Banner SJ, Lau KF, ShawCE,Miller CCJ, Cooper JD, McLoughlin
DM (2002) Expression of the Fe65 adapter protein in adult and developing
mouse brain. Neuroscience 115:951–60.
Kim HS, Kim EM, Lee JP, Park CH, Kim S, Seo JH, Chang KA, Yu E, Jeong
SJ, Chong YH, Suh YH (2003) C-terminal fragments of amyloid precursor
protein exert neurotoxicity by inducing glycogen synthase kinase-3beta
expression. FASEB J 17:1951–3.
KimMY,Mo JS,AnnEJ, Yoon JH, Jung J, Choi YH,KimSM,KimHY,Ahn JS, Kim
H, Kim K, Hoe HS, Park HS (2011) Regulation of Notch1 signaling by the
APP intracellular domain facilitates degradation of the Notch1 intracellular
domain and RBP-Jk. J Cell Sci 124:1831–43.
Kimberly WT, Zheng JB, Guenette SY, Selkoe DJ (2001) The intracellular
domain of the beta-amyloid precursor protein is stabilized by Fe65 and
translocates to the nucleus in a notch-like manner. J Biol Chem 276:40288–92.
Kimura Y, Tanaka K (2010) Regulatory mechanisms involved in the control of
ubiquitin homeostasis. J Biochem 147:793–8.
Kinoshita A, Whelan CM, Berezovska O, Hyman BT (2002) The gamma
secretase-generated carboxyl-terminal domain of the amyloid precursor
protein induces apoptosis via Tip60 in H4 cells. J Biol Chem 277:28530–6.
121
Bibliography
Kleĳnen MF, Shih AH, Zhou P, Kumar S, Soccio RE, Kedersha NL, Gill G,
Howley PM (2000) The hPLIC proteins may provide a link between the
ubiquitination machinery and the proteasome. Mol Cell 6:409–19.
Knobloch M, Konietzko U, Krebs DC, Nitsch RM (2007) Intracellular Abeta
and cognitive deficits precede beta-amyloid deposition in transgenic arcAbeta
mice. Neurobiol Aging 28:1297–306.
Kohli BM, Pflieger D, Mueller LN, Carbonetti G, Aebersold R, Nitsch RM,
Konietzko U (2012) Interactome of the amyloid precursor protein APP in
brain reveals a protein network involved in synaptic vesicle turnover and a
close association with Synaptotagmin-1. J Proteome Res 11:4075—4090.
Konietzko U, Goodger ZV, Meyer M, Kohli BM, Bosset J, Lahiri DK, Nitsch
RM (2010) Co-localization of the amyloid precursor protein and Notch
intracellular domains in nuclear transcription factories. Neurobiol Aging
31:58–73.
Kozik P, Francis RW, SeamanMNJ, Robinson MS (2010) A screen for endocytic
motifs. Traffic 11:843–55.
Kravtsova-Ivantsiv Y, Ciechanover A (2012) Non-canonical ubiquitin-based
signals for proteasomal degradation. J Cell Sci 125:539–48.
Kuan YH,Gruebl T, Soba P, Eggert S, Nesic I, Back S, Kirsch J, Beyreuther K, Kins
S (2006) PAT1a modulates intracellular transport and processing of amyloid
precursor protein (APP), APLP1, and APLP2. J Biol Chem 281:40114–23.
Lam YA, Pickart CM, Alban A, Landon M, Jamieson C, Ramage R, Mayer
RJ, Layfield R (2000) Inhibition of the ubiquitin-proteasome system in
Alzheimer’s disease. Proc Natl Acad Sci USA 97:9902–6.
Lee EJ, Hyun S, Chun J, Shin SH, Kang SS (2009) Ubiquitylation of Fe65
adaptor protein by neuronal precursor cell expressed developmentally down
regulated 4-2 (Nedd4-2) via the WW domain interaction with Fe65. Exp Mol
Med 41:555–68.
Lee PCW, Sowa ME, Gygi SP, Harper JW (2011) Alternative ubiquitin acti-
vation/conjugation cascades interact with N-end rule ubiquitin ligases to
control degradation of RGS proteins. Mol Cell 43:392–405.
Lenkkeri U, Kestila M, Lamerdin J, McCready P, Adamson A, Olsen A, Tryggva-
son K (1998) Structure of the human amyloid-precursor-like protein gene
APLP1 at 19q13.1. Hum Genet 102:192–6.
122
Bibliography
Lévy F, Johnsson N, Rümenapf T, Varshavsky A (1996) Using ubiquitin to
follow the metabolic fate of a protein. Proc Natl Acad Sci USA 93:4907–12.
Li H, Wang B, Wang Z, Guo Q, Tabuchi K, Hammer RE, Sudhof TC, Zheng H
(2010) Soluble amyloid precursor protein (APP) regulates transthyretin and
Klotho gene expression without rescuing the essential function of APP. Proc
Natl Acad Sci USA 107:17362–7.
Li Q, Sudhof TC (2004) Cleavage of amyloid-beta precursor protein and
amyloid-beta precursor-like protein by BACE 1. J Biol Chem 279:10542–50.
Lichtenthaler SF, Haass C, Steiner H (2011) Regulated intramembrane
proteolysis–lessons from amyloid precursor protein processing. J Neurochem
117:779–96.
Liu Q, Zerbinatti CV, Zhang J, Hoe HS, Wang B, Cole SL, Herz J, Muglia L,
Bu G (2007) Amyloid precursor protein regulates brain apolipoprotein E
and cholesterol metabolism through lipoprotein receptor LRP1. Neuron
56:66–78.
Lorent K, Overbergh L, Moechars D, De Strooper B, Van Leuven F, Van den
Berghe H (1995) Expression in mouse embryos and in adult mouse brain
of three members of the amyloid precursor protein family, of the alpha-2-
macroglobulin receptor/low density lipoprotein receptor-related protein and
of its ligands apolipoprotein e, lipoprotein lipase, alpha-2-macroglobulin
and the 40,000 molecular weight receptor-associated protein. Neuroscience
65:1009–25.
Lu DC, Rabizadeh S, Chandra S, Shayya RF, Ellerby LM, Ye X, Salvesen GS,
Koo EH, Bredesen DE (2000) A second cytotoxic proteolytic peptide derived
from amyloid beta-protein precursor. Nat Med 6:397–404.
LupasAN, Koretke KK (2003) Bioinformatic analysis of ClpS, a proteinmodule
involved in prokaryotic and eukaryotic protein degradation. J Struct Biol
141:77–83.
Lyckman AW, Confaloni AM, Thinakaran G, Sisodia SS, Moya KL (1998) Post-
translational processing and turnover kinetics of presynaptically targeted
amyloid precursor superfamily proteins in the central nervous system. J Biol
Chem 273:11100–6.
MaH, Lesne S, Kotilinek L, Steidl-Nichols JV, ShermanM, Younkin L, Younkin S,
Forster C, Sergeant N, Delacourte A, Vassar R, Citron M, Kofuji P, Boland LM,
123
Bibliography
Ashe KH (2007) Involvement of beta-site APP cleaving enzyme 1 (BACE1) in
amyloid precursor protein-mediated enhancement of memory and activity-
dependent synaptic plasticity. Proc Natl Acad Sci USA 104:8167–72.
Ma QH, Futagawa T, Yang WL, Jiang XD, Zeng L, Takeda Y, Xu RX, Bagnard
D, Schachner M, Furley AJ, Karagogeos D, Watanabe K, Dawe GS, Xiao ZC
(2008) A TAG1-APP signalling pathway through Fe65 negatively modulates
neurogenesis. Nat Cell Biol 10:283–94.
Madeira A, Pommet JM, Prochiantz A, Allinquant B (2005) SET protein
(TAF1beta, I2PP2A) is involved in neuronal apoptosis induced by an amyloid
precursor protein cytoplasmic subdomain. FASEB J 19:1905–7.
Maretto S, Cordenonsi M, Dupont S, Braghetta P, Broccoli V, Hassan AB, Volpin
D, Bressan GM, Piccolo S (2003) Mapping Wnt/beta-catenin signaling
during mouse development and in colorectal tumors. Proc Natl Acad Sci
USA 100:3299–304.
Matrone C, Luvisetto S, La Rosa LR, Tamayev R, Pignataro A, Canu N, Yang
L, Barbagallo APM, Biundo F, Lombino F, Zheng H, Ammassari-Teule
M, D’Adamio L (2012) Tyr682 in the Aβ-precursor protein intracellular
domain regulates synaptic connectivity, cholinergic function, and cognitive
performance. Aging Cell 11:1084–93.
Mattson MP, Cheng B, Culwell AR, Esch FS, Lieberburg I, Rydel RE
(1993) Evidence for excitoprotective and intraneuronal calcium-regulating
roles for secreted forms of the beta-amyloid precursor protein. Neuron
10:243–54.
Mayeux R, Stern Y (2012) Epidemiology of Alzheimer disease. Cold Spring
Harb Perspect Med 2:a006239.
MerdesG, Soba P, LoewerA, BilicMV, Beyreuther K, Paro R (2004) Interference
of human andDrosophila APP andAPP-like proteins with PNS development
in Drosophila. Embo J 23:4082–95.
Moehlmann T, Winkler E, Xia X, Edbauer D, Murrell J, Capell A, Kaether C,
Zheng H, Ghetti B, Haass C, Steiner H (2002) Presenilin-1 mutations of
leucine 166 equally affect the generation of the Notch and APP intracellular
domains independent of their effect on Abeta 42 production. Proc Natl Acad
Sci USA 99:8025–30.
124
Bibliography
Morel E, Chamoun Z, Lasiecka ZM, Chan RB, Williamson RL, Vetanovetz C,
Dall’Armi C, Simoes S, Point Du Jour KS, McCabe BD, Small SA, Di Paolo G
(2013) Phosphatidylinositol-3-phosphate regulates sorting and processing
of amyloid precursor protein through the endosomal system. Nat Commun
4:2250.
Mott RT, Hulette CM (2005) Neuropathology of Alzheimer’s disease. Neu-
roimaging Clin N Am 15:755–65, ix.
Muller T, Meyer HE, Egensperger R, Marcus K (2008) The amyloid precursor
protein intracellular domain (AICD) as modulator of gene expression, apop-
tosis, and cytoskeletal dynamics-relevance for Alzheimer’s disease. Prog
Neurobiol 85:393–406.
Müller U, Wild K (2013) Structure and Function of the APP Intracellular
domain in Health and Disease. In: Understanding Alzheimer’s Disease.
InTech.
Müller UC, Zheng H (2012) Physiological functions of APP family proteins.
Cold Spring Harb Perspect Med 2:a006288.
Nakayama K, Ohkawara T, Hiratochi M, Koh CS, Nagase H (2008) The in-
tracellular domain of amyloid precursor protein induces neuron-specific
apoptosis. Neurosci Lett 444:127–31.
Nikolaev A, McLaughlin T, O’Leary DDM, Tessier-Lavigne M (2009) APP
binds DR6 to trigger axon pruning and neuron death via distinct caspases.
Nature 457:981–9.
Nunan J, Williamson NA, Hill AF, Sernee MF, Masters CL, Small
DH (2003) Proteasome-mediated degradation of the C-terminus of the
Alzheimer’s disease beta-amyloid protein precursor: effect of C-terminal
truncation on production of beta-amyloid protein. J Neurosci Res 74:378–85.
Olsson F, Schmidt S, Althoff V, Munter LM, Jin S, Rosqvist S, Lendahl U,
Multhaup G, Lundkvist J (2014) Characterization of intermediate steps in
amyloid beta (Aβ) production under near-native conditions. J Biol Chem
289:1540–50.
Pardossi-Piquard R, Checler F (2012) The physiology of the beta-amyloid
precursor protein intracellular domain AICD. J Neurochem 120 Suppl
1:109–24.
125
Bibliography
Pardossi-Piquard R, Petit A, Kawarai T, Sunyach C, Alves da Costa C, Vincent
B, Ring S, D’Adamio L, Shen J, Müller U, St George Hyslop P, Checler F
(2005) Presenilin-dependent transcriptional control of the Abeta-degrading
enzyme neprilysin by intracellular domains of betaAPP and APLP. Neuron
46:541–54.
Pastorino L, Ikin AF, Lamprianou S, Vacaresse N, Revelli JP, Platt K, Paganetti
P, Mathews PM, Harroch S, Buxbaum JD (2004) BACE (beta-secretase)
modulates the processing of APLP2 in vivo. Mol Cell Neurosci 25:642–9.
Peña MMO, Xing YY, Koli S, Berger FG (2006) Role of N-terminal residues
in the ubiquitin-independent degradation of human thymidylate synthase.
Biochem J 394:355–63.
Perl DP (2010) Neuropathology of Alzheimer’s disease. Mt Sinai J Med
77:32–42.
Pickart CM (2001) Mechanisms underlying ubiquitination. AnnuRev Biochem
70:503–33.
Pimplikar SW, Suryanarayana A (2011) Detection of APP intracellular domain
in brain tissue. Methods in molecular biology 670:85–91.
Pinnix I, Musunuru U, Tun H, Sridharan A, Golde T, Eckman C, Ziani-Cherif
C, Onstead L, Sambamurti K (2001) A novel gamma-secretase assay based
on detection of the putative C-terminal fragment-gamma of amyloid beta
protein precursor. J Biol Chem 276:481–7.
Qi-Takahara Y, Morishima-Kawashima M, Tanimura Y, Dolios G, Hirotani N,
Horikoshi Y, Kametani F,MaedaM, Saido TC,WangR, Ihara Y (2005) Longer
forms of amyloid beta protein: implications for the mechanism of intramem-
brane cleavage by gamma-secretase. J Neurosci 25:436–45.
Radzimanowski J, Simon B, Sattler M, Beyreuther K, Sinning I, Wild K
(2008) Structure of the intracellular domain of the amyloid precursor protein
in complex with Fe65-PTB2. EMBO Rep 9:1134–40.
Ramelot TA, Gentile LN, Nicholson LK (2000) Transient structure of the
amyloid precursor protein cytoplasmic tail indicates preordering of structure
for binding to cytosolic factors. Biochemistry 39:2714–25.
Ravid T, Hochstrasser M (2008) Diversity of degradation signals in the
ubiquitin-proteasome system. Nat Rev Mol Cell Biol 9:679–90.
126
Bibliography
Riederer BM, Leuba G, Vernay A, Riederer IM (2011) The role of the ubiquitin
proteasome system in Alzheimer’s disease. Exp Biol Med (Maywood)
236:268–76.
Ring S, Weyer SW, Kilian SB, Waldron E, Pietrzik CU, Filippov MA, Herms
J, Buchholz C, Eckman CB, Korte M, Wolfer DP, Muller UC (2007) The
secreted beta-amyloid precursor protein ectodomain APPs alpha is sufficient
to rescue the anatomical, behavioral, and electrophysiological abnormalities
of APP-deficient mice. J Neurosci 27:7817–26.
Ryman DC, Acosta-Baena N, Aisen PS, Bird T, Danek A, Fox NC, Goate A, From-
melt P, Ghetti B, Langbaum JBS, Lopera F, Martins R, Masters CL, Mayeux
RP, McDade E, Moreno S, Reiman EM, Ringman JM, Salloway S, Schofield
PR, Sperling R, Tariot PN, Xiong C, Morris JC, Bateman RJ, Dominantly
Inherited Alzheimer Network (2014) Symptom onset in autosomal domi-
nant Alzheimer disease: a systematic review and meta-analysis. Neurology
83:253–60.
Sabo SL, Ikin AF, Buxbaum JD, Greengard P (2003) The amyloid precursor
protein and its regulatory protein, FE65, in growth cones and synapses in
vitro and in vivo. J Neurosci 23:5407–15.
Sapountzi V, Logan IR, Robson CN (2006) Cellular functions of TIP60. Int J
Biochem Cell Biol 38:1496–509.
Sato T, Dohmae N, Qi Y, Kakuda N, Misonou H, Mitsumori R, Maruyama
H, Koo EH, Haass C, Takio K, Morishima-Kawashima M, Ishiura S, Ihara
Y (2003) Potential link between amyloid beta-protein 42 and C-terminal
fragment gamma 49-99 of beta-amyloid precursor protein. J Biol Chem
278:24294–301.
Scheinfeld MH, Ghersi E, Laky K, Fowlkes BJ, D’Adamio L (2002) Processing
of beta-amyloid precursor-like protein-1 and -2 by gamma-secretase regulates
transcription. J Biol Chem 277:44195–201.
Scheinfeld MH, Matsuda S, D’Adamio L (2003) JNK-interacting protein-1
promotes transcription of A beta protein precursor but not A beta precursor-
like proteins, mechanistically different than Fe65. Proc Natl Acad Sci USA
100:1729–34.
Schulman BA, Harper JW (2009) Ubiquitin-like protein activation by E1 en-
zymes: the apex for downstream signalling pathways. Nat Rev Mol Cell Biol
10:319–31.
127
Bibliography
Seabrook GR, Smith DW, Bowery BJ, Easter A, Reynolds T, Fitzjohn SM, Morton
RA, Zheng H, Dawson GR, Sirinathsinghji DJ, Davies CH, Collingridge GL,
Hill RG (1999) Mechanisms contributing to the deficits in hippocampal
synaptic plasticity in mice lacking amyloid precursor protein. Neurophar-
macology 38:349–59.
Selkoe DJ (2001) Alzheimer’s disease: genes, proteins, and therapy. Physiol
Rev 81:741–66.
Shankar GM, Welzel AT, McDonald JM, Selkoe DJ, Walsh DM (2011) Isolation
of low-n amyloid beta-protein oligomers from cultured cells, CSF, and brain.
Methods Mol Biol 670:33–44.
Shen J, Kelleher r R J (2007) The presenilin hypothesis of Alzheimer’s disease:
evidence for a loss-of-function pathogenic mechanism. Proc Natl Acad Sci
USA 104:403–9.
Slunt HH, Thinakaran G, Von Koch C, Lo AC, Tanzi RE, Sisodia SS
(1994) Expression of a ubiquitous, cross-reactive homologue of the mouse
beta-amyloid precursor protein (APP). J Biol Chem 269:2637–44.
Smith E, Claudinot S, Lehal R, Pellegrinet L, Barrandon Y, Radtke F
(2012) Generation and characterization of a Notch1 signaling-specific re-
porter mouse line. Genesis 50:700–10.
Soba P, Eggert S, Wagner K, Zentgraf H, Siehl K, Kreger S, Lower A, Langer A,
Merdes G, Paro R, Masters CL, Muller U, Kins S, Beyreuther K (2005) Homo-
and heterodimerization of APP family members promotes intercellular
adhesion. Embo J 24:3624–34.
Sriram S, Lee JH, Mai BK, Jiang Y, Kim Y, Yoo YD, Banerjee R, Lee SH, Lee
MJ (2013) Development and characterization of monomeric N-end rule
inhibitors through in vitro model substrates. J Med Chem 56:2540–6.
Sriram SM, Kim BY, Kwon YT (2011) The N-end rule pathway: emerging
functions and molecular principles of substrate recognition. Nat Rev Mol
Cell Biol 12:735–47.
Stahl R, Schilling S, Soba P, Rupp C, Hartmann T, Wagner K, Merdes G, Eggert
S, Kins S (2014) Shedding of APP limits its synaptogenic activity and cell
adhesion properties. Front Cell Neurosci 8:410.
128
Bibliography
Stieren ES, El Ayadi A, Xiao Y, Siller E, Landsverk ML, Oberhauser AF, Barral
JM, Boehning D (2011) Ubiquilin-1 is a molecular chaperone for the amyloid
precursor protein. J Biol Chem 286:35689–98.
Sun Y, Jiang X, Price BD (2010) Tip60: connecting chromatin to DNA damage
signaling. Cell Cycle 9:930–6.
Svedružić ZM, Popović K, Smoljan I, Sendula-Jengić V (2012) Modulation of
γ-secretase activity by multiple enzyme-substrate interactions: implications
in pathogenesis of Alzheimer’s disease. PLoS One 7:e32293.
Takalo M, Haapasalo A, Natunen T, Viswanathan J, Kurkinen KM, Tanzi RE,
Soininen H, HiltunenM (2013) Targeting ubiquilin-1 in Alzheimer’s disease.
Expert Opin Ther Targets 17:795–810.
Tanzi RE, Haines JL, Watkins PC, Stewart GD, Wallace MR, Hallewell R, Wong
C, Wexler NS, Conneally PM, Gusella JF (1988) Genetic linkage map of
human chromosome 21. Genomics 3:129–36.
Tapiola T, PennanenC, TapiolaM, Tervo S,KivipeltoM,HänninenT, Pihlajamäki
M, Laakso MP, Hallikainen M, Hämäläinen A, Vanhanen M, Helkala EL,
Vanninen R, Nissinen A, Rossi R, Frisoni GB, Soininen H (2008) MRI of
hippocampus and entorhinal cortex in mild cognitive impairment: a follow-
up study. Neurobiol Aging 29:31–8.
Tasaki T, Kwon YT (2007) The mammalian N-end rule pathway: new insights
into its components and physiological roles. Trends Biochem Sci 32:520–8.
Tasaki T,Mulder LCF, IwamatsuA, LeeMJ, Davydov IV, VarshavskyA,Muesing
M, Kwon YT (2005) A family ofmammalian E3 ubiquitin ligases that contain
the UBR box motif and recognize N-degrons. Mol Cell Biol 25:7120–36.
Tasaki T, Sriram SM, Park KS, Kwon YT (2012) The N-end rule pathway. Annu
Rev Biochem 81:261–89.
Taylor JM, Song YJ, Huang Y, Farrer MJ, Delatycki MB, Halliday GM, Lockhart
PJ (2007) Parkin co-regulated gene (PACRG) is regulated by the ubiquitin-
proteasomal system and is present in the pathological features of parkinso-
nian diseases. Neurobiology of disease 27:238–47.
Thinakaran G, Koo EH (2008) Amyloid precursor protein trafficking, process-
ing, and function. J Biol Chem 283:29615–9.
129
Bibliography
Tsvetkov P, Reuven N, Shaul Y (2009) The nanny model for IDPs. Nat Chem
Biol 5:778–81.
Tyan SH, Shih AY, Walsh JJ, Maruyama H, Sarsoza F, Ku L, Eggert S, Hof PR,
Koo EH, Dickstein DL (2012) Amyloid precursor protein (APP) regulates
synaptic structure and function. Mol Cell Neurosci 51:43–52.
van der Veen AG, Ploegh HL (2012) Ubiquitin-like proteins. Annu Rev
Biochem 81:323–57.
Van Nostrand WE, Schmaier AH, Neiditch BR, Siegel RS, Raschke WC, Sisodia
SS, Wagner SL (1994) Expression, purification, and characterization of
the kunitz-type proteinase inhibitor domain of the amyloid beta-protein
precursor-like protein-2. Biochim Biophys Acta 1209:165–70.
Varshavsky A (1992) The N-end rule. Cell 69:725–35.
Varshavsky A (2011) The N-end rule pathway and regulation by proteolysis.
Protein Science 20:1298–1345.
Varshavsky A, Byrd C (1996) The N-end rule: Functions, mysteries, uses.
Molecular Biology of the Cell 7:2946–2946.
Verma R, Deshaies RJ (2000) A proteasome howdunit: the case of the missing
signal. Cell 101:341–4.
Vingtdeux V, Hamdane M, Begard S, Loyens A, Delacourte A, Beauvillain
JC, Buee L, Marambaud P, Sergeant N (2007) Intracellular pH regulates
amyloid precursor protein intracellular domain accumulation. Neurobiol
Dis 25:686–96.
Viswanathan J, Haapasalo A, Kurkinen KMA, Natunen T, Mäkinen P, Bertram L,
Soininen H, Tanzi RE, HiltunenM (2013) Ubiquilin-1 modulates γ-secretase-
mediated ε-site cleavage in neuronal cells. Biochemistry 52:3899–912.
von Koch CS, Zheng H, Chen H, Trumbauer M, Thinakaran G, van der Ploeg
LH, Price DL, Sisodia SS (1997) Generation of APLP2 KO mice and early
postnatal lethality in APLP2/APP double KOmice. Neurobiol Aging 18:661–
9.
von Rotz RC, Kohli BM, Bosset J, Meier M, Suzuki T, Nitsch RM, Konietzko U
(2004) The APP intracellular domain forms nuclear multiprotein complexes
and regulates the transcription of its own precursor. J Cell Sci 117:4435–48.
130
Bibliography
Walsh DM, Fadeeva JV, LaVoie MJ, Paliga K, Eggert S, Kimberly WT, Wasco W,
Selkoe DJ (2003) gamma-Secretase cleavage and binding to FE65 regulate
the nuclear translocation of the intracellular C-terminal domain (ICD) of the
APP family of proteins. Biochemistry 42:6664–73.
Wang P, Yang G, Mosier DR, Chang P, Zaidi T, Gong YD, Zhao NM, Dominguez
B, Lee KF, Gan WB, Zheng H (2005) Defective neuromuscular synapses in
mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J
Neurosci 25:1219–25.
Wasco W, Bupp K, Magendantz M, Gusella JF, Tanzi RE, Solomon F
(1992) Identification of a mouse brain cDNA that encodes a protein re-
lated to the Alzheimer disease-associated amyloid beta protein precursor.
Proc Natl Acad Sci USA 89:10758–62.
WascoW, Gurubhagavatula S, ParadisMD, RomanoDM, Sisodia SS, Hyman BT,
Neve RL, Tanzi RE (1993) Isolation and characterization of APLP2 encoding
a homologue of the Alzheimer’s associated amyloid beta protein precursor.
Nat Genet 5:95–100.
Watanabe T, Hikichi Y, Willuweit A, Shintani Y, Horiguchi T (2012) FBL2
regulates amyloid precursor protein (APP) metabolism by promoting
ubiquitination-dependent APP degradation and inhibition of APP endocyto-
sis. J Neurosci 32:3352–65.
Weyer SW, Klevanski M, Delekate A, Voikar V, Aydin D, Hick M, Filippov M,
Drost N, Schaller KL, Saar M, Vogt MA, Gass P, Samanta A, Jaschke A, Korte
M, Wolfer DP, Caldwell JH, Muller UC (2011) APP and APLP2 are essential
at PNS and CNS synapses for transmission, spatial learning and LTP. EMBO
J 30:2266–80.
Wiley JC, HudsonM, Kanning KC, Schecterson LC, BothwellM (2005) Familial
Alzheimer’s disease mutations inhibit gamma-secretase-mediated liberation
of beta-amyloid precursor protein carboxy-terminal fragment. J Neurochem
94:1189–201.
Wimo A, Prince M (2010) World Alzheimer Report 2010 - the global economic
impact of dementia. Technical report, Alzheimer’s Disease International.
Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW (1999) A family of
mammalian F-box proteins. Curr Biol 9:1180–2.
131
Bibliography
Wolfe MS (2007) When loss is gain: reduced presenilin proteolytic function
leads to increased Abeta42/Abeta40. talking point on the role of presenilin
mutations in Alzheimer disease. EMBO Rep 8:136–40.
Yanagida K, Okochi M, Tagami S, Nakayama T, Kodama TS, Nishitomi K, Jiang
J, Mori K, Tatsumi S, Arai T, Ikeuchi T, Kasuga K, Tokuda T, Kondo M, Ikeda
M, Deguchi K, Kazui H, Tanaka T, Morihara T, Hashimoto R, Kudo T, Steiner
H, Haass C, Tsuchiya K, Akiyama H, Kuwano R, Takeda M (2009) The
28-amino acid form of an APLP1-derived Abeta-like peptide is a surrogate
marker for Abeta42 production in the central nervous system. EMBOMol
Med 1:223–35.
Yang Y, Kitagaki J, Dai RM, Tsai YC, Lorick KL, Ludwig RL, Pierre SA, Jensen
JP, Davydov IV, Oberoi P, Li CCH, Kenten JH, Beutler JA, Vousden KH,
Weissman AM (2007) Inhibitors of ubiquitin-activating enzyme (E1), a new
class of potential cancer therapeutics. Cancer Res 67:9472–81.
Zhang YW, Wang R, Liu Q, Zhang H, Liao FF, Xu H (2007) Presenilin/gamma-
secretase-dependent processing of beta-amyloid precursor protein regulates
EGF receptor expression. Proc Natl Acad Sci USA 104:10613–8.
Zheng H, Jiang M, Trumbauer ME, Sirinathsinghji DJ, Hopkins R, Smith DW,
Heavens RP, DawsonGR, Boyce S, ConnerMW, Stevens KA, Slunt HH, Sisoda
SS, Chen HY, Van der Ploeg LH (1995) beta-Amyloid precursor protein-
deficient mice show reactive gliosis and decreased locomotor activity. Cell
81:525–31.
Zheng H, Koo EH (2011) Biology and pathophysiology of the amyloid precur-
sor protein. Molecular neurodegeneration 6:27.
132
